0001457612-21-000063.txt : 20210429 0001457612-21-000063.hdr.sgml : 20210429 20210429160405 ACCESSION NUMBER: 0001457612-21-000063 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210429 DATE AS OF CHANGE: 20210429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENOCEA BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001457612 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 510596811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36289 FILM NUMBER: 21870400 BUSINESS ADDRESS: STREET 1: 100 ACORN PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-876-8191 MAIL ADDRESS: STREET 1: 100 ACORN PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 FORMER COMPANY: FORMER CONFORMED NAME: GENOCEA BIOSCIENCES INC DATE OF NAME CHANGE: 20090304 10-Q 1 gnca-20210331.htm 10-Q gnca-20210331
0001457612false--12-312021Q100014576122021-01-012021-03-31xbrli:shares00014576122021-04-27iso4217:USD00014576122021-03-3100014576122020-12-31iso4217:USDxbrli:shares00014576122020-01-012020-03-310001457612us-gaap:CommonStockMember2020-12-310001457612us-gaap:PreferredStockMember2020-12-310001457612us-gaap:AdditionalPaidInCapitalMember2020-12-310001457612us-gaap:RetainedEarningsMember2020-12-310001457612us-gaap:CommonStockMember2021-01-012021-03-310001457612us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001457612us-gaap:RetainedEarningsMember2021-01-012021-03-310001457612us-gaap:CommonStockMember2021-03-310001457612us-gaap:PreferredStockMember2021-03-310001457612us-gaap:AdditionalPaidInCapitalMember2021-03-310001457612us-gaap:RetainedEarningsMember2021-03-310001457612us-gaap:CommonStockMember2019-12-310001457612us-gaap:PreferredStockMember2019-12-310001457612us-gaap:AdditionalPaidInCapitalMember2019-12-310001457612us-gaap:RetainedEarningsMember2019-12-3100014576122019-12-310001457612us-gaap:CommonStockMember2020-01-012020-03-310001457612us-gaap:PreferredStockMember2020-01-012020-03-310001457612us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001457612us-gaap:RetainedEarningsMember2020-01-012020-03-310001457612us-gaap:CommonStockMember2020-03-310001457612us-gaap:PreferredStockMember2020-03-310001457612us-gaap:AdditionalPaidInCapitalMember2020-03-310001457612us-gaap:RetainedEarningsMember2020-03-3100014576122020-03-31gnca:segments0001457612gnca:MaterialTransferAgreementMembergnca:ShionogiCo.Ltd.Member2020-05-012020-05-310001457612gnca:MaterialTransferAgreementMembergnca:ShionogiCo.Ltd.Member2021-03-310001457612us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-03-310001457612us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2021-03-310001457612us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-03-310001457612us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2021-03-310001457612us-gaap:FairValueMeasurementsRecurringMember2021-03-310001457612us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-03-310001457612us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001457612us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-03-310001457612us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2021-03-310001457612us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel1Member2021-03-310001457612us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2021-03-310001457612us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2021-03-310001457612us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-12-310001457612us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2020-12-310001457612us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-12-310001457612us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2020-12-310001457612us-gaap:FairValueMeasurementsRecurringMember2020-12-310001457612us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310001457612us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001457612us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310001457612us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2020-12-310001457612us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel1Member2020-12-310001457612us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2020-12-310001457612us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2020-12-310001457612us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2020-12-310001457612us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-03-310001457612us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2021-03-31gnca:floor0001457612gnca:LeaseExtensionMember2021-03-31xbrli:pure0001457612gnca:MasterFacilitiesOperatingLeaseDueFebruary282025Member2020-12-310001457612gnca:MasterFacilitiesOperatingLeaseDueFebruary282025Member2021-03-310001457612us-gaap:PatentsMember2021-01-012021-03-310001457612gnca:A2018TermLoanAgreementMemberus-gaap:LineOfCreditMember2018-04-240001457612gnca:A2018TermLoanAgreementMemberus-gaap:LineOfCreditMemberus-gaap:PrimeRateMember2018-04-240001457612gnca:A2018TermLoanAgreementMemberus-gaap:LineOfCreditMember2019-11-300001457612gnca:A2021TermLoanMemberus-gaap:NotesPayableToBanksMember2021-02-180001457612gnca:A2018TermLoanAgreementMemberus-gaap:LineOfCreditMember2021-02-182021-02-180001457612gnca:A2021TermLoanMemberus-gaap:NotesPayableToBanksMember2021-02-182021-02-180001457612gnca:A2021TermLoanMemberus-gaap:PrimeRateMemberus-gaap:NotesPayableToBanksMember2021-02-182021-02-180001457612gnca:A2021TermLoanMembergnca:SVBWarrantMemberus-gaap:NotesPayableToBanksMember2021-02-180001457612us-gaap:LineOfCreditMembergnca:TermLoan2014Tranche1Member2021-03-310001457612us-gaap:LineOfCreditMembergnca:TermLoan2014Tranche1Member2020-12-310001457612gnca:TermLoan2014Memberus-gaap:LineOfCreditMember2021-01-012021-03-310001457612gnca:TermLoan2014Memberus-gaap:LineOfCreditMember2020-01-012020-03-310001457612gnca:A2021TermLoanMemberus-gaap:NotesPayableToBanksMember2021-03-310001457612gnca:LincolnParkCapitalMemberus-gaap:CommonStockMember2019-10-012019-10-310001457612gnca:LincolnParkCapitalMembersrt:MaximumMemberus-gaap:CommonStockMember2019-10-012019-10-310001457612gnca:LincolnParkCapitalMembersrt:MaximumMemberus-gaap:CommonStockMember2019-10-310001457612gnca:LincolnParkCapitalMemberus-gaap:CommonStockMember2021-03-310001457612gnca:AtTheMarketEquityOfferingProgramMemberus-gaap:PrivatePlacementMemberus-gaap:CommonStockMember2016-01-012016-09-300001457612gnca:AtTheMarketEquityOfferingProgramMemberus-gaap:PrivatePlacementMemberus-gaap:CommonStockMember2021-01-012021-03-310001457612gnca:AtTheMarketEquityOfferingProgramMemberus-gaap:CommonStockMember2015-03-022021-03-310001457612gnca:AtTheMarketEquityOfferingProgramMemberus-gaap:CommonStockMember2021-03-310001457612gnca:SecondWarrantMember2021-03-310001457612gnca:PublicOfferingWarrantsMember2021-03-310001457612gnca:InitialClosingPrivatePlacementWarrantsMember2021-03-310001457612gnca:InitialClosingPreFundedWarrantsMember2021-03-310001457612gnca:A2020WarrantsMember2021-03-310001457612gnca:A2020PreFundedWarrantsMember2021-03-310001457612gnca:SVBWarrantMember2021-03-310001457612gnca:WarrantsToPurchaseCommonStockMember2021-03-310001457612us-gaap:WarrantMembergnca:A2018WarrantsMemberus-gaap:FairValueInputsLevel3Member2018-01-010001457612us-gaap:WarrantMembergnca:A2018WarrantsMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-03-310001457612us-gaap:WarrantMembergnca:A2018WarrantsMemberus-gaap:FairValueInputsLevel3Member2020-01-012020-03-310001457612us-gaap:WarrantMembergnca:A2018WarrantsMemberus-gaap:FairValueInputsLevel3Member2021-03-310001457612us-gaap:WarrantMembergnca:A2018WarrantsMemberus-gaap:FairValueInputsLevel3Member2020-12-310001457612us-gaap:MeasurementInputSharePriceMemberus-gaap:WarrantMembergnca:A2018WarrantsMember2021-03-310001457612us-gaap:MeasurementInputSharePriceMemberus-gaap:WarrantMembergnca:A2018WarrantsMember2020-12-310001457612srt:MinimumMemberus-gaap:MeasurementInputPriceVolatilityMembergnca:A2018WarrantsMember2021-03-310001457612srt:MaximumMemberus-gaap:MeasurementInputPriceVolatilityMembergnca:A2018WarrantsMember2021-03-310001457612srt:MinimumMemberus-gaap:MeasurementInputPriceVolatilityMembergnca:A2018WarrantsMember2020-12-310001457612srt:MaximumMemberus-gaap:MeasurementInputPriceVolatilityMembergnca:A2018WarrantsMember2020-12-310001457612us-gaap:MeasurementInputExpectedTermMemberus-gaap:WarrantMembergnca:A2018WarrantsMember2021-03-310001457612us-gaap:MeasurementInputExpectedTermMemberus-gaap:WarrantMembergnca:A2018WarrantsMember2020-12-310001457612us-gaap:WarrantMembergnca:A2018WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2021-03-310001457612us-gaap:WarrantMembergnca:A2018WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2020-12-310001457612us-gaap:WarrantMembergnca:A2018WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-03-310001457612us-gaap:WarrantMembergnca:A2018WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2020-12-310001457612us-gaap:WarrantMembergnca:A2018WarrantsMembergnca:MeasurementInputAcquisitionEventProbabilityMember2021-03-310001457612us-gaap:WarrantMembergnca:A2018WarrantsMembergnca:MeasurementInputAcquisitionEventProbabilityMember2020-12-310001457612gnca:A2020WarrantsMemberus-gaap:WarrantMember2020-07-240001457612gnca:A2020WarrantsMemberus-gaap:WarrantMember2021-01-012021-03-310001457612gnca:A2020WarrantsMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2021-03-310001457612gnca:A2020WarrantsMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2020-12-310001457612us-gaap:MeasurementInputSharePriceMembergnca:A2020WarrantsMemberus-gaap:WarrantMember2021-03-310001457612us-gaap:MeasurementInputSharePriceMembergnca:A2020WarrantsMemberus-gaap:WarrantMember2020-07-310001457612gnca:A2020WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMemberus-gaap:WarrantMember2021-03-310001457612gnca:A2020WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMemberus-gaap:WarrantMember2020-07-310001457612gnca:A2020WarrantsMemberus-gaap:MeasurementInputExpectedTermMemberus-gaap:WarrantMember2021-03-310001457612gnca:A2020WarrantsMemberus-gaap:MeasurementInputExpectedTermMemberus-gaap:WarrantMember2020-07-310001457612gnca:A2020WarrantsMemberus-gaap:WarrantMemberus-gaap:MeasurementInputExpectedDividendRateMember2021-03-310001457612gnca:A2020WarrantsMemberus-gaap:WarrantMemberus-gaap:MeasurementInputExpectedDividendRateMember2020-07-310001457612gnca:A2020WarrantsMemberus-gaap:WarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-03-310001457612gnca:A2020WarrantsMemberus-gaap:WarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2020-07-310001457612gnca:A2020WarrantsMemberus-gaap:WarrantMembergnca:MeasurementInputAcquisitionEventProbabilityMember2021-03-310001457612gnca:A2020WarrantsMemberus-gaap:WarrantMembergnca:MeasurementInputAcquisitionEventProbabilityMember2020-12-310001457612gnca:AmendedandRestated2014EquityIncentivePlanMemberus-gaap:EmployeeStockMember2021-03-310001457612us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310001457612us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-03-310001457612us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-03-310001457612us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-03-310001457612gnca:EmployeeAndNonemployeeStockOptionMember2020-12-310001457612gnca:EmployeeAndNonemployeeStockOptionMember2021-01-012021-03-310001457612gnca:EmployeeAndNonemployeeStockOptionMember2021-03-310001457612us-gaap:RestrictedStockUnitsRSUMember2020-12-310001457612us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001457612us-gaap:RestrictedStockUnitsRSUMember2021-03-310001457612us-gaap:EmployeeStockMember2021-03-310001457612us-gaap:WarrantMemberus-gaap:CommonStockMember2021-01-012021-03-310001457612us-gaap:WarrantMemberus-gaap:CommonStockMember2020-01-012020-03-310001457612gnca:EmployeeAndNonemployeeStockOptionMember2021-01-012021-03-310001457612gnca:EmployeeAndNonemployeeStockOptionMember2020-01-012020-03-310001457612us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001457612us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-03-310001457612us-gaap:CommonStockMember2021-01-012021-03-310001457612us-gaap:CommonStockMember2020-01-012020-03-31

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
☒      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2021
OR
☐        TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to            
Commission File Number: 001-36289
gnca-20210331_g1.jpg
GENOCEA BIOSCIENCES, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware 51-0596811
(State or Other Jurisdiction of Incorporation or Organization) (I.RS. Employer Identification No.)
100 Acorn Park Drive, Cambridge, MA 02140
(Address of principal executive offices, including zip code)
(617) 876-8191
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Common Stock, $0.001 par valueGNCANasdaqCapital Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  ☒ Yes  ☐ No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  ☒ Yes  ☐ No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company☒
Emerging growth company☐
If an emerging growth company, indicate by a check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  ☐ Yes  ☒ No
The number of shares outstanding of the registrant’s common stock as of April 27, 2021 was 54,434,839.


TABLE OF CONTENTS


PART I. FINANCIAL INFORMATION
Item 1.        Financial Statements
Genocea Biosciences, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands, except share data)
March 31, 2021December 31, 2020
Assets 
Current assets: 
Cash and cash equivalents$66,035 $79,769 
Prepaid expenses and other current assets2,785 2,458 
Total current assets68,820 82,227 
Property and equipment, net4,853 5,123 
Right of use assets8,831 9,308 
Restricted cash631 631 
Other non-current assets803 1,204 
Total assets$83,938 $98,493 
Liabilities and stockholders’ equity 
Current liabilities: 
Accounts payable$1,034 $534 
Accrued expenses and other current liabilities4,593 7,344 
Deferred revenue1,641 1,641 
Lease liabilities2,156 1,614 
Current portion of long-term debt2,000 13,862 
Total current liabilities11,424 24,995 
Non-current liabilities: 
Warrant liabilities55,264 56,118 
Lease liabilities, net of current portion7,839 8,398 
Long-term debt, net of current portion7,649 — 
Total liabilities82,176 89,511 
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.001 par value; (25,000,000 shares authorized at March 31, 2021
   and December 31, 2020; — shares issued and outstanding at March 31, 2021 and
   December 31, 2020)
— — 
Common stock, $0.001 par value; (170,000,000 shares authorized at
   March 31, 2021 and December 31, 2020, 54,368,582 shares issued and
   outstanding at March 31, 2021 and 53,018,813 shares issued and outstanding at
   December 31, 2020)
54 53 
Additional paid-in capital388,359 383,597 
Accumulated deficit(386,651)(374,668)
Total stockholders’ equity1,762 8,982 
Total liabilities and stockholders’ equity$83,938 $98,493 
See accompanying notes to the condensed consolidated financial statements.
3

Genocea Biosciences, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited)
(in thousands, except per share data) 
Three Months Ended March 31
 20212020
Operating expenses:
Research and development$8,751 $9,987 
General and administrative3,671 3,388 
Total operating expenses12,422 13,375 
Loss from operations(12,422)(13,375)
Other income (expense):
Change in fair value of warrants854 781 
Interest expense, net(279)(259)
Other expense(136)— 
Total other income439 522 
Net loss$(11,983)$(12,853)
Comprehensive loss$(11,983)$(12,853)
Net loss per share:
Basic$(0.18)$(0.46)
Diluted$(0.17)$(0.46)
Weighted-average number of shares used in
   computing net loss per share:
Basic66,158 28,141 
Diluted74,220 28,141 
See accompanying notes to the condensed consolidated financial statements.
4

Genocea Biosciences, Inc.
Condensed Consolidated Statements of Stockholders' Equity
(unaudited)
(in thousands)
Preferred AdditionalTotal
Common StockStockPaid-InAccumulatedStockholders’
SharesAmountAmountCapitalDeficitEquity
Balance at December 31, 202053,019 $53 $— $383,597 $(374,668)$8,982 
Issuance of common stock, net1,301 1 — 3,978 — 3,979 
Stock-based compensation expense— — — 580 — 580 
Issuance of warrants— — — 120 — 120 
Issuance of common stock under employee benefit
   plans		49 — — 84 — 84 
Net loss— — — — (11,983)(11,983)
Balance at March 31, 202154,369 $54 $— $388,359 $(386,651)$1,762 

PreferredAdditionalTotal
Common StockStockPaid-InAccumulatedStockholders’
SharesAmountAmountCapitalDeficitEquity
Balance at December 31, 201927,453 $27 $701 $355,268 $(330,954)$25,042 
Issuance of common stock, net187 1 — 439 — 440 
Stock-based compensation expense— — — 384 — 384 
Issuance of common stock under employee benefit
   plans		4 — — — — — 
Net loss— — — — (12,853)(12,853)
Balance at March 31, 202027,644 $28 $701 $356,091 $(343,807)$13,013 
See accompanying notes to the condensed consolidated financial statements.
5

Genocea Biosciences, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands)
 Three Months Ended March 31
 20212020
Operating activities  
Net loss$(11,983)$(12,853)
Adjustments to reconcile net loss to net cash used in operating activities: 
Depreciation and amortization381 276 
Stock-based compensation580 384 
Change in fair value of warrant liability(854)(781)
Non-cash interest expense117 109 
Other101 84 
Changes in operating assets and liabilities(735)(1,015)
Net cash used in operating activities(12,393)(13,796)
Investing activities 
Purchases of property and equipment(1,109)(233)
Proceeds from sale of equipment65 16 
Net cash used in investing activities(1,044)(217)
Financing activities  
Proceeds from issuance of common stock, net 3,979 440 
Proceeds from issuance of common stock under employee benefit plans84 — 
Payments on finance lease(23)(45)
Payment of deferred financing costs(289)— 
Proceeds from long-term debt10,000 — 
Debt prepayment costs(88)— 
Repayment of long-term debt(13,960)— 
Net cash provided by (used in) financing activities(297)395 
Net decrease in cash, cash equivalents and restricted cash(13,734)(13,618)
Cash, cash equivalents and restricted cash at beginning of period80,400 40,758 
Cash, cash equivalents and restricted cash at end of period$66,666 $27,140 
Non-cash financing activities and supplemental cash flow information  
Property and equipment included in accounts payable and accrued expenses$306 $— 
Right-of-use asset obtained in exchange for lease liabilities$— $5,931 
Cash paid in connection with operating lease liabilities$709 $394 
Cash paid for interest$166 $261 
See accompanying notes to the condensed consolidated financial statements.
6

Genocea Biosciences, Inc.
Notes to the Condensed Consolidated Financial Statements
(unaudited)
1. Organization and operations
Genocea Biosciences, Inc. ("Genocea" or the "Company”) is a biopharmaceutical company that was incorporated in Delaware on August 16, 2006 and has a principal place of business in Cambridge, Massachusetts. The Company is dedicated to discovering and developing novel cancer immunotherapies using its proprietary ATLASTM platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or “antigen” identified by next generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, InhibigensTM, that drive pro-tumor immune responses. Genocea believes this approach ensures that cancer immunotherapies, such as vaccines and cellular therapies, focus T cell responses on the tumor targets most vulnerable to T cell targeting. Consequently, the Company believes that ATLAS may enable more immunogenic and efficacious cancer immunotherapies. Genocea operates as one segment, which is discovering, researching, developing and commercializing novel cancer immunotherapies.
Genocea's GEN-011 program is an adoptive T cell therapy comprising neoantigen-targeted peripheral T cells ("NPTs"). NPTs are peripheral blood-derived T cells targeted to ATLAS-identified anti-tumor antigens. By employing ATLAS to optimize neoantigen selection and by using T cells derived from peripheral blood, Genocea believes GEN-011 will enable potential patient efficacy, accessibility and cost advantages over other autologous T cell therapies. The Company is conducting a first-in-human clinical trial for GEN-011. Genocea's GEN-009 program is a neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified anti-tumor neoantigens. After reporting initial clinical responses for GEN-009 delivered in combination with standard-of-care checkpoint inhibitors ("CPIs") in 2020, the Company continues to monitor patients to confirm these initial efficacy signals.
Genocea is devoting substantially all of its efforts to product research and development, initial market development, and raising capital. The Company has not generated any product revenue related to its primary business purpose to date and is subject to a number of risks and uncertainties common to companies in the biotech and pharmaceutical industry, including, but not limited to, the risks associated with the uncertainty of success of its preclinical and clinical trials; the challenges associated with gaining regulatory approval of product candidates; the risks associated with commercializing pharmaceutical products, if approved for marketing and sale; the potential for development by third parties of new technological innovations that may compete with Genocea's products; the dependence on key personnel; the challenges of protecting proprietary technology; the need to comply with government regulations; the high cost of drug development; competition from other companies; the uncertainty of being able to secure additional capital when needed to fund operations; and the challenges and uncertainty associated with the outbreak of the novel coronavirus ("COVID-19") that could adversely impact the Company's operations, supply chain, preclinical development work, clinical trials and ability to raise capital.
The Company regularly evaluates whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the financial statements are issued. As of March 31, 2021, Genocea had an accumulated deficit of $386.7 million and anticipates that it will continue to incur significant operating losses for the foreseeable future as it continues to develop its product candidates. Until such time, if ever, as the Company can generate substantial product revenue and achieve profitability, Genocea expects to finance its cash needs through a combination of equity offerings, strategic transactions, or other sources of funding. If the Company is unable to raise additional funds when needed, it may be required to implement further cost reduction strategies, including ceasing development of GEN-011 or other corporate programs and activities.
Genocea had available cash and cash equivalents of $66.0 million at March 31, 2021. In addition, the Company used cash of $12.4 million in its operating activities for the three months ended March 31, 2021. Genocea’s available cash and cash equivalents at March 31, 2021 are expected to fund operations for a period of at least a year from the date the financial statements are issued.
2. Summary of significant accounting policies
Basis of presentation
The condensed consolidated financial statements include the accounts of the Company and a wholly owned subsidiary. Intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements and accompanying notes in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ materially from those estimates. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and accompanying notes included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “2020 10-K”).
Significant accounting policies
Genocea's significant accounting policies have not changed materially from those disclosed in the 2020 10-K.
7

New Accounting Pronouncements
In 2019, the Financial Accounting Standards Board issued a new standard on Simplifying the Accounting for Income Taxes. The new standard simplifies the accounting for income taxes and became effective beginning after December 15, 2020. The Company adopted this standard on January 1, 2021. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements and related disclosures.
3. Revenue
In May 2020, Genocea entered into a material transfer agreement (the “MTA”) with Shionogi & Co., Ltd. (“Shionogi”) pursuant to which the Company agreed to transfer certain HSV-2 antigens from its GEN-003 program to Shionogi to evaluate the potential development of a novel HSV-2 vaccine. In connection with the agreement, Genocea provided Shionogi with an option to negotiate an exclusive development and commercialization license for the HSV-2 antigens.
Under the terms of the MTA, Shionogi paid the Company a total of $3.0 million in non-refundable, creditable (with respect to the up-front fee pursuant to a development and commercialization agreement) fees. Prior to the expiration of the MTA, Shionogi has the option to negotiate a development and commercialization agreement. If executed, the terms of the development and commercialization agreement are expected to include an upfront payment, regulatory and sales milestones, and tiered royalties. Final terms of the development and commercialization agreement will be based on evaluation of the HSV-2 assets and overall diligence. If licensed, Shionogi will assume responsibility for global development and commercialization of an HSV-2 vaccine product.
Genocea evaluated the promised goods and services within the MTA and determined those which represented separate performance obligations. As a result, the Company concluded there were two separate performance obligations at the inception of the MTA: (i) a combined performance obligation consisting of a limited use research license and the delivery of the initial antigen materials and (ii) the right to negotiate a license prior to expiration of the MTA, which was deemed to be a material right. The Company determined that the exclusive limited use research license and the delivery of the initial antigen materials should be combined as they are not capable of being distinct. A third party would not be able to provide the initial antigen materials as it contains Genocea’s proprietary intellectual property, and Shionogi could not benefit from the research license without the initial antigen materials. The Company determined that the option to negotiate the development and commercialization agreement prior to the expiration of the MTA is a material right. The $3.0 million fee associated with the MTA is creditable against the upfront fee for the development and commercialization agreement and represents a discount that would otherwise not be available to the customer without entering into the MTA.
Genocea estimated the standalone selling price of the initial antigen materials based on the expected cost plus a margin approach. The Company developed its standalone selling price for the material right by applying a probability-weighted likelihood that Shionogi will exercise its option to license the HSV-2 assets.
As of March 31, 2021, $1.6 million allocated to the material right is considered a contract liability and is recorded as deferred revenue on the Company's condensed consolidated balance sheet. Revenue associated with the material right will be recognized upon either (i) the execution of a development and commercialization agreement or (ii) the termination of the MTA.
4. Fair value of financial instruments
Genocea has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.
•Level 1—Fair values are determined by utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access;
•Level 2—Fair values are determined by utilizing quoted prices for similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates; and
•Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
The Company's financial assets and liabilities measured at fair value consist of cash equivalents and warrant liabilities, respectively.
The fair value of Genocea’s cash equivalents is determined using quoted prices in active markets. The Company's cash equivalents consist of money market funds that are classified as Level 1.
The fair value of Genocea’s warrant liabilities is determined using a Monte Carlo simulation. See Note 9. Warrants for assumptions used and methodologies utilized in calculating the estimated fair value. The Company’s warrant liabilities are classified as Level 3.
8

The following table sets forth the Company's assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in thousands):
Quoted prices in active marketsSignificant other observable inputsSignificant unobservable inputs
Total(Level 1)(Level 2)(Level 3)
March 31, 2021
Assets:
Cash equivalents$64,144 $64,144 $— $— 
Total assets$64,144 $64,144 $— $— 
Liabilities:
Warrant liabilities$55,264 $— $— $55,264 
Total liabilities$55,264 $— $— $55,264 
December 31, 2020
Assets:
Cash equivalents$76,866 $76,866 $— $— 
Total assets$76,866 $76,866 $— $— 
Liabilities:
Warrant liabilities$56,118 $— $— $56,118 
Total liabilities$56,118 $— $— $56,118 
The following table reflects the change in Genocea’s Level 3 warrant liabilities (in thousands):
Warrant Liabilities
Balance at December 31, 2020
$56,118 
Change in fair value(854)
Balance at March 31, 2021
$55,264 
5. Accrued expenses and other current liabilities
Accrued expenses and other current liabilities consisted of the following (in thousands):
March 31, 2021December 31, 2020
Research and development costs$2,817 $2,592 
Payroll and employee-related costs910 2,779 
Other current liabilities866 1,973 
Total$4,593 $7,344 
6. Commitments and contingencies
Operating leases
As of March 31, 2021, Genocea has a lease for two floors of lab and office space in a multi-tenant building in Cambridge, Massachusetts through February 2025. A portion of this leased space is an expansion of the Company's initial lease. Genocea's right to use and control this expansion space began in March 2020. Genocea has the option to extend the lease term for an additional five years, which is not included in the Company's ROU assets and associated lease liabilities as of March 31, 2021. In the fourth quarter of 2020, Genocea incurred costs related to improvements made to its leased office space that were determined to be lessee assets and which were partially reimbursed by the lessor. In the first quarter of 2021, the Company recognized an increase in its lease liabilities of $0.5 million, which reflects the cash received from the lessor during the quarter for previously approved reimbursements. The Company will amortize the reimbursement as an increase to the ROU asset and a reduction in lease expense over the remaining lease term.
In January 2021, Genocea entered into a sublease agreement for one floor of lab and office space through June 2022, with an option for the sublessee to extend the sublease for an additional two months. After the initial option, which is at the sublessee’s sole discretion, the sublease agreement contains additional options for the Company and the sublessee to mutually extend the sublease for up to an additional eighteen months. As Genocea retained its obligations under the sublease, it will record the payments received from the sublease as a reduction of lease expense. For the three months ended March 31, 2021, the Company recorded sublease income of $0.4 million.
9

For the three months ended March 31, 2021 and 2020 lease expense, net of sublease income, was $0.3 million and $0.5 million, respectively.
The weighted average remaining lease term and weighted average discount rate of the Company's operating leases are as follows:
March 31, 2021December 31, 2020
Weighted average remaining lease term in years3.914.17
Weighted average discount rate8.13 %8.12 %
The following table summarizes the presentation of leases in the Company's condensed consolidated balance sheets (in thousands):
ClassificationMarch 31, 2021December 31, 2020
Assets
OperatingRight of use assets$8,831 $9,278 
FinanceRight of use assets— 30 
Total lease assets$8,831 $9,308 
Liabilities
Current
   OperatingLease liabilities$2,156 $1,592 
   FinanceLease liabilities— 22 
Non-current
   OperatingLease liabilities, net of current portion7,839 8,398 
Total lease liabilities$9,995 $10,012 
The minimum lease payments related to the Company's operating leases as of March 31, 2021 were as follows (in thousands):
Remainder of 2021$2,162 
20222,943 
20233,017 
20243,092 
2025517 
Total lease payments11,731 
Less imputed interest(1,736)
Total$9,995 
At March 31, 2021 and December 31, 2020, the Company had an outstanding letter of credit of $0.6 million, with a financial institution related to a security deposit for the office and lab space lease, which is secured by cash on deposit and expires in February 2025.
Contractual obligations
Genocea has entered into certain agreements with various universities, contract research organizations and contract manufacturing organizations, which generally include cancellation clauses.
Harvard University license agreement
Genocea has an exclusive license agreement with Harvard University (“Harvard”), granting the Company an exclusive, worldwide, royalty-bearing, sublicensable license to three patent families, to develop, make, have made, use, market, offer for sale, sell, have sold and import licensed products and to perform licensed services related to the ATLAS discovery platform. Genocea is also obligated to pay Harvard milestone payments up to $1.6 million in the aggregate upon the achievement of certain development and regulatory milestones. As of March 31, 2021, the Company has paid $0.3 million in aggregate milestone payments. Genocea is obligated under this license agreement to use commercially reasonable efforts to develop, market and sell licensed products in compliance with an agreed-upon development plan. In addition, the Company is obligated to achieve specified development milestones and in the event Genocea is unable to meet its development milestones for any type of product or service, absent any reasonable proposed extension or amendment thereof, Harvard has the right, depending on the type of product or service, to terminate this agreement with respect to such products or to convert the license to a non-exclusive, non-sublicensable license with respect to such products and services.
10

Upon commercialization of the Company's products covered by the licensed patent rights or discovered using the licensed methods, Genocea is obligated to pay Harvard royalties on the net sales of such products and services sold by the Company, the Company's affiliates, and the Company's sublicensees. This royalty varies depending on the type of product or service but is in the low single digits. The sales-based royalty due by the Company’s sublicensees is the greater of the applicable royalty rate or a percentage in the high single digits or the low double digits of the royalties Genocea receives from such sublicensee, depending on the type of product. Based on the type of commercialized product or service, royalties are payable until the expiration of the last-to-expire valid claim under the licensed patent rights or for a period of 10 years from first commercial sale of such product or service. The royalties payable to Harvard are subject to reduction, capped at a specified percentage, for any third-party payments required to be made. In addition to the royalty payments, if the Company receives any additional revenue (cash or non-cash) under any sublicense, it must pay Harvard a percentage of such revenue, excluding certain categories of payments, varying from the low single digits to up to the low double digits depending on the scope of the license that includes the sublicense.
The license agreement with Harvard will expire on a product-by-product or service-by-service and country-by-country basis until the expiration of the last-to-expire valid claim under the licensed patent rights. The Company may terminate the agreement at any time by giving Harvard advance written notice. Harvard may also terminate the agreement in the event of a material breach by the Company that remains uncured; in the event of the Company's insolvency, bankruptcy, or similar circumstances; or if Genocea challenges the validity of any patents licensed to it.
Oncovir license and supply agreement
Genocea has a license and supply agreement with Oncovir, Inc. (“Oncovir”) under which Oncovir will manufacture and supply an immunomodulator and vaccine adjuvant, Hiltonol® (poly-ICLC) (“Hiltonol”), to the Company for use in connection with the research, development, use, sale, manufacture, commercialization and marketing of products combining Hiltonol with the Company's technology (the “Combination Product”). Hiltonol is the adjuvant component of GEN-009, which will consist of synthetic long peptides or neoantigens identified using the Company's proprietary ATLAS platform, formulated with Hiltonol. 
Oncovir granted the Company a non-exclusive, assignable, royalty-bearing worldwide license, with the right to grant sublicenses through one tier, to certain of Oncovir’s intellectual property in connection with the research, development, or commercialization of Combination Products, including the use of Hiltonol, but not the use of Hiltonol for manufacturing or the use or sale of Hiltonol alone. The license will become perpetual, fully paid-up, and royalty-free on the later of January 25, 2028 or the date on which the last valid claim of any patent licensed to the Company under the agreement expires.
Under this agreement, Genocea is obligated to pay Oncovir low to mid six figure milestone payments upon the achievement of certain clinical trial milestones for each Combination Product and the first marketing approval for each Combination Product in certain territories, as well as tiered royalties in the low-single digits on a product-by-product basis based on the net sales of Combination Products.
Genocea may terminate the agreement upon a decision to discontinue the development of the Combination Product or upon a determination by the Company or an applicable regulatory authority that Hiltonol or a Combination Product is not clinically safe or effective. The agreement may also be terminated by either party due to a material uncured breach by the other party, or due to the other party’s bankruptcy, insolvency, or dissolution.
7.  Debt
In April 2018, the Company entered into an amended and restated loan and security agreement, which was subsequently amended in November 2019 (as amended, the “Hercules Loan Agreement”), with Hercules Capital, Inc. (“Hercules”). The Hercules Loan Agreement provided a $14.0 million secured term loan that was scheduled to mature on May 1, 2021 and that accrued interest at a floating rate per annum equal to the greater of (i) 8.00%, or (ii) the sum of 3.00% plus the prime rate. The Company was also obligated to pay a final payment charge of $1.0 million at maturity.
On February 18, 2021 (the "2021 Loan Closing Date"), Genocea entered into a Loan and Security Agreement (the "2021 Loan Agreement") with Silicon Valley Bank ("SVB") for a $10 million secured term loan (the "2021 Term Loan"). $9.0 million of the proceeds from the 2021 Term Loan were used to repay the Company's borrowings that were outstanding at the 2021 Loan Closing Date under its previous loan and security agreement with Hercules, paying off all obligations owing under, and extinguishing, the Hercules Loan Agreement on the 2021 Loan Closing Date. The remaining proceeds from the 2021 Term Loan of $1.0 million were received by the Company for working capital and general corporate purposes.
11

The 2021 Term Loan will mature on September 1, 2023, which may be extended to March 1, 2024 if certain performance milestones are achieved and no event of default has occurred or is continuing. The 2021 Term Loan accrues interest at a floating per annum rate equal to the greater of (i) 6.25% or (ii) the sum of 3.0% plus the prime rate. The 2021 Term Loan provides for interest-only payments until September 30, 2021, which may be extended to March 31, 2022 if certain performance milestones are achieved and no event of default has occurred or is continuing. Thereafter, amortization payments will be payable monthly in equal installments of principal and interest (subject to recalculation upon a change in prime rates) upon expiration of the interest-only period through maturity. The 2021 Term Loan is subject to a final payment charge of $0.5 million. The 2021 Term Loan may be prepaid in whole (but not in part), subject to a prepayment charge of 3.0%, if prepaid in any of the first twelve (12) months following the Closing Date, 2.0%, if prepaid after twelve (12) months following the Closing Date but on or prior to twenty four (24) months following the Closing Date, and 1.0% thereafter.
The 2021 Term Loan is secured by a lien on substantially all of the assets of the Company, other than intellectual property, provided that such lien on substantially all assets includes any rights to payments and proceeds from the sale, licensing or disposition of intellectual property.
The 2021 Loan Agreement contains customary covenants and representations, including a financial reporting covenant and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. There are no financial covenants. As of March 31, 2021, the Company was in compliance with all covenants under the 2021 Loan Agreement.
The 2021 Loan Agreement also includes customary events of default, including payment defaults, breaches of covenants, change of control and occurrence of a material adverse effect. Amounts outstanding during an event of default shall be payable on demand and shall accrue interest at an additional rate of 4.0% per annum of the past due amount outstanding. The Company has determined that the risk of subjective acceleration under the material adverse events clause was remote and therefore has classified the long-term portion of the outstanding principal in non-current liabilities.
In connection with the 2021 Loan Agreement, Genocea issued to SVB a warrant, dated February 18, 2021 (the "SVB Warrant") to purchase 43,478 shares of the common stock of the Company. See Note 9. Warrants. The Company recorded the fair value of the SVB warrant as a discount on the 2021 Term Loan that will be amortized over the expected term of the loan.
As of March 31, 2021 and December 31, 2020, the Company had outstanding borrowings, net of unamortized debt issuance costs, of $9.6 million and $13.9 million, respectively. Interest expense was $0.3 million and $0.4 million for the three months ended March 31, 2021 and 2020, respectively.
Future principal payments, including final payment charges, as of March 31, 2021 are as follows:
Principal Payments on Long-Term Debt
Remainder of 2021$1,250 
20225,000 
20234,250 
$10,500 
8. Stockholders' equity
Agreement with Lincoln Park Capital
Genocea has a purchase agreement with Lincoln Park Capital (“LPC”) pursuant to which, for a period of 30 months beginning in October 2019, the Company has the right, at its sole discretion, to sell up to an additional $27.5 million of the Company's common stock to LPC based on prevailing market prices of its common stock at the time of each sale. The purchase agreement limits the Company's sales of shares of common stock to LPC to approximately 5.2 million shares of common stock, representing 19.99% of the shares of common stock outstanding on the date of the purchase agreement. The purchase agreement also prohibits the Company from directing LPC to purchase any shares of common stock if those shares, when aggregated with all other shares of the Company's common stock then beneficially owned by LPC and its affiliates, would result in LPC and its affiliates having beneficial ownership, at any single point in time, of more than 9.99% of the then total outstanding shares of the Company's common stock. As of March 31, 2021, the Company had $24.0 million remaining under its agreement with LPC.
At-the-market equity offering program
Genocea has an agreement with Cowen and Company, LLC ("Cowen") to establish an at-the-market equity offering program (“ATM”) pursuant to which Cowen is able to offer and sell up to $50.0 million of the Company's common stock at prevailing market prices. In the three months ended March 31, 2021, the Company sold approximately 1.3 million shares under the ATM program and received net proceeds of $4.0 million, after deducting commissions. Through March 31, 2021, the Company has sold an aggregate of approximately 4.2 million shares under the ATM and received $13.8 million in net proceeds. As of March 31, 2021, the Company had $35.8 million in gross proceeds remaining under the ATM.
12

9. Warrants
As of March 31, 2021, the Company had the following potentially issuable shares of common stock related to unexercised warrants outstanding (shares in thousands):
SharesExercise PriceExpiration DateClassification
Hercules Warrant41 $6.80 Q2 2023Equity
2018 Warrants3,617 $9.60 Q1 2023Liability
2019 Warrants933 $4.52 Q1 2024Equity
2019 Pre-Funded Warrants531 $0.08 Q1 2039Equity
2020 Warrants33,613 $2.25 Q3 2024Liability
2020 Pre-Funded Warrants12,223 $0.01 N/AEquity
SVB Warrant43 $3.45 Q1 2026Equity
51,001 
Hercules Warrant
The exercise price and the number of shares are subject to adjustment upon a merger event, reclassification of the shares of common stock, subdivision or combination of the shares of common stock or certain dividend payments. Genocea determined that the Hercules Warrant should be equity-classified.
2018 Warrants
The exercise price and the number of shares are subject to adjustment upon a merger event, reclassification of the shares of common stock, subdivision or combination of the shares of common stock or certain dividend payments. In the event of an “Acquisition,” defined generally to include a merger or consolidation resulting in the sale of 50% or more of the voting securities of the Company, the sale of all, or substantially all, of the assets or voting securities of the Company, or other change of control transaction, as defined in the 2018 Warrants, Genocea will be obligated to use its best efforts to ensure that the holders of the 2018 Warrants receive new warrants from the surviving or acquiring entity (the “Acquirer”). The new warrants to purchase shares in the Acquirer shall have the same expiration date as the 2018 Warrants and a strike price that is based on the proportion of the value of the Acquirer’s stock to the Company’s common stock. If the Company is unable, despite its best efforts, to cause the Acquirer to issue new warrants in the Acquisition as described above, then, if the Company’s stockholders are to receive cash in the Acquisition, Genocea will settle the 2018 Warrants in cash and if the Company’s stockholders are to receive stock in the Acquisition, Genocea will issue shares of its common stock to each Warrant holder.
As a result, the Company determined that the 2018 Warrants should be liability-classified. As the 2018 Warrants are liability-classified, the Company remeasures the fair value at each reporting date. Genocea initially recorded the 2018 Warrants at their estimated fair value of $18.2 million. In connection with the Company's remeasurement of the 2018 Warrants to fair value, it recorded income of $0.2 million and $0.8 million for the three months ended March 31, 2021 and 2020, respectively. The fair value of the warrant liability related to the 2018 Warrants is $1.5 million and $1.7 million as of March 31, 2021 and December 31, 2020, respectively.
The following table details the assumptions used in the Monte Carlo simulation models used to estimate the fair value of the 2018 Warrants as of March 31, 2021 and December 31, 2020, respectively:
March 31, 2021December 31, 2020
Stock price$2.71 $2.42 
Volatility
50.0% - 95.3%
50.0% - 101.5%
Remaining term (years)1.82.0
Expected dividend yield— %— %
Risk-free rate0.16 %0.13 %
Acquisition event probability25.0 %25.0 %
2019 Warrants and 2019 Pre-Funded Warrants
The exercise price of the warrants is subject to appropriate adjustment in the event of stock dividends, subdivisions, stock splits, stock combinations, reclassifications, reorganizations or a change of control affecting the Company's common stock. Genocea determined that the 2019 Warrants and the 2019 Pre-Funded Warrants should be equity-classified. The Company also determined that the 2019 Pre-Funded Warrants should be included in the determination of basic earnings per share.
13

2020 Warrants and 2020 Pre-Funded Warrants
The exercise price of the 2020 Pre-Funded Warrants and the 2020 Warrants is subject to adjustment in the event of stock dividends, subdivisions, stock splits, stock combinations, reclassifications, reorganizations or a change of control affecting the Company's common stock. Genocea determined that the 2020 Pre-Funded Warrants should be equity-classified and be included in the determination of basic earnings per share.
The holders of the 2020 Warrants are entitled to down round protection until July 24, 2021. The Company is required to obtain shareholder approval for the adjustment to the exercise price as a result of any common stock issuance at a price per share less than $2.25. As a result, Genocea determined that the 2020 Warrants should be liability-classified for the period from issuance through July 2021. As the 2020 Warrants are liability-classified, the Company remeasures the fair value at each reporting date. Genocea initially recorded the 2020 Warrants at their estimated fair value of $62.5 million. In connection with the Company's remeasurement of the 2020 Warrants to fair value, the Company recorded income of $0.7 million for the three months ended March 31, 2021. The fair value of the warrant liability related to the 2020 Warrants is $53.8 million and $54.5 million as of March 31, 2021 and December 31, 2020, respectively.
The following table details the assumptions used in the Monte Carlo simulation models used to estimate the fair value of the 2020 Warrants as of March 31, 2021 and December 31, 2020, respectively:
March 31, 2021December 31, 2020
Stock price$2.71 $2.42 
Volatility93.9 %119.1 %
Remaining term (years)3.33.6
Expected dividend yield— — 
Risk-free rate0.44 %0.22 %
Acquisition event probability40.0 %40.0 %
SVB Warrant
In connection with the 2021 Loan Agreement, Genocea issued to SVB the SVB Warrant to purchase 43,478 shares of the common stock of the Company. See Note 7. Debt. The exercise price and the number of shares are subject to adjustment upon a merger event, reclassification of the shares of common stock, subdivision or combination of the shares of common stock or certain dividend payments. The Company determined that the SVB Warrant should be equity-classified.
10. Employee benefit plans
Genocea grants equity awards in the form of stock options and service-based and market-based restricted stock units (“RSUs”) to employees and directors of, and consultants and advisors to, the Company through its Amended and Restated 2014 Equity Incentive Plan, ("2014 Equity Incentive Plan"). As of March 31, 2021, there were approximately 0.7 million shares remaining for future issuance under the 2014 Equity Incentive Plan.
The options have a ten-year term and were issued with an exercise price equal to the closing market price of Genocea’s common stock on the grant date. For equity awards with service-based vesting conditions, the Company recognizes compensation expense over the vesting period, which is generally over a four-year period. For equity awards with a market-based vesting condition, the Company recognizes compensation expense over the requisite service period. The number of shares issuable, if any, when a market-based RSU award vests will depend on the degree of achievement of the corporate stock price metrics within the performance period of the award. The Company measures the fair value of stock options on the date of grant using the Black-Scholes option pricing model. The fair value of the service-based RSUs is the closing market price of Genocea's common stock on the grant date.
Determining the fair value of market-based RSUs
The Company measures the fair value of market-based RSUs on the date of grant using a Monte Carlo simulation model. The Monte Carlo simulation requires the input of assumptions, including the Company's stock price, the volatility of its stock price, remaining term in years, expected dividend yield, and risk-free rate. In addition, the valuation model considers the Company's probability of being acquired within the term of the market-based RSUs, as an acquisition event can potentially impact the vesting. The Company used its own trading history to calculate the expected volatility of the market-based RSUs granted. The risk-free interest rate is determined by reference to implied yields available from U.S. Treasury securities with a remaining term equal to the expected term assumed at the grant date.
14

The following table details the assumptions used in the Monte Carlo simulation model used to estimate the fair value of the market-based RSUs granted during the three months ended March 31, 2021:
Three Months Ended March 31
2021
Stock price$3.01 
Volatility97.65 %
Remaining term (years)2.8
Risk-free rate0.29 %
Annual acquisition event probability33.0 %
Stock-based compensation expense
Total stock-based compensation expense recognized for stock options and RSUs is as follows (in thousands):
Three Months Ended March 31
20212020
Research and development$258 $160 
General and administrative322 224 
Total$580 $384 
Stock options
The following table summarizes stock option activity (shares and aggregate intrinsic value in thousands):
SharesWeighted-Average
Exercise Price		Weighted-Average
Remaining Contractual
Term (years)		Aggregate
Intrinsic Value
Outstanding at December 31, 2020
2,329 $7.05 $505 
Granted1,614 $3.01   
Exercised(38)$2.22   
Forfeited/cancelled(66)$12.82   
Outstanding at March 31, 2021
3,839 $5.30 8.8$715 
Exercisable at March 31, 2021
930 $12.61 7.0$134 
RSUs
The following table summarizes RSU activity (shares in thousands):
SharesWeighted-Average Grant Date Fair Value
Outstanding as of December 31, 2020
550 $2.13 
Granted(1)
1,904 $2.52 
Vested(11)$1.98 
Forfeited/cancelled(9)$2.11 
Outstanding as of March 31, 2021
2,434 $2.44 
    _________________________
1.The number granted represents the number of shares issuable upon vesting of service-based and market-based RSUs, assuming the Company achieves its corporate stock price metrics at the target achievement level.
Employee stock purchase plan
The 2014 Employee Stock Purchase Plan, as amended (the "ESPP"), issues shares of common stock to participating eligible employees during two six-month offering periods each year. As of March 31, 2021, there were approximately 0.1 million shares remaining for future issuance under the ESPP.
15

11. Net loss per share
Basic and diluted net loss per share was calculated as follows for the three months ended March 31, 2021 and 2020 (in thousands, except per share amounts):
Three Months Ended March 31
20212020
Numerator:
Net loss$(11,983)$(12,853)
Less: Change in fair value of 2020 Warrants
673 — 
Adjusted net loss$(12,656)$(12,853)
Denominator:
Weighted average common stock outstanding – basic66,158 28,141 
Dilutive effect of common stock issuable from
   assumed exercise of warrants		8,062 — 
Weighted average common stock outstanding – diluted74,220 28,141 
Net loss per share:
Basic$(0.18)$(0.46)
Diluted$(0.17)$(0.46)
The following potential common shares were excluded from the calculation of net loss per share due to their anti-dilutive effect for the three months ended March 31, 2021 and 2020 (in thousands):
 Three Months Ended March 31
 20212020
Warrants4,634 4,591 
Stock options3,839 1,370 
RSUs2,434 45 
Total10,907 6,006 
The 2020 Warrants have been included in the calculation of diluted net loss per share for the three months ended March 31, 2021 as the warrants are both liability-classified and in-the-money. The Company used the treasury stock method to determine the number of dilutive shares.
16

FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results and other future conditions. The words “anticipate”, “believe”, “contemplate”, “continue”, “could”, “estimate”, “expect”, “forecast”, “goal”, “intend”, “may”, “plan”, “potential”, “predict”, “project”, “should”, “target”, “will”, “would”, or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed in our Annual Report on Form 10-K for the year ended December 31, 2020 (the "2020 10-K") and other filings with the Securities Exchange Commission (the “SEC”), including the following:
•our estimates regarding the timing and amount of funds we require to conduct clinical trials for GEN-011, to continue preclinical studies for our other product candidates and to continue our investments in immuno-oncology;
•our estimates regarding the timing and costs of manufacturing GEN-011;
•our estimates regarding the timing of GEN-011 patient enrollment and dosing;
•our estimates regarding GEN-011 third-party manufacturing capacity;
•our estimates regarding the timing and amount of funds we require to perform monitoring activities to support the GEN-009 clinical trial;
•our estimates regarding expenses, future revenues, capital requirements, the sufficiency of our current and expected cash resources and our need for additional financing;
•our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
•the timing of, and our ability to, obtain and maintain regulatory approvals for our product candidates;
•the effect of the novel coronavirus (COVID-19) pandemic on the economy generally and on our business and operations specifically, including our research and development efforts, our clinical trials and our employees, and the potential disruptions in supply chains and to our third party manufacturers, including the availability of materials and equipment;
•the potential benefits of strategic partnership agreements and our ability to enter into strategic partnership arrangements;
•our expectations regarding our ability to obtain and maintain intellectual property protection for our manufacturing methods and product candidates;
•the rate and degree of market acceptance and clinical utility of any approved product candidate;
•our ability to quickly and efficiently identify and develop product candidates; and
•our commercialization, marketing and manufacturing capabilities and strategy.
These factors are discussed more fully in our 2020 10-K and elsewhere in this and other reports we file with the SEC. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and investors should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make or collaborations or strategic partnerships we may enter into. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
17

Item 2.        Management’s Discussion and Analysis of Financial Condition and Results of Operations
Management's discussion and analysis of our financial condition and results of operations should be read in conjunction with our 2020 10-K and our unaudited condensed consolidated financial statements and accompanying notes and other disclosures included in this Quarterly Report on Form 10-Q.
Overview
We are a biopharmaceutical company dedicated to discovering and developing novel cancer immunotherapies using our proprietary ATLASTM platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or “antigen” identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, InhibigensTM, that drive pro-tumor immune responses. We believe this approach ensures that cancer immunotherapies, such as vaccines and cellular therapies, focus T cell responses on the tumor targets most vulnerable to T cell targeting. Consequently, we believe that ATLAS may enable more immunogenic and efficacious cancer immunotherapies.
Our GEN-011 program is an adoptive T cell therapy comprising neoantigen-targeted peripheral cells ("NPTs"). NPTs are peripheral blood-derived T cells targeted to ATLAS-identified anti-tumor antigens. By employing ATLAS to optimize neoantigen selection and by using T cells derived from peripheral blood, we believe GEN-011 will enable potential patient efficacy, accessibility and cost advantages over other autologous T cell therapies. We are conducting a first-in-human clinical trial (the “TITAN trial”) for GEN-011. Our GEN-009 program is a neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified anti-tumor neoantigens. After reporting initial clinical responses for GEN-009 delivered in combination with standard-of-care checkpoint inhibitors ("CPIs") in 2020, we continue to monitor patients to further evaluate these initial efficacy signals.
ATLAS platform
Harnessing and directing T cells to kill tumor cells is increasingly viewed as having potential to treat many cancers. Vaccines or cellular therapies employing this approach must target specific differences from normal tissue present in the patient, such as antigens arising from genetic mutations or cancer-causing viruses. However, the discovery of optimal antigens for such immunotherapies has been particularly challenging for two reasons. First, the number of candidate antigens can be very large, with up to thousands of candidates per patient in some cancers. Second, the genetic diversity of human T cell responses means that effective antigens may vary from person to person. An effective antigen selection system must therefore account both for each patient's tumor and for their T cell repertoire.
ATLAS selects antigens through an ex vivo assay that unveils CD4+ and CD8+ T cell immune responses each patient has made to nearly any possible tumor-specific antigen, including candidate neoantigens, tumor-associated antigens and tumor-associated viral antigens. In doing so, we believe that ATLAS provides the most comprehensive and accurate system for identifying the right and wrong antigens for cancer immunotherapies. Previously, all candidate antigens were thought either to be targets of effective anti-tumor responses (stimulatory) or irrelevant. However, using ATLAS, we have identified Inhibigens and demonstrated, in preclinical studies, that such antigens can promote rapid tumor growth, reduce or eliminate the protection of an otherwise effective vaccine, and dampen or reverse the effects of checkpoint inhibitors. We have also demonstrated that classical antigen prediction methodologies often mischaracterize Inhibigens as stimulatory. We therefore believe that both by identifying the optimal neoantigens and by excluding Inhibigens, ATLAS enables differentiated immune responses and clinical efficacy.
We believe ATLAS could have beneficial uses beyond cancer. We have previously demonstrated its effectiveness in identifying novel protective antigens for infectious disease therapies, and we believe it also could provide benefits in autoimmune and other disease therapies. While we believe Inhibigens should be avoided in cancer immunotherapies, they could prove to be beneficial in other therapies. ATLAS could be a key tool in optimizing antigen selection for therapies across a number of diseases.
Intellectual property
Our ATLAS and immuno-oncology intellectual property portfolio comprises eight patent families and two additional pending patent families, all but one of which are wholly owned by us. The first patent family, in-licensed from Harvard University, is directed to one arm of the ATLAS method for identifying antigens. This patent family is comprised of issued United States ("U.S.") patents, with patent terms ranging from 2027 to 2031, as well as granted foreign patents. The second family is directed to expanded ATLAS methods for identifying antigens, as currently practiced by us. This family is comprised of issued U.S. patents, with patent terms ranging from 2029 to 2030, as well as granted foreign patents and pending U.S. and foreign applications. The third family is directed to ATLAS-based methods for selecting or deselecting Inhibigens and stimulatory antigens, cancer diagnosis, prognosis and patient selection, as well as related compositions. This patent family is comprised of an issued U.S. patent with a patent term to 2038, pending applications in eleven foreign jurisdictions, and a pending U.S. application. Additional patents issuing from these applications are expected to have patent terms until at least 2038. The fourth, fifth and sixth families are directed to various methods using ATLAS-identified antigens. These families comprise pending U.S. and foreign applications. Patents issuing from these applications are expected to have patent terms until at least 2039. The two further families and two potential additional families currently comprise Patent Cooperation Treaty ("PCT") applications or U.S. provisional applications and are directed to further methods using ATLAS-identified antigens, to dose regimens for GEN-009, and to our cell-based therapy GEN-011.
18

Our immuno-oncology programs
GEN-009
GEN-009 is a neoantigen vaccine candidate delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. We are conducting a Phase 1/2a clinical trial for GEN-009 across a range of solid tumor types. Part A of the trial is assessing the monotherapy GEN-009 for safety, immunogenicity and ability to prevent disease relapse in certain cancer patients with no detectable tumor at the time of vaccination but with a risk of relapse. Part B of the trial is assessing the safety, immunogenicity and preliminary antitumor activity of GEN-009 in combination with CPI therapy in patients with advanced or metastatic tumors.
We have observed the following from our data presented at various medical meetings throughout 2020:
In Part A of the trial, we have observed the following in the eight dosed patients:
•100% of patients had measurable CD4+ and/or CD8+ T cell responses to their GEN-009 vaccine;
•Responses were detected against 99% of the administered vaccine neoantigens (N=88 administered antigens), a response rate in excess of that which has been reported previously by others in response to candidate neoantigen vaccines;
•GEN-009 was well tolerated, with no dose-limiting toxicities observed; and
•Only one of the eight vaccinated patients has developed a recurrence of their tumor.
In Part B of the trial, we continue to evaluate immune responses and efficacy in two cohorts of patients, those who are checkpoint-sensitive and those who are checkpoint-resistant.
•In the checkpoint-sensitive cohort, we believe we have shown compelling signals of response.
◦Of the nine checkpoint-sensitive patients, three have independent RECIST™ criteria responses that appear to be attributable to GEN-009.
◦Of those three patients, one patient achieved a complete response and two patients achieved a partial response after vaccination.
•In the checkpoint resistant cohort, we believe that GEN-009 has shown early evidence of stabilization of disease.
◦This group of seven patients initially started their CPI therapy but quickly progressed and transitioned to standard of care therapy which generally consists of radiation and/or chemotherapy. After completing the standard-of-care therapy, these patients received GEN-009 vaccination.
◦Of the seven patients, five appear to have achieved initial disease stabilization.
We believe the GEN-009 data confirm the potential antigen selection advantages of ATLAS and suggest a differentiating advantage for GEN-011.
GEN-011
We believe that GEN-011 represents a new category of solid tumor adoptive T cell therapy, neoantigen-targeted peripheral T cells ("NPTs"). The first neoantigen-targeted T cell therapy to demonstrate clinical efficacy in patients with solid tumors is tumor-infiltrating lymphocyte ("TIL") therapy. TILs consist of a subset of lymphocytes that have invaded a tumor but, importantly, are not all necessarily specific for tumor antigens. TIL therapy requires a fresh, uncontaminated, viable tumor resection from each patient, from which TILs will be obtained. These TILs are then non-specifically expanded in the presence of high dose interleukin-2 ("IL-2") ex vivo and infused into that same patient, who has undergone lymphodepletion preconditioning, followed by high dose IL-2 treatment. In certain patients with solid tumors resistant to CPI therapy, TIL therapy has resulted in durable clinical responses. TIL therapy has some drawbacks: it is infeasible to get sufficient tumor or TILs from some patients, the need for fresh tumor adds time and cost to the therapy, and the therapy – particularly because of the high dose IL-2 – may cause serious adverse events.
GEN-011 differs from TIL therapy in two critical ways. First, we use ATLAS to design the product to be highly specific for the neoantigens of anti-tumor T cell responses. Second, we rely on T cells extracted from peripheral blood, which is readily available. We believe these differences may result in GEN-011, if approved, offering efficacy, patient accessibility and cost advantages over other neoantigen-targeting solid tumor T cell therapies.
The potential efficacy advantages derive from the following product features:
•Targeting up to 30 tumor-specific antigens simultaneously to limit tumor escape, with minimal bystander, non-tumor-specific T cells;
•Avoiding T cells specific for Inhibigens that may be detrimental to clinical response;
•Including both CD4+ and CD8+ tumor antigen-specific T cells; and
•Using peripheral blood-derived T cells, which are believed to have potential for superior activity and persistence when compared to TILs.
19

The potential patient accessibility and cost advantages derive from the fact that:
•No extra surgery or viable tumor is required as starter material;
•GEN-011 can treat any patient, while some adoptive T cell therapies engineer T cells for applicability to certain human leukocyte antigen types, often limiting their clinical utility to certain subsets of western Caucasians; and
•The GEN-011 cell expansion process is comparatively straightforward, with no T cell receptor ("TCR") vector design or transduction required.
Across more than 16 development and engineering runs in blood derived from cancer patients and healthy donors, we have demonstrated that GEN-011 NPTs:
•Are 99% T cells made up of both CD4+ and CD8+ T cells with the desired T cell phenotype (>98% central and effector memory, on average);
•Highly neoantigen-specific (96% neoantigen-specific, with activity against 89% of target neoantigens on average);
•Powerfully cytolytic against their targets with no off-target cytotoxicity in vitro;
•Polyfunctional, secreting effector, stimulatory and chemoattractive mediators; and
•Highly active and potent.
We are conducting the TITAN trial, treating patients with GEN-011 as monotherapy for tumors that have not achieved an adequate response after CPI therapy. Our target indications include melanoma, non-small cell lung cancer, small cell lung cancer, squamous cell carcinoma of the head and neck, urothelial carcinoma, renal cell carcinoma, cutaneous squamous cell carcinoma, and anal squamous cell carcinoma.
The TITAN trial will contain two patient cohorts:
•Cohort A patients will receive GEN-011 in a repeated low dose regimen with no lymphodepletion and an intermediate dose of IL-2 after each GEN-011 dose;
•Cohort B patients will receive GEN-011 as a single high dose with both lymphodepletion and high dose IL-2.
The TITAN trial’s objectives are safety, clinical activity including overall response rate and duration of response and GEN-011’s proliferation and persistence as well as tumor T cell penetration. We expect to have initial data from a small subset of patients late in the fourth quarter of 2021 or the first quarter of 2022. However, patient accrual to clinical trials and subsequent dosing and compliance are dependent upon both patient choice and health, and investigator decisions. Predictions of data availability and release of results may be affected by individual patient events among other factors.
Other research activities
In addition to our two clinical programs, we are conducting research in several areas:
•Exploring the potential for novel antigens of protective T cell responses to SARS-CoV-2 ("COVID-19") to provide effectiveness against multiple virus strains, partly in collaboration with the University of Massachusetts Medical School;
•Identifying TCRs to ATLAS-identified shared neoantigens, in collaboration with the University of Minnesota;
•Exploring T cell responses to oncoviruses associated with certain cancers such as Epstein-Barr virus and human papilloma virus;
•Identifying shared antigen immunotherapies encompassing shared neoantigens and non-mutated tumor-associated antigens;
•Exploring Inhibigen biology; and
•Further optimizing ATLAS.
Since these other research activities are early stage, we cannot provide specific timelines for if, or when, these activities may result in new clinical candidates.
Business update regarding COVID-19
The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting our employees, patients, communities and business operations, as well as the U.S. economy and financial markets. The full extent to which the COVID-19 pandemic will directly or indirectly affect our business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets.
20

To date, we have been able to continue our operations and do not anticipate any material interruptions for the foreseeable future. However, we are continuing to assess the potential impact of the COVID-19 pandemic on our business and operations, including our expenses, supply chain and pre-clinical and clinical trials.
Our third-party contract manufacturing partners continue to operate their manufacturing facilities at or near normal levels. While we currently do not anticipate any interruptions in our supply chain, it is possible that the COVID-19 pandemic and response efforts may have an impact in the future on our and/or our third-party suppliers and contract manufacturing partners' ability to manufacture our products or the products of our partners.
Financing and business operations
We commenced business operations in August 2006. To date, our operations have been limited to organizing and staffing our company, acquiring and developing our proprietary ATLAS technology, identifying potential product candidates, and undertaking preclinical studies and clinical trials for our product candidates. We have not generated any product revenue and do not expect to do so for the foreseeable future. We have financed our operations primarily through the issuance of our equity securities and through debt financings. As of March 31, 2021, we had received an aggregate of $447.5 million in net proceeds from the issuance of equity securities, we had outstanding borrowings of $10.5 million, and our cash and cash equivalents were $66.0 million.
Since inception, we have incurred significant operating losses. We expect to incur significant expenses and increasing operating losses for the foreseeable future. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year. We will need to generate significant revenue to achieve profitability, and we may never do so.
In January 2021, we entered into a sublease agreement for one floor of lab and office space through June 2022, with an option for the sublessee to extend the sublease for an additional two months. After the initial option, which is at the sublessee’s sole discretion, the sublease agreement contains additional options for us and the sublessee to mutually extend the sublease for up to an additional eighteen months. As we retained our obligations under the sublease, we are recording the payments received from the sublease as a reduction of lease expense. Sublease income was $0.4 million during the three months ended March 31, 2021.
On February 18, 2021 (the "2021 Loan Closing Date"), we entered into a Loan and Security Agreement (the "2021 Loan Agreement") with Silicon Valley Bank ("SVB") for a $10 million secured term loan (the "2021 Term Loan"). $9.0 million of the proceeds from the 2021 Term Loan were used to repay our borrowings that were outstanding at the 2021 Loan Closing Date under our previous loan and security agreement with Hercules Capital, Inc. (“Hercules”), paying off all obligations owing under, and extinguishing, the previous loan and security agreement with Hercules on the 2021 Loan Closing Date. The remaining proceeds from the 2021 Term Loan of $1.0 million were received by us for working capital and general corporate purposes.
We have an agreement with Cowen and Company, LLC ("Cowen") to establish an at-the-market equity offering program (“ATM”) pursuant to which Cowen is able to offer and sell up to $50.0 million of our common stock at prevailing market prices. In the three months ended March 31, 2021, we sold approximately 1.3 million shares under our ATM program and received net proceeds of $4.0 million, after deducting commissions. Through March 31, 2021, we have sold an aggregate of approximately 4.2 million shares under the ATM and received $13.8 million in net proceeds. As of March 31, 2021, we had $35.8 million in gross proceeds remaining under the ATM.
We have a purchase agreement with Lincoln Park Capital (“LPC”) pursuant to which, for a period of 30 months beginning in October 2019, we have the right, at our sole discretion, to sell up to $27.5 million of our common stock to LPC based on prevailing market prices of our common stock at the time of each sale. The purchase agreement limits our sales of shares of common stock to LPC to approximately 5.2 million shares of common stock, representing 19.99% of the shares of common stock outstanding on the date of the purchase agreement. The purchase agreement also prohibits us from directing LPC to purchase any shares of common stock if those shares, when aggregated with all other shares of our common stock then beneficially owned by LPC and its affiliates, would result in LPC and its affiliates having beneficial ownership, at any single point in time, of more than 9.99% of the then total outstanding shares of our common stock. As of March 31, 2021, we had $24.0 million remaining under our agreement with LPC.
As reflected in our condensed consolidated financial statements, we used cash of $12.4 million to fund operating activities for the three months ended March 31, 2021 and had $66.0 million available in cash and cash equivalents at March 31, 2021. In addition, we had an accumulated deficit of $386.7 million and anticipate that we will continue to incur significant operating losses for the foreseeable future as we continue to develop our product candidates. Until such time, if ever, as we attempt to generate substantial product revenue and achieve profitability, we expect to finance our cash needs through a combination of equity offerings and strategic transactions, and other sources of funding. If we are unable to raise additional funds when needed, we may be required to implement cost reduction strategies, including ceasing development of GEN-009, GEN-011 or other corporate programs and activities. Our available cash and cash equivalents at March 31, 2021 are expected to fund operations to mid-2022, and we have strategic plans to extend our operating cash to the end of 2022.
21

Costs related to clinical trials can be unpredictable and there can be no guarantee that our current balances of cash and cash equivalents, combined with proceeds received from other sources, will be sufficient to fund our trials or operations through this period. These funds will not be sufficient to enable us to conduct pivotal clinical trials for, seek marketing approval for, or commercially launch GEN-009, GEN-011 or any other product candidate. Accordingly, we will be required to obtain further funding through public or private equity offerings, collaboration and licensing arrangements, or other sources. Adequate additional financing may not be available to us on acceptable terms, or at all, which could result in a decision to pause or delay development or advancement of clinical trials for one or more of our product candidates. Similarly, we may decide to pause or delay development or advancement of clinical trials for one or more of our product candidates if we believe that such development or advancement is imprudent or impractical.
Financial Overview
Revenues
We have not generated any revenues from product sales to date, and we do not expect to generate revenues from product sales for the foreseeable future.
Research and development expenses
Research and development expenses consist primarily of costs incurred to advance our preclinical and clinical candidates, which include:
•salary and related expenses;
•expenses incurred under agreements with contract research organizations, contract manufacturing organizations, consultants, and other vendors that conduct our clinical trials and preclinical activities;
•costs of acquiring, developing, and manufacturing clinical trial materials and lab supplies; and
•facility costs, depreciation, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance, and other supplies.
The following table identifies research and development expenses for our product candidates as follows (in thousands):
 Three Months Ended March 31
 20212020
Phase 1/2a programs$5,776 $4,793 
Discovery and pre-IND1,786 3,809 
Other research and development1,189 1,385 
Total research and development$8,751 $9,987 
Phase 1/2a programs are Phase 1 or Phase 2 development activities. Discovery and pre-IND includes costs incurred to support our discovery research and translational science efforts up to the initiation of Phase 1 development. Other research and development include costs that are not specifically allocated to active programs, including facilities costs, depreciation expense, and other costs.
General and administrative expenses
General and administrative expenses consist primarily of salaries and related expenses for personnel in executive and other administrative functions. Other general and administrative expenses include facility costs, professional fees associated with consulting, corporate and intellectual property legal expenses, and accounting services.
Other income/(expense)
Other income/(expense) consists of the change in the fair value of the warrant liability, transaction expenses, interest expense, net of interest income, gains and losses on sale and disposal of assets, and gains and losses on foreign currency.
Critical Accounting Policies and Significant Judgments and Estimates
Our critical accounting policies have not changed from those described in the 2020 10-K.
22

Results of Operations
Comparison of the three months ended March 31, 2021 and 2020
Research and development expenses
Three Months Ended March 31
20212020
(in thousands)
Research and development$8,751 $9,987 
Research and development expenses decreased $1.2 million in the three months ended March 31, 2021, as compared to the three months ended March 31, 2020. The decrease was largely due to decreased external manufacturing costs of $1.3 million, lower clinical costs of $0.3 million and decreased costs for lab supplies of $0.2 million, partially offset by increased headcount-related costs of $0.6 million.
General and administrative expenses
Three Months Ended March 31
20212020
(in thousands)
General and administrative$3,671 $3,388 
General and administrative expenses increased $0.3 million in the three months ended March 31, 2021, as compared to the three months ended March 31, 2020. The increase was primarily due to an increase in headcount-related costs of $0.4 million and higher professional services fees of $0.2 million, partially offset by decreased rent expense, net of sublease income, of $0.3 million.
Change in fair value of warrants
Three Months Ended March 31
20212020
(in thousands)
Change in fair value of warrants$854 $781 
Change in fair value of warrants reflects the non-cash change in the fair value of the 2020 Warrants and the 2018 Warrants, which are recorded at their fair value on the date of issuance and then remeasured at the end of each reporting period. In the three months ended March 31, 2021, the change in the fair value of warrants was primarily attributed to the increase in our stock price between December 31, 2020 and March 31, 2021.
Interest expense, net
Three Months Ended March 31
20212020
(in thousands)
Interest expense, net$279 $259 
Interest expense, net, consists primarily of interest expense on our long-term debt facilities, partially offset by interest earned on our cash equivalents.
Other expense
Three Months Ended March 31
20212020
(in thousands)
Other expense$136 $— 
Other expense consists primarily of debt prepayment and extinguishment costs.
Liquidity and Capital Resources
Overview
Since our inception in 2006, we have funded operations primarily through proceeds from issuances of common stock and long-term debt.
As of March 31, 2021, we had $66.0 million in cash and cash equivalents.
23

In April 2018, we entered into an amended and restated loan and security agreement, which was subsequently amended in November 2019 (as amended, the “Hercules Loan Agreement”), with Hercules. The Hercules Loan Agreement provided a $14.0 million secured term loan that was scheduled to mature on May 1, 2021 and that accrued interest at a floating rate per annum equal to the greater of (i) 8.00%, or (ii) the sum of 3.00% plus the prime rate. We were also obligated to pay a final payment charge of $1.0 million at maturity.
On the 2021 Loan Closing Date, we entered into the 2021 Loan Agreement with SVB for the $10 million 2021 Term Loan. $9.0 million of the proceeds from the 2021 Term Loan were used to repay our borrowings that were outstanding at the 2021 Loan Closing Date under the Hercules Loan Agreement, paying off all obligations owing under, and extinguishing, the Hercules Loan Agreement, on the 2021 Loan Closing Date. The remaining proceeds from the 2021 Term Loan of $1.0 million were received by us for working capital and general corporate purposes.
We have not generated any revenues from product sales to date, and we do not expect to generate revenues from product sales for the foreseeable future.
We have an agreement with Cowen to establish an ATM program pursuant to which Cowen is able to offer and sell up to $50.0 million of our common stock at prevailing market prices. In the three months ended March 31, 2021, we sold approximately 1.3 million shares under our ATM program and received net proceeds of $4.0 million, after deducting commissions. Through March 31, 2021, we have sold an aggregate of approximately 4.2 million shares under the ATM and received $13.8 million in net proceeds. As of March 31, 2021, we had $35.8 million in gross proceeds remaining under the ATM.
We have a purchase agreement with LPC pursuant to which, for a period of 30 months beginning in October 2019, we have the right, at our sole discretion, to sell up to $27.5 million of our common stock to LPC based on prevailing market prices of our common stock at the time of each sale. The purchase agreement limits our sales of shares of common stock to LPC to approximately 5.2 million shares of common stock, representing 19.99% of the shares of common stock outstanding on the date of the purchase agreement. The purchase agreement also prohibits us from directing LPC to purchase any shares of common stock if those shares, when aggregated with all other shares of our common stock then beneficially owned by LPC and its affiliates, would result in LPC and its affiliates having beneficial ownership, at any single point in time, of more than 9.99% of the then total outstanding shares of our common stock. As of March 31, 2021, we had $24.0 million remaining under our agreement with LPC.
Cash flows from operating activities
Cash flows from operating activities consist of our net loss adjusted for various non-cash items, changes in working capital and changes in certain other balance sheet accounts. Cash used in operating activities for the three months ended March 31, 2021 and 2020 was $12.4 million and $13.8 million, respectively. Cash used in operating activities decreased $1.4 million for the three months ended March 31, 2021 compared to the three months ended March 31, 2020, primarily due to a decrease in our research and development expenses due to lower clinical and external development costs for GEN-009.
Cash flows from investing activities
Investing activities consumed $1.0 million of cash in three months ended March 31, 2021 compared to $0.2 million in three months ended March 31, 2020. Cash used by investing activities was primarily for purchases of property and equipment in both of the three months ended March 31, 2021 and 2020.
Cash flows from financing activities
Financing activities used $0.3 million in the three months ended March 31, 2021 compared to $0.4 million provided in the three months ended March 31, 2020. In the three months ended March 31, 2021, we repaid $14.0 million in long-term debt and paid deferred financing charges of $0.3 million, partially offset by the issuance of long-term debt for proceeds of $10.0 million and the issuance of shares under our ATM program for net proceeds of $4.0 million. In the three months ended March 31, 2020, we issued shares of common stock to LPC for net proceeds of $0.4 million.
Operating capital requirements
Our primary uses of capital are for payroll and employee-related expenses, manufacturing costs for preclinical and clinical materials, third-party clinical trial services, laboratory and related supplies, legal and other regulatory expenses, and general overhead costs. We expect these costs will continue to be the primary operating capital requirements for the near future.
We expect that our existing cash and cash equivalents are sufficient to support our operations to mid-2022, and we have strategic plans to extend our operating cash to the end of 2022. We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products coupled with the global economic uncertainty that has arisen with the outbreak of the coronavirus, or referred to as COVID-19, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:
•the timing and costs of our planned clinical trials for GEN- 011;
24

•the progress, timing, and costs of manufacturing GEN-011;
•the timing of GEN-011 patient enrollment and dosing;
•the availability of GEN-011 third-party manufacturing capacity;
•the timing and costs we require to perform monitoring activities to support the GEN-009 clinical trial;
•the initiation, progress, timing, costs, and results of preclinical studies and clinical trials for our other product candidates and potential product candidates;
•the terms and timing of any future collaborations, grants, licensing, consulting, or other arrangements that we may establish;
•the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights, including milestone payments, royalty payments and patent prosecution fees that we are obligated to pay pursuant to our license agreements;
•the costs of preparing, filing, and prosecuting patent applications, maintaining and protecting our intellectual property rights, and defending against intellectual property related claims;
•the extent to which we in-license or acquire other products and technologies;
•the receipt of marketing approval;
•the costs of commercialization activities for GEN-009, GEN-011 and other product candidates, if we receive marketing approval, including the costs and timing of establishing product sales, marketing, distribution, and manufacturing capabilities; and
•revenue received from commercial sales of our product candidates.
We will need to obtain substantial additional funding in order to complete clinical trials and receive regulatory approval for GEN-009, GEN-011 and our other product candidates. To the extent that we raise additional capital through the sale of our common stock, convertible securities, or other equity securities, the ownership interests of our existing stockholders may be materially diluted and the terms of these securities could include liquidation or other preferences that could adversely affect the rights of our existing stockholders. If we are unable to raise capital when needed or on attractive terms, we could be forced to significantly delay, scale back, or discontinue the development of GEN-009, GEN-011 or our other product candidates, seek collaborators at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available, and relinquish or license, potentially on unfavorable terms, our rights to GEN-009, GEN-011 or our other product candidates that we otherwise would seek to develop or commercialize ourselves.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements.
Item 3.        Quantitative and Qualitative Disclosures about Market Risk
We had cash and cash equivalents of $66.0 million as of March 31, 2021. The primary objectives of our investment activities are to preserve principal, provide liquidity and maximize income without significantly increasing risk. Our primary exposure to market risk relates to fluctuations in interest rates, which are affected by changes in the general level of U.S. interest rates. Given the short-term nature of our cash and cash equivalents, we believe that a sudden change in market interest rates would not be expected to have a material impact on our financial condition and/or results of operations. We do not own any derivative financial instruments.
We do not believe that our cash and cash equivalents have significant risk of default or illiquidity. While we believe our cash and cash equivalents do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits.
We currently do not have significant exposure to foreign currencies as we hold no foreign exchange contracts, option contracts, or other foreign hedging arrangements. Further, our operations are primarily denominated in U.S. dollars. Our operations may be subject to fluctuations in foreign currency exchange rates in the future.
Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our results of operations during the three months ended March 31, 2021.
25

Item 4.        Controls and Procedures
Management’s Evaluation of our Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), is (1) recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.
Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2021 (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of March 31, 2021, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control Over Financial Reporting
During the three months ended March 31, 2021, there have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15(d)-15(f) promulgated under the Exchange Act that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
26

PART II. OTHER INFORMATION
Item 1.        Legal Proceedings
In the ordinary course of business, we are from time to time involved in lawsuits, claims, investigations, proceedings, and threats of litigation relating to intellectual property, commercial arrangements and other matters. We do not believe we are currently party to any pending legal action, arbitration proceeding or governmental proceeding, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business or operating results. We are not a party to any material proceedings in which any director, member of senior management or affiliate of ours is either a party adverse to us or our subsidiaries or has a material interest adverse to us or our subsidiaries.
Item 1A.    Risk Factors
There have been no material changes from the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2020.
27

Item 6.        Exhibits
Exhibit
Number		Exhibit
3.1
3.2
3.3
3.4
3.5
10.1*†
31.1*
31.2*
32**
101.INS*Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document
101.SCH*Inline XBRL Taxonomy Extension Schema Document.
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*Cover Page Interactive Date File (embedded within the Inline XBRL document)
_________________________
*    Filed herewith
**    Furnished herewith
†    Indicates a management contract or compensatory plan
28

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 Genocea Biosciences, Inc.
  
Date: April 29, 2021By:/s/ WILLIAM D. CLARK
  William D. Clark
  President and Chief Executive Officer and Director
(Principal Executive Officer)
Date: April 29, 2021By:/s/ DIANTHA DUVALL
  Diantha Duvall
  Chief Financial Officer
(Principal Financial and Accounting Officer)
29
 EX-10.1 2 a2021q1ex101.htm EX-10.1 Document

Name of Grantee:
[_________]
Target Number of PSUs:
[_________]
Date of Grant:
[_________]
Genocea Biosciences, Inc.
2014 Equity Incentive Plan
Performance-Based Restricted Stock Unit Award Agreement
This agreement (this “Agreement”) evidences an award (the “Award”) of performance-based restricted stock units granted by Genocea Biosciences, Inc. (the “Company”) to the individual named above (the “Grantee”), pursuant to and subject to the terms of the Genocea Biosciences, Inc. 2014 Equity Incentive Plan (as amended from time to time, the “Plan”).
1.Grant of PSUs. The Company grants to the Grantee on the date set forth above (the “Date of Grant”) the target number of performance-based Restricted Stock Units (the “PSUs”) set forth above (the “Target Award”), giving the Grantee the conditional right to receive, without payment and pursuant to and subject to the terms set forth in this Agreement and in the Plan, one share of Stock (a “Share”) with respect to each PSU forming part of the Award, subject to adjustment pursuant to Section 7(b) of the Plan in respect of transactions occurring after the date hereof. The percentage of the Target Award that may be earned by the Grantee will be determined in accordance with Exhibit A hereto.
2.Meaning of Certain Terms. Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan. The following terms have the following meanings:
(a)“Beneficiary” means, in the event of the Grantee’s death, the beneficiary named in the written designation (in a form acceptable to the Administrator) most recently filed with the Administrator by the Grantee prior to the Grantee’s death and not subsequently revoked, or, if there is no such designated beneficiary, the executor or administrator of the Grantee’s estate. An effective beneficiary designation will be treated as having been revoked only upon receipt by the Administrator, prior to the Grantee’s death, of an instrument of revocation in form acceptable to the Administrator.
3.Earning; Vesting; Cessation of Employment.
(a)Earned PSUs. The PSUs shall become “Earned PSUs” following the end of the Performance Period (as defined in Exhibit A) to the extent earned in accordance with the performance criteria set forth on Exhibit A (the “Performance Criteria”), based on the Administrator’s determination, in its sole discretion, of the level of achievement of the Performance Criteria.
(b)Vesting of Earned PSUs. Unless earlier terminated, forfeited, relinquished or expired, the Earned PSUs will vest in full on the date on or following the end of the Performance Period on which the Administrator determines the extent to which, if any, the Performance Criteria have been met and the number of Earned PSUs (not later than January 31, 2024) (the “Vesting Date”), subject to the Grantee remaining in continuous Employment from the Date of Grant through the Vesting Date except as described in Section 2(c) below.
(c)Cessation of Employment. Automatically and immediately upon the cessation of the Grantee’s Employment, except as expressly provided for in an employment, severance-benefit or other agreement between the Grantee and the Company that is in effect at the time of such termination of Employment, (i) the unvested portion of the Award will terminate and be forfeited for no consideration, and (ii) the vested portion of the Award, if any, will terminate and be forfeited for no consideration if the Grantee’s Employment is terminated in connection with an act or failure to act constituting Cause (as the Administrator, in its sole discretion, may determine), or such termination of Employment occurs in circumstances that in the determination of the Administrator would have entitled the Company and its subsidiaries to terminate the Grantee’s Employment for Cause.
4.Delivery of Shares. Subject to Section 5 below, the Company shall, as soon as practicable upon the vesting of any PSUs (but in no event later than March 15th of the year following the year in which such PSUs vest), effect delivery of the Shares with respect to such vested PSUs to the Grantee (or, in the event of the Grantee’s death following the vesting of such portion of the Award, to the Grantee’s Beneficiary). No Shares will be issued pursuant to the Award unless and until all legal requirements applicable to the issuance or transfer of such Shares have been complied with to the satisfaction of the Administrator.
5.Forfeiture; Recovery of Compensation. The Administrator may cancel, rescind, withhold or otherwise limit or restrict the Award at any time if the Grantee is not in compliance with all applicable provisions of this Agreement and the Plan. By accepting, or being deemed to have accepted, the Award, the Grantee expressly acknowledges and agrees that his or her rights, and those of any Beneficiary or permitted transferee of the Award, under the Award, including the right to any Shares acquired under the Award or proceeds from the disposition thereof, are subject to Section 6(a)(5) of the Plan (including any successor provision). The Grantee further agrees to be bound by the terms of any clawback, recoupment or similar policy of the Company or any of its Affiliates and any policy of the Company or any of its Affiliates that relates to trading on non-public information and permitted transactions with respect to shares of Stock, including limitations on hedging and pledging. Nothing in the preceding sentence will be construed as limiting the general application of Section 10 of this Agreement.
6.Dividends; Other Rights. The Award may not be interpreted to bestow upon the Grantee any equity interest or ownership in the Company or any subsidiary prior to the date on which the Company delivers Shares to the Grantee. The Grantee is not entitled to vote any Shares by reason of the granting of the Award or to receive or be credited with any dividends declared and payable on any Share prior to the date on which any such Share is delivered to the Grantee hereunder. The Grantee will have the rights of a shareholder only as to those Shares, if any, that are actually delivered under the Award.
7.Nontransferability. The Award may not be transferred except as expressly permitted under Section 6(a)(3) of the Plan.
-2-
8.Withholding. The Grantee expressly acknowledges that the vesting or settlement of the PSUs granted hereunder may give rise to “wages” subject to withholding. The Grantee expressly acknowledges and agrees that the Grantee’s rights hereunder, including the right to receive Shares following the vesting of any portion of the Award, are subject to the satisfaction of all taxes required to be withheld with respect to the Award. Unless otherwise determined by the Company, the Company shall automatically satisfy these tax withholding obligations by withholding from the Shares that would otherwise be delivered in connection with such vesting date a number of Shares having a fair market value equal to the minimum statutory amount required to be withheld to satisfy such tax withholding obligations and/or by causing such number of Shares to be sold in accordance with a sell-to-cover arrangement. The Grantee authorizes the Company and its subsidiaries to withhold any amounts due in respect of any required tax withholdings by withholding from the Shares otherwise deliverable in connection with this Award, by causing such Shares to be sold in accordance with a sell-to-cover arrangement and/or by withholding from any amounts otherwise owed to the Grantee. The Grantee acknowledges and agrees that he or she shall be solely responsible for any brokerage or third-party fees associated with any such sell-to-cover arrangement. Nothing in this Section 8 shall be construed as relieving the Grantee of any liability for satisfying his or her tax obligations relating to the Award.
9.Effect on Employment. Neither the grant of the Award, nor the issuance of Shares upon the vesting of the Award, will give the Grantee any right to be retained in the employ or service of the Company or any of its subsidiaries, affect the right of the Company or any of its subsidiaries to terminate the Employment of the Grantee at any time, or affect any right of the Grantee to terminate his or her Employment at any time.
10.Provisions of the Plan. This Agreement is subject in its entirety to the provisions of the Plan, which are incorporated herein by reference. A copy of the Plan as in effect on the Date of Grant has been furnished to the Grantee. By accepting, or being deemed to have accepted, all or any portion of the Award, the Grantee agrees to be bound by the terms of the Plan and this Agreement. In the event of any conflict between the terms of this Agreement and the Plan, the terms of the Plan will control.
11.Acknowledgements. The Grantee acknowledges and agrees that (i) this Agreement may be executed in two or more counterparts, each of which will be an original and all of which together will constitute one and the same instrument, (ii) this Agreement may be executed and exchanged using facsimile, portable document format (PDF) or electronic signature, which, in each case, will constitute an original signature for all purposes hereunder, and (iii) such signature by the Company will be binding against the Company and will create a legally binding agreement when this Agreement is countersigned by the Grantee.

[Signature page follows.]
-3-
    The Company, by its duly authorized officer, and the Grantee have executed this Agreement.
                            
                            GENOCEA BIOSCIENCES, INC.

By: ______________________________
Name: ___________________________
Title: ______________________________
Agreed and Accepted:

By_______________________________
Signature Page to Performance-Based Restricted Stock Unit Award Agreement


Exhibit A
Performance Criteria

1.General. The Target Award will be eligible to be earned subject to the terms and conditions of Section 3 of this Exhibit A based on the Stock Price at the end of the Performance Period. Stock Price shall be the Performance Criterion under the Award.
2.Definitions. The terms set forth below, as used in this Exhibit A, shall the following meanings:
(a)“Performance Period” shall mean the period beginning on the Performance Period Start Date and ending on the Performance Period End Date or, if earlier, the consummation of a Covered Transaction.
(b)“Performance Period End Date” shall mean December 31, 2023.
(c)“Performance Period Start Date” shall mean the Date of Grant.
(d)“Stock Price” means the average closing price of a share of Stock over the sixty (60)-trading days immediately preceding the Performance Period End Date or, if a Covered Transaction is consummated on or before the Performance Period End Date, the closing price of a share of Stock on the date such Covered Transaction is consummated.
3.Earning of PSUs. No PSUs shall become earned unless the Stock Price equals or exceeds $7.00* as of the end of the Performance Period. If the Stock Price equals or exceeds $7.00* as of the end of the Performance Period, the number of PSUs that become Earned PSUs shall be equal to the number of PSUs subject to the Target Award multiplied by the “Applicable Percentage” set forth in the table below. In the event that the Stock Price falls between two of the prices listed in the table below at the end of the Performance Period, the Applicable Percentage shall be interpolated on a straight-line basis and the percentage of the Target Award earned shall be based on such interpolated percentage. If Stock Price equals or exceeds $12.00* as of the end of the Performance Period, the Applicable Percentage shall be one hundred and fifty percent (150%).
Stock Price*Applicable Percentage
$7.0075%
$8.00100%
$10.00125%
$12.00150%
*Subject to adjustment in accordance with the Plan.




4.Determinations by Administrator. At the end of the Performance Period, the Administrator shall determine the extent to which, if any, the Performance Criterion have been met and the number of PSUs that are earned hereunder. Any PSUs that are earned hereunder or that are deemed earned are referred to as “Earned PSUs”. Other than in connection with a Covered Transaction as set forth in the Plan, no PSUs shall be earned and shall vest until the Administrator determines that the Performance Criteria have been met and determines the extent to which they have so been met. The Administrator shall make such determination not later than January 31st following the end of the Performance Period. Earned PSUs shall vest and be settled as set forth in the Agreement. All determinations under this Exhibit A shall be made by the Administrator and will be final and binding on the Grantee.



EX-31.1 3 a2021q1ex311.htm EX-31.1 Document
Exhibit 31.1
PRINCIPAL EXECUTIVE OFFICER CERTIFICATION 
I, William D. Clark, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Genocea Biosciences, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
 /s/ WILLIAM D. CLARK
 William D. Clark
 President and Chief Executive Officer and Director
 (Principal Executive Officer)
Date:April 29, 2021 


 EX-31.2 4 a2021q1ex312.htm EX-31.2 Document
Exhibit 31.2
PRINCIPAL FINANCIAL OFFICER CERTIFICATION 
I, Diantha Duvall, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Genocea Biosciences, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 /s/ DIANTHA DUVALL
 Diantha Duvall
 Chief Financial Officer
 
Date:April 29, 2021 


 EX-32 5 a2021q1ex32.htm EX-32 Document
Exhibit 32
CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002 
I, William D. Clark, certify to the best of my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Genocea Biosciences, Inc. on Form 10-Q for the three months ended March 31, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-Q fairly presents in all material respects the financial condition and results of operations of Genocea Biosciences, Inc. at the dates and for the periods indicated.
 /s/ WILLIAM D. CLARK
 William D. Clark
 President and Chief Executive Officer and Director
  
Date:April 29, 2021 
I, Diantha Duvall, certify to the best of my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Genocea Biosciences, Inc. on Form 10-Q for the three months ended March 31, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-Q fairly presents in all material respects the financial condition and results of operations of Genocea Biosciences, Inc. at the dates and for the periods indicated.
 /s/ DIANTHA DUVALL
 Diantha Duvall
 Chief Financial Officer
  
Date:April 29, 2021 

 EX-101.SCH 6 gnca-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Consolidated Consolidated Statements of Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization and operations link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Organization and operations (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2105103 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2107104 - Disclosure - Fair value of financial instruments link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Fair value of financial instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Fair value of financial instruments - Schedule of cash equivalents and investments carried at fair value (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Fair value of financial instruments - Change in the Company’s Level 3 Warrant liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2111105 - Disclosure - Accrued expenses and other current liabilities link:presentationLink link:calculationLink link:definitionLink 2312302 - Disclosure - Accrued expenses and other current liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - Accrued expenses and other current liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2114106 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 2315303 - Disclosure - Commitments and contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2416406 - Disclosure - Commitments and contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2417407 - Disclosure - Commitments and contingencies - Operating Lease Term and Discount Rate (Details) link:presentationLink link:calculationLink link:definitionLink 2418408 - Disclosure - Commitments and contingencies - Supplemental Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 2419409 - Disclosure - Commitments and contingencies - Future minimum lease payments (Details) link:presentationLink link:calculationLink link:definitionLink 2120107 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2321304 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2422410 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2423411 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2124108 - Disclosure - Stockholders' equity link:presentationLink link:calculationLink link:definitionLink 2425412 - Disclosure - Stockholders' equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2126109 - Disclosure - Warrants Warrants link:presentationLink link:calculationLink link:definitionLink 2327305 - Disclosure - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 2428413 - Disclosure - Warrants - Issuable Shares of Common Stock Related to Unexercised Warrants Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 2429414 - Disclosure - Warrants - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2430415 - Disclosure - Warrants - Fair Value Warrant Liability Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2131110 - Disclosure - Employee benefit plans link:presentationLink link:calculationLink link:definitionLink 2332306 - Disclosure - Employee benefit plans (Tables) link:presentationLink link:calculationLink link:definitionLink 2433416 - Disclosure - Employee benefit plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2434417 - Disclosure - Employee benefit plans - Weighted-average assumptions used (Details) link:presentationLink link:calculationLink link:definitionLink 2435418 - Disclosure - Employee benefit plans - Stock based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 2436419 - Disclosure - Employee benefit plans - Stock option activity (Details) link:presentationLink link:calculationLink link:definitionLink 2137111 - Disclosure - Net loss per share link:presentationLink link:calculationLink link:definitionLink 2338307 - Disclosure - Net loss per share (Tables) link:presentationLink link:calculationLink link:definitionLink 2439420 - Disclosure - Net loss per share - Schedule of earnings per share, basic and diluted (Details) link:presentationLink link:calculationLink link:definitionLink 2440421 - Disclosure - Net loss per share - Attributable to common stockholders (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 gnca-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 gnca-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 gnca-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Type Document Type Outstanding at the beginning of the period (in dollars) Outstanding at the end of the period (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Other expense Other Nonoperating Income (Expense) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Payables and Accruals [Abstract] Payables and Accruals [Abstract] 2020 Warrants 2020 Warrants [Member] 2020 Warrants Level 3 Fair Value, Inputs, Level 3 [Member] Total Finance and Operating Lease, Liability Finance and Operating Lease, Liability Schedule of Stockholders' Equity Note, Warrants or Rights Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Debt Instrument, Covenant Compliance, Prepayment Charge, Period Three, Percent Debt Instrument, Covenant Compliance, Prepayment Charge, Period Three, Percent Debt Instrument, Covenant Compliance, Prepayment Charge, Period Three, Percent Statistical Measurement [Domain] Statistical Measurement [Domain] Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Line of Credit Line of Credit [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock option activity for employees and nonemployees Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Proceeds from long-term debt Proceeds from Issuance of Debt Preferred Shares Preferred Stock [Member] Security Exchange Name Security Exchange Name Forfeited/cancelled, Weighted-Average Grant Date Fair Value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value Loss from operations Operating Income (Loss) Total current liabilities Liabilities, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Variable Rate [Domain] Variable Rate [Domain] Variable Rate [Axis] Variable Rate [Axis] Commitments and contingencies (Note 6) Commitments and Contingencies Assets Assets [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Entity Address, State or Province Entity Address, State or Province Cash paid in connection with operating lease liabilities Operating Lease, Payments Accounts payable Accounts Payable, Current Sublease Income Sublease Income Accumulated deficit Retained Earnings (Accumulated Deficit) Operating lease, right-of-use asset Operating Lease, Right-of-Use Asset 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Customer [Axis] Customer [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Total operating expenses Operating Expenses Exercisable at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Debt prepayment costs Payment for Debt Extinguishment or Debt Prepayment Cost Payment of deferred financing costs Payments of Financing Costs Payments on finance lease Finance Lease, Principal Payments Issuance of common stock under employee benefit plans Stock Issued During Period, Value, Employee Benefit Plan 2014 Term Loan, First Tranche Term Loan2014 Tranche1 [Member] Represents information pertaining to the first tranche of the 2014 Term Loan. Annual acquisition event probability Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Annual Acquisition Event Probability Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Annual Acquisition Event Probability Liability Class [Axis] Liability Class [Axis] Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Amended and Restated 2014 Equity Incentive Plan Amended and Restated 2014 Equity Incentive Plan [Member] Amended and Restated 2014 Equity Incentive Plan [Member] Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) Hercules Warrant Second Warrant [Member] Second Warrant [Member] Measurement Frequency [Domain] Measurement Frequency [Domain] Share price (in dollars per share) Share Price Lease Assets [Abstract] Lease Assets [Abstract] Lease Assets [Abstract] Statement [Line Items] Statement [Line Items] Schedule of common stock equivalents, presented on converted basis, were excluded from calculation of net loss per share due to anti-dilutive effect Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Class of Stock [Domain] Class of Stock [Domain] Net loss per share: Earnings Per Share, Basic and Diluted [Abstract] Warrants [Abstract] Warrants [Abstract] Warrants [Abstract] Proceeds from sale of equipment Proceeds from Sale of Machinery and Equipment Vested, Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Measurement Input Type [Domain] Measurement Input Type [Domain] Statement [Table] Statement [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Preferred stock, shares issued (in dollars per share) Preferred Stock, Shares Issued Assets And Liabilities, Lessee Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Warrant liabilities Derivative Liability, Noncurrent Exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Debt Instrument, Covenant Compliance, Prepayment Charge, Period Two, Percent Debt Instrument, Covenant Compliance, Prepayment Charge, Period Two, Percent Debt Instrument, Covenant Compliance, Prepayment Charge, Period Two, Percent Entity Small Business Entity Small Business Lessee, Operating Lease, Liability, Payment, Due [Abstract] Lessee, Operating Lease, Liability, Payment, Due [Abstract] Increase (Decrease) in Redeemable Convertible Preferred Stock and Stockholders' (Deficit) Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Licensing agreement, amount Commitments and Contingencies, Licensing Agreement, Amount Commitments and Contingencies, Licensing Agreement, Amount Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Exercisable at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Proceeds from issuance of common stock, net Proceeds from issuance of common stock Proceeds from Issuance of Common Stock 2018 Term Loan 2018 Term Loan Agreement [Member] 2018 Term Loan Agreement [Member] Amendment Flag Amendment Flag Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Fair value of each employee stock award on the grant date and the assumptions regarding the fair value of the underlying common stock Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Disclosure of Share-based Compensation Arrangements by Share-based Payment Award Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Lease Liabilities [Abstract] Lease Liabilities [Abstract] Lease Liabilities [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Beginning Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Ending Balance Issuance of Warrants Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 2019 Warrants Initial Closing Private Placement Warrants [Member] Initial Closing Private Placement Warrants [Member] Outstanding borrowings Long-term Line of Credit Repayment of long-term debt Repayments of Debt Repayments of Debt 2014 Term Loan Term Loan2014 [Member] Represents information pertaining to the 2014 Term Loan. Net cash used in operating activities Cash used in operating activities Net Cash Provided by (Used in) Operating Activities Entity Central Index Key Entity Central Index Key Measurement Frequency [Axis] Measurement Frequency [Axis] Proceeds from Loans Proceeds from Loans Issuance of common stock under employee benefit plans (in shares) Stock Issued During Period, Shares, Employee Benefit Plan Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Warrants Warrants Disclosure [Text Block] Represents the entire disclosure pertaining to warrants. Property and equipment included in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Change in fair value of warrant liability Fair Value Adjustment of Warrants Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Dilutive effect of shares of common stock equivalents (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] ESPP Employee Stock [Member] Income Statement Location [Axis] Income Statement Location [Axis] Expected dividend yield Measurement Input, Expected Dividend Rate [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Income Statement Location [Domain] Income Statement Location [Domain] Accrued expenses and other current liabilities Accrued Expenses and Other Current Liabilities Accrued Expenses and Other Current Liabilities Represents the amount of total accrued expenses and other current liabilities which are due within one year or within the normal operating cycle if longer. 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two 2018 Warrants Public Offering Warrants [Member] Public Offering Warrants [Member] Lease, Cost Lease, Cost [Table Text Block] Number of floors leased Operating Lease, Number of Floors Operating Lease, Number of Floors 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Other non-current assets Other Assets, Noncurrent Plan Name [Axis] Plan Name [Axis] Shares outstanding of affiliate beneficial ownership, agreement threshold, percent Common Stock, Shares Outstanding of Affiliate Beneficial Ownership, Agreement Threshold, Percent Common Stock, Shares Outstanding of Affiliate Beneficial Ownership, Agreement Threshold, Percent Issuance of common stock, net Stock Issued During Period, Value, New Issues Included in cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Financial Liabilities Fair Value Disclosure, Total Financial Liabilities Fair Value Disclosure Total assets Assets Interest expense Interest Expense, Debt At-the-market equity offering program At-The-Market Equity Offering Program [Member] At-The-Market Equity Offering Program [Member] Title of 12(b) Security Title of 12(b) Security Schedule of accrued expenses and other current liabilities Schedule of Accrued Liabilities [Table Text Block] Granted, Weighted-Average Grant Date Fair Value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Stockholders' equity Common Stock Number of Shares Par Value and Other Disclosures [Text Block] The entire disclosure regarding common stock of the entity. Antidilutive Securities [Axis] Antidilutive Securities [Axis] Stock price Measurement Input, Share Price [Member] Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award Options Outstanding Aggregate Intrinsic Value [Abstract] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Interest expense, net Interest Expense Sale of stock, consideration received on transaction Sale of Stock, Consideration Received on Transaction Product and Service [Axis] Product and Service [Axis] Total liabilities Liabilities Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2023 Long-Term Debt, Maturity, Year Two Net Income (Loss) Available to Common Stockholders, Basic, Total Net Income (Loss) Available to Common Stockholders, Basic Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Proceeds from issuance of common stock under employee benefit plans Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised Level 1 Fair Value, Inputs, Level 1 [Member] Operating lease expense Operating Lease, Expense Licensing agreement, milestone payment, amount Commitments and Contingencies, Licensing Agreement, Milestone Payment, Amount Commitments and Contingencies, Licensing Agreement, Milestone Payment, Amount Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Changes in operating assets and liabilities Increase (Decrease) in Other Operating Assets and Liabilities, Net Change in fair value of warrants Unrealized Gain (Loss) on Derivatives SVB Warrant SVB Warrant [Member] SVB Warrant Vested, Weighted-Average Grant Date Fair Value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Debt Instrument [Axis] Debt Instrument [Axis] Additional Paid-In Capital Additional Paid-in Capital [Member] Preferred Stock Dividends and Other Adjustments Preferred Stock Dividends and Other Adjustments Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Remaining term (years) Measurement Input, Expected Term [Member] Payments for Other Operating Activities Other Operating Activities, Cash Flow Statement Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Class of Stock [Line Items] Class of Stock [Line Items] Warrant liabilities Derivative Liability Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Balance - Stockholders' Equity (Deficit) (in shares) Balance - Stockholders' Equity (Deficit) (in shares) Shares, Issued 2018 Warrants 2018 Warrants [Member] 2018 Warrants Fair value of financial instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Lease Liabilities, Current [Abstract] Lease Liabilities, Current [Abstract] Lease Liabilities, Current [Abstract] Research and development Research and Development Expense Outstanding at the beginning of the period (in dollars per share) Outstanding at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Notes Payable to Banks Notes Payable to Banks [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Income Statement [Abstract] Income Statement [Abstract] 2020 Pre-Funded Warrants 2020 Pre-Funded Warrants [Member] 2020 Pre-Funded Warrants Debt Instrument, Interest Rate, Default Rate, Additional Annual Interest Rate, Percent Debt Instrument, Interest Rate, Default Rate, Additional Annual Interest Rate, Percent Debt Instrument, Interest Rate, Default Rate, Additional Annual Interest Rate, Percent Operating Lease, Liability, Noncurrent Operating Lease, Liability, Noncurrent Current assets: Assets, Current [Abstract] Investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Acquisition event probability Measurement Input, Acquisition Event Probability [Member] Measurement Input, Acquisition Event Probability [Member] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Patents Patents [Member] Shionogi & Co., Ltd. Shionogi & Co., Ltd. [Member] Shionogi & Co., Ltd. [Member] Preferred stock, par or stated value per share (in dollars per share) Preferred Stock, Par or Stated Value Per Share 2022 Long-Term Debt, Maturity, Year One Legal Entity [Axis] Legal Entity [Axis] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment City Area Code City Area Code Document Period End Date Document Period End Date Debt Long-term Debt [Text Block] Shares reserved for future issuance Common Stock, Capital Shares Reserved for Future Issuance Beginning Balance, Weighted-Average Grant Date Fair Value (in dollars per share) Ending Balance, Weighted-Average Grant Date Fair Value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Stock-based compensation Share-based Payment Arrangement, Noncash Expense Entity [Domain] Entity [Domain] 1250000 Long-Term Debt, Maturity, Remainder of Fiscal Year Cover [Abstract] Cover [Abstract] Purchase agreement period (in months) Long-term Purchase Commitment, Period Measurement Input Type [Axis] Measurement Input Type [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Debt Instrument, Covenant Compliance, Prepayment Charge, Period One, Percent Debt Instrument, Covenant Compliance, Prepayment Charge, Period One, Percent Debt Instrument, Covenant Compliance, Prepayment Charge, Period One, Percent Restricted cash and cash equivalents Restricted Cash and Cash Equivalents Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Equity Components [Axis] Equity Components [Axis] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Minimum Minimum [Member] Operating Lease, Liability, Current Operating Lease, Liability, Current Forfeited/cancelled, Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares Right-of-use asset obtained in exchange for lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Entity Interactive Data Current Entity Interactive Data Current Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Fair value of financial instruments Fair Value Disclosures [Text Block] Schedule of stock option activity for employees and nonemployees Share-based Payment Arrangement, Option, Activity [Table Text Block] Customer [Domain] Customer [Domain] Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Master Facilities Operating Lease Due February 28, 2025 Master Facilities Operating Lease Due February 28, 2025 [Member] Master Facilities Operating Lease Due February 28, 2025 [Member] Entity Registrant Name Entity Registrant Name Beginning Balance (in shares) Ending Balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Assets, Fair Value Disclosure [Abstract] Assets, Fair Value Disclosure [Abstract] Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Research and development Research and Development Expense [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Total lease payments Lessee, Operating Lease, Liability, to be Paid End of term charge Debt Instrument, End Of Term Charge Debt Instrument, End Of Term Charge Shares outstanding, agreement threshold, percent Common Stock, Shares Outstanding, Agreement Threshold, Percent Common Stock, Shares Outstanding, Agreement Threshold, Percent Sale of Stock [Axis] Sale of Stock [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Research and development costs Accrued Research And Development Costs, Current Accrued Research And Development Costs, Current Accrued expenses and other current liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Document Transition Report Document Transition Report Stock Based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Shares Class of Warrant or Right, Outstanding Warrants Warrant [Member] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Other income (expense): Nonoperating Income (Expense) [Abstract] Debt Instrument, Face Amount Debt Instrument, Face Amount Level 2 Fair Value, Inputs, Level 2 [Member] Document Quarterly Report Document Quarterly Report Liabilities, Fair Value Disclosure [Abstract] Liabilities, Fair Value Disclosure [Abstract] Canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period General and administrative General and Administrative Expense [Member] Equity [Abstract] Equity [Abstract] Assets, Fair Value Disclosure Assets, Fair Value Disclosure Lease liabilities Finance and Operating Lease, Liability, Current Finance and Operating Lease, Liability, Current Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Deferred revenue Contract with Customer, Liability, Current Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Diluted (in shares) Weighted average common stock outstanding - Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Schedule of financial instruments measured at fair value on recurring basis Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Basic (in dollars per share) Earnings Per Share, Basic Remaining term (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Number of operating segments Number of Operating Segments Entity File Number Entity File Number Debt Disclosure [Abstract] Debt Disclosure [Abstract] Weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Amortization of Debt Issuance Costs and Discounts Amortization of Debt Issuance Costs and Discounts Common stock, $0.001 par value; (170,000,000 shares authorized at March 31, 2021 and December 31, 2020, 54,368,582 shares issued and outstanding at March 31, 2021 and 53,018,813 shares issued and outstanding at December 31, 2020) Common Stock, Value, Outstanding Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Issuance of warrants Adjustments to Additional Paid in Capital, Warrant Issued Total stock-based compensation expense Share-based Payment Arrangement, Expense Revenue Revenue from Contract with Customer, Including Assessed Tax Weighted-Average Remaining Contractual Term (years) Share-based Compensation Arrangement by Share-based Payment Award Options Weighted Average Remaining Contractual Term [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Exercisable at the end of the period (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] 2021 Term Loan 2021 Term Loan [Member] 2021 Term Loan Current portion of long-term debt Long-term Debt, Current Maturities Entity Current Reporting Status Entity Current Reporting Status Volatility Measurement Input, Price Volatility [Member] Material Transfer Agreement Material Transfer Agreement [Member] Material Transfer Agreement [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Common stock, shares issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Risk-free rate Measurement Input, Risk Free Interest Rate [Member] Operating lease liability Total Operating Lease, Liability Long-term debt, net of current portion Long-term Debt, Excluding Current Maturities Long-Term Debt Debt Instrument [Line Items] Total stockholders’ equity Balance - Stockholders' Equity (Deficit) Balance - Stockholders' Equity (Deficit) Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Entity Address, City or Town Entity Address, City or Town Payroll and employee-related costs Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] General and administrative General and Administrative Expense Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Useful life (in years) Finite-Lived Intangible Asset, Useful Life Equity Component [Domain] Equity Component [Domain] Property and equipment, net Property, Plant and Equipment, Net Lincoln Park Capital Lincoln Park Capital [Member] Lincoln Park Capital [Member] Entity Tax Identification Number Entity Tax Identification Number Warrants and rights outstanding, term Warrants and Rights Outstanding, Term Employee benefit plans Share-based Payment Arrangement [Text Block] Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Other Liabilities, Current Other Liabilities, Current Remainder of 2021 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Leases [Abstract] Leases [Abstract] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Operating expenses: Operating Expenses [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Class of Warrant or Right, Number of Securities Called by Warrants or Rights Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus Stock options Employee And Nonemployee Stock Option [Member] Employee And Nonemployee Stock Option [Member] Represents information pertaining to employee and non-employee stock options. Revenue Recognition and Deferred Revenue [Abstract] Revenue Recognition and Deferred Revenue [Abstract] Non-cash financing activities and supplemental cash flow information Supplemental Cash Flow Information [Abstract] Entity Filer Category Entity Filer Category Schedule of stock-based compensation expense for stock options granted to employees and non-employees Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Common Stock Common Stock [Member] Product and Service [Domain] Product and Service [Domain] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Issuance of common stock (in shares) Stock Issued During Period, Shares, New Issues Interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Money market funds Money Market Funds [Member] Preferred stock, $0.001 par value; (25,000,000 shares authorized at March 31, 2021 and December 31, 2020; — shares issued and outstanding at March 31, 2021 and December 31, 2020) Preferred Stock, Value, Outstanding Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Total other income Nonoperating Income (Expense) Finance Lease, Right-of-Use Asset Finance Lease, Right-of-Use Asset, after Accumulated Amortization 2019 Pre-Funded Warrants Initial Closing Pre-Funded Warrants [Member] Initial Closing Pre-Funded Warrants [Member] Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Basis of presentation Basis of Accounting, Policy [Policy Text Block] Basic (in shares) Weighted average common stock outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Debt Instrument, Basis Spread on Variable Rate Debt Instrument, Basis Spread on Variable Rate Risk-free rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Canceled (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Shares authorized for issuance, remaining amount (in shares) Sale of stock, Shares Authorized for Issuance, Remaining Amount Sale of stock, Shares Authorized for Issuance, Remaining Amount Sale of Stock [Domain] Sale of Stock [Domain] Plan Name [Domain] Plan Name [Domain] Revenue Revenue from Contract with Customer [Text Block] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Organization and operations Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Additional paid-in capital Additional Paid in Capital Class of Stock [Axis] Class of Stock [Axis] Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Schedule of future principal payments Schedule of Maturities of Long-term Debt [Table Text Block] Lease Liabilities, Noncurrent [Abstract] Lease Liabilities, Noncurrent [Abstract] Lease Liabilities, Noncurrent [Abstract] Diluted (in dollars per share) Earnings Per Share, Diluted Finance Lease, Liability, Current Finance Lease, Liability, Current Local Phone Number Local Phone Number Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Measurement Input Warrants and Rights Outstanding, Measurement Input Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Long-term debt Long-term Debt, Gross Depreciation and amortization Depreciation Entity Address, Address Line One Entity Address, Address Line One Prime rate Prime Rate [Member] Entity Emerging Growth Company Entity Emerging Growth Company Right of use assets Finance and Operating Lease, Right-of-Use Asset Finance and Operating Lease, Right-of-Use Asset Finance and Operating Lease, Right-of-Use Asset Debt financing Line of Credit Facility, Maximum Borrowing Capacity Award Type [Axis] Award Type [Axis] Maximum Maximum [Member] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Accumulated Deficit Retained Earnings [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Lease liabilities, net of current portion Finance and Operating lease, Liability, Noncurrent Finance and Operating lease, Liability, Noncurrent Total Warrants To Purchase Common Stock [Member] Represents information pertaining to warrants that gives right to purchase common stock. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Summary of significant accounting policies Significant Accounting Policies [Text Block] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Outstanding at the beginning/end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Domain] Award Type [Domain] Non-current liabilities: Liabilities, Noncurrent [Abstract] Variable rate (as a percent) Derivative, Basis Spread on Variable Rate Trading Symbol Trading Symbol Exercisable at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted-average number of shares used in computing net loss per share: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Lease Extension for office and lab space Lease Extension [Member] Lease Extension [Member] Private placement Private Placement [Member] Net loss per share Earnings Per Share [Text Block] Shares authorized for issuance, value Sale of Stock, Shares Authorized for Issuance, Value Sale of Stock, Shares Authorized for Issuance, Value Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Current liabilities: Liabilities, Current [Abstract] Financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Entity Shell Company Entity Shell Company Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Significant accounting policies New Accounting Pronouncements, Policy [Policy Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] EX-101.PRE 10 gnca-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 gnca-20210331_g1.jpg begin 644 gnca-20210331_g1.jpg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end XML 12 gnca-20210331_htm.xml IDEA: XBRL DOCUMENT 0001457612 2021-01-01 2021-03-31 0001457612 2021-04-27 0001457612 2021-03-31 0001457612 2020-12-31 0001457612 2020-01-01 2020-03-31 0001457612 us-gaap:CommonStockMember 2020-12-31 0001457612 us-gaap:PreferredStockMember 2020-12-31 0001457612 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001457612 us-gaap:RetainedEarningsMember 2020-12-31 0001457612 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001457612 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001457612 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001457612 us-gaap:CommonStockMember 2021-03-31 0001457612 us-gaap:PreferredStockMember 2021-03-31 0001457612 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001457612 us-gaap:RetainedEarningsMember 2021-03-31 0001457612 us-gaap:CommonStockMember 2019-12-31 0001457612 us-gaap:PreferredStockMember 2019-12-31 0001457612 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001457612 us-gaap:RetainedEarningsMember 2019-12-31 0001457612 2019-12-31 0001457612 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001457612 us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0001457612 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001457612 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001457612 us-gaap:CommonStockMember 2020-03-31 0001457612 us-gaap:PreferredStockMember 2020-03-31 0001457612 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001457612 us-gaap:RetainedEarningsMember 2020-03-31 0001457612 2020-03-31 0001457612 gnca:ShionogiCo.Ltd.Member gnca:MaterialTransferAgreementMember 2020-05-01 2020-05-31 0001457612 gnca:ShionogiCo.Ltd.Member gnca:MaterialTransferAgreementMember 2021-03-31 0001457612 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001457612 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001457612 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001457612 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001457612 us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001457612 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001457612 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001457612 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001457612 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001457612 us-gaap:FairValueInputsLevel1Member us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001457612 us-gaap:FairValueInputsLevel2Member us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001457612 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001457612 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001457612 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001457612 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001457612 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001457612 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001457612 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001457612 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001457612 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001457612 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001457612 us-gaap:FairValueInputsLevel1Member us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001457612 us-gaap:FairValueInputsLevel2Member us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001457612 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001457612 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2020-12-31 0001457612 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2021-01-01 2021-03-31 0001457612 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2021-03-31 0001457612 gnca:LeaseExtensionMember 2021-03-31 0001457612 gnca:MasterFacilitiesOperatingLeaseDueFebruary282025Member 2020-12-31 0001457612 gnca:MasterFacilitiesOperatingLeaseDueFebruary282025Member 2021-03-31 0001457612 us-gaap:PatentsMember 2021-01-01 2021-03-31 0001457612 gnca:A2018TermLoanAgreementMember us-gaap:LineOfCreditMember 2018-04-24 0001457612 gnca:A2018TermLoanAgreementMember us-gaap:LineOfCreditMember us-gaap:PrimeRateMember 2018-04-24 0001457612 gnca:A2018TermLoanAgreementMember us-gaap:LineOfCreditMember 2019-11-30 0001457612 gnca:A2021TermLoanMember us-gaap:NotesPayableToBanksMember 2021-02-18 0001457612 gnca:A2018TermLoanAgreementMember us-gaap:LineOfCreditMember 2021-02-18 2021-02-18 0001457612 gnca:A2021TermLoanMember us-gaap:NotesPayableToBanksMember 2021-02-18 2021-02-18 0001457612 gnca:A2021TermLoanMember us-gaap:NotesPayableToBanksMember us-gaap:PrimeRateMember 2021-02-18 2021-02-18 0001457612 gnca:SVBWarrantMember gnca:A2021TermLoanMember us-gaap:NotesPayableToBanksMember 2021-02-18 0001457612 gnca:TermLoan2014Tranche1Member us-gaap:LineOfCreditMember 2021-03-31 0001457612 gnca:TermLoan2014Tranche1Member us-gaap:LineOfCreditMember 2020-12-31 0001457612 gnca:TermLoan2014Member us-gaap:LineOfCreditMember 2021-01-01 2021-03-31 0001457612 gnca:TermLoan2014Member us-gaap:LineOfCreditMember 2020-01-01 2020-03-31 0001457612 gnca:A2021TermLoanMember us-gaap:NotesPayableToBanksMember 2021-03-31 0001457612 us-gaap:CommonStockMember gnca:LincolnParkCapitalMember 2019-10-01 2019-10-31 0001457612 srt:MaximumMember us-gaap:CommonStockMember gnca:LincolnParkCapitalMember 2019-10-01 2019-10-31 0001457612 srt:MaximumMember us-gaap:CommonStockMember gnca:LincolnParkCapitalMember 2019-10-31 0001457612 us-gaap:CommonStockMember gnca:LincolnParkCapitalMember 2021-03-31 0001457612 gnca:AtTheMarketEquityOfferingProgramMember us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2016-01-01 2016-09-30 0001457612 gnca:AtTheMarketEquityOfferingProgramMember us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2021-01-01 2021-03-31 0001457612 gnca:AtTheMarketEquityOfferingProgramMember us-gaap:CommonStockMember 2015-03-02 2021-03-31 0001457612 gnca:AtTheMarketEquityOfferingProgramMember us-gaap:CommonStockMember 2021-03-31 0001457612 gnca:SecondWarrantMember 2021-03-31 0001457612 gnca:PublicOfferingWarrantsMember 2021-03-31 0001457612 gnca:InitialClosingPrivatePlacementWarrantsMember 2021-03-31 0001457612 gnca:InitialClosingPreFundedWarrantsMember 2021-03-31 0001457612 gnca:A2020WarrantsMember 2021-03-31 0001457612 gnca:A2020PreFundedWarrantsMember 2021-03-31 0001457612 gnca:SVBWarrantMember 2021-03-31 0001457612 gnca:WarrantsToPurchaseCommonStockMember 2021-03-31 0001457612 gnca:A2018WarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2018-01-01 0001457612 gnca:A2018WarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2021-01-01 2021-03-31 0001457612 gnca:A2018WarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2020-01-01 2020-03-31 0001457612 gnca:A2018WarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2021-03-31 0001457612 gnca:A2018WarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2020-12-31 0001457612 gnca:A2018WarrantsMember us-gaap:WarrantMember us-gaap:MeasurementInputSharePriceMember 2021-03-31 0001457612 gnca:A2018WarrantsMember us-gaap:WarrantMember us-gaap:MeasurementInputSharePriceMember 2020-12-31 0001457612 srt:MinimumMember gnca:A2018WarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2021-03-31 0001457612 srt:MaximumMember gnca:A2018WarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2021-03-31 0001457612 srt:MinimumMember gnca:A2018WarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001457612 srt:MaximumMember gnca:A2018WarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001457612 gnca:A2018WarrantsMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedTermMember 2021-03-31 0001457612 gnca:A2018WarrantsMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedTermMember 2020-12-31 0001457612 gnca:A2018WarrantsMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-03-31 0001457612 gnca:A2018WarrantsMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0001457612 gnca:A2018WarrantsMember us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-03-31 0001457612 gnca:A2018WarrantsMember us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001457612 gnca:A2018WarrantsMember us-gaap:WarrantMember gnca:MeasurementInputAcquisitionEventProbabilityMember 2021-03-31 0001457612 gnca:A2018WarrantsMember us-gaap:WarrantMember gnca:MeasurementInputAcquisitionEventProbabilityMember 2020-12-31 0001457612 gnca:A2020WarrantsMember us-gaap:WarrantMember 2020-07-24 0001457612 gnca:A2020WarrantsMember us-gaap:WarrantMember 2021-01-01 2021-03-31 0001457612 gnca:A2020WarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2021-03-31 0001457612 gnca:A2020WarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2020-12-31 0001457612 gnca:A2020WarrantsMember us-gaap:WarrantMember us-gaap:MeasurementInputSharePriceMember 2021-03-31 0001457612 gnca:A2020WarrantsMember us-gaap:WarrantMember us-gaap:MeasurementInputSharePriceMember 2020-07-31 0001457612 gnca:A2020WarrantsMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2021-03-31 0001457612 gnca:A2020WarrantsMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2020-07-31 0001457612 gnca:A2020WarrantsMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedTermMember 2021-03-31 0001457612 gnca:A2020WarrantsMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedTermMember 2020-07-31 0001457612 gnca:A2020WarrantsMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-03-31 0001457612 gnca:A2020WarrantsMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-07-31 0001457612 gnca:A2020WarrantsMember us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-03-31 0001457612 gnca:A2020WarrantsMember us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-07-31 0001457612 gnca:A2020WarrantsMember us-gaap:WarrantMember gnca:MeasurementInputAcquisitionEventProbabilityMember 2021-03-31 0001457612 gnca:A2020WarrantsMember us-gaap:WarrantMember gnca:MeasurementInputAcquisitionEventProbabilityMember 2020-12-31 0001457612 us-gaap:EmployeeStockMember gnca:AmendedandRestated2014EquityIncentivePlanMember 2021-03-31 0001457612 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001457612 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001457612 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001457612 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001457612 gnca:EmployeeAndNonemployeeStockOptionMember 2020-12-31 0001457612 gnca:EmployeeAndNonemployeeStockOptionMember 2021-01-01 2021-03-31 0001457612 gnca:EmployeeAndNonemployeeStockOptionMember 2021-03-31 0001457612 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001457612 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001457612 us-gaap:RestrictedStockUnitsRSUMember 2021-03-31 0001457612 us-gaap:EmployeeStockMember 2021-03-31 0001457612 us-gaap:WarrantMember us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001457612 us-gaap:WarrantMember us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001457612 gnca:EmployeeAndNonemployeeStockOptionMember 2021-01-01 2021-03-31 0001457612 gnca:EmployeeAndNonemployeeStockOptionMember 2020-01-01 2020-03-31 0001457612 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001457612 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001457612 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001457612 us-gaap:CommonStockMember 2020-01-01 2020-03-31 shares iso4217:USD iso4217:USD shares gnca:segments gnca:floor pure 0001457612 false --12-31 2021 Q1 10-Q true 2021-03-31 false 001-36289 GENOCEA BIOSCIENCES, INC. DE 51-0596811 100 Acorn Park Drive Cambridge MA 02140 617 876-8191 Common Stock, $0.001 par value GNCA NASDAQ Yes Yes Non-accelerated Filer true false false 54434839 66035000 79769000 2785000 2458000 68820000 82227000 4853000 5123000 8831000 9308000 631000 631000 803000 1204000 83938000 98493000 1034000 534000 4593000 7344000 1641000 1641000 2156000 1614000 2000000 13862000 11424000 24995000 55264000 56118000 7839000 8398000 7649000 0 82176000 89511000 0.001 0.001 25000000 25000000 0 0 0 0 0 0 0.001 0.001 170000000 170000000 54368582 54368582 53018813 53018813 54000 53000 388359000 383597000 -386651000 -374668000 1762000 8982000 83938000 98493000 8751000 9987000 3671000 3388000 12422000 13375000 -12422000 -13375000 854000 781000 279000 259000 -136000 0 439000 522000 -11983000 -12853000 -11983000 -12853000 -0.18 -0.46 -0.17 -0.46 66158000 28141000 74220000 28141000 53019000 53000 0 383597000 -374668000 8982000 1301000 1000 3978000 3979000 580000 580000 120000 120000 49000 84000 84000 -11983000 -11983000 54369000 54000 0 388359000 -386651000 1762000 27453000 27000 701000 355268000 -330954000 25042000 187000 1000 0 439000 440000 384000 384000 4000 0 0 -12853000 -12853000 27644000 28000 701000 356091000 -343807000 13013000 -11983000 -12853000 381000 276000 580000 384000 -854000 -781000 117000 109000 101000 84000 735000 1015000 -12393000 -13796000 1109000 233000 65000 16000 -1044000 -217000 3979000 440000 84000 0 23000 45000 289000 0 10000000 0 88000 0 13960000 0 -297000 395000 -13734000 -13618000 80400000 40758000 66666000 27140000 306000 0 0 5931000 709000 394000 166000 261000 Organization and operations<div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genocea Biosciences, Inc. ("Genocea" or the "Company”) is a biopharmaceutical company that was incorporated in Delaware on August 16, 2006 and has a principal place of business in Cambridge, Massachusetts. The Company is dedicated to discovering and developing novel cancer immunotherapies using its proprietary ATLAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform. The ATLAS platform can profile each patient's CD4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and CD8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> T cell immune responses to every potential target or “antigen” identified by next generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, Inhibigens</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that drive pro-tumor immune responses. Genocea believes this approach ensures that cancer immunotherapies, such as vaccines and cellular therapies, focus T cell responses on the tumor targets most vulnerable to T cell targeting. Consequently, the Company believes that ATLAS may enable more immunogenic and efficacious cancer immunotherapies. Genocea operates as one segment, which is discovering, researching, developing and commercializing novel cancer immunotherapies.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genocea's GEN-011 program is an adoptive T cell therapy comprising neoantigen-targeted peripheral T cells ("NPTs"). NPTs are peripheral blood-derived T cells targeted to ATLAS-identified anti-tumor antigens. By employing ATLAS to optimize neoantigen selection and by using T cells derived from peripheral blood, Genocea believes GEN-011 will enable potential patient efficacy, accessibility and cost advantages over other autologous T cell therapies. The Company is conducting a first-in-human clinical trial for GEN-011. Genocea's GEN-009 program is a neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified anti-tumor neoantigens. After reporting initial clinical responses for GEN-009 delivered in combination with standard-of-care checkpoint inhibitors ("CPIs") in 2020, the Company continues to monitor patients to confirm these initial efficacy signals.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genocea is devoting substantially all of its efforts to product research and development, initial market development, and raising capital. The Company has not generated any product revenue related to its primary business purpose to date and is subject to a number of risks and uncertainties common to companies in the biotech and pharmaceutical industry, including, but not limited to, the risks associated with the uncertainty of success of its preclinical and clinical trials; the challenges associated with gaining regulatory approval of product candidates; the risks associated with commercializing pharmaceutical products, if approved for marketing and sale; the potential for development by third parties of new technological innovations that may compete with Genocea's products; the dependence on key personnel; the challenges of protecting proprietary technology; the need to comply with government regulations; the high cost of drug development; competition from other companies; the uncertainty of being able to secure additional capital when needed to fund operations; and the challenges and uncertainty associated with the outbreak of the novel coronavirus ("COVID-19") that could adversely impact the Company's operations, supply chain, preclinical development work, clinical trials and ability to raise capital.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly evaluates whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the financial statements are issued. As of March 31, 2021, Genocea had an accumulated deficit of $386.7 million and anticipates that it will continue to incur significant operating losses for the foreseeable future as it continues to develop its product candidates. Until such time, if ever, as the Company can generate substantial product revenue and achieve profitability, Genocea expects to finance its cash needs through a combination of equity offerings, strategic transactions, or other sources of funding. If the Company is unable to raise additional funds when needed, it may be required to implement further cost reduction strategies, including ceasing development of GEN-011 or other corporate programs and activities.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genocea had available cash and cash equivalents of $66.0 million at March 31, 2021. In addition, the Company used cash of $12.4 million in its operating activities for the three months ended March 31, 2021. Genocea’s available cash and cash equivalents at March 31, 2021 are expected to fund operations for a period of at least a year from the date the financial statements are issued.</span></div> 1 -386700000 66000000.0 -12400000 Summary of significant accounting policies<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and a wholly owned subsidiary. Intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements and accompanying notes in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ materially from those estimates. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and accompanying notes included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “2020 10-K”).</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant accounting policies</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genocea's significant accounting policies have not changed materially from those disclosed in the 2020 10-K.</span></div>New Accounting Pronouncements<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Financial Accounting Standards Board issued a new standard on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span>Simplifying the Accounting for Income Taxes. The new standard simplifies the accounting for income taxes and became effective beginning after December 15, 2020. The Company adopted this standard on January 1, 2021. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements and related disclosures. <div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and a wholly owned subsidiary. Intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements and accompanying notes in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ materially from those estimates. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and accompanying notes included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “2020 10-K”).</span></div> <div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant accounting policies</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genocea's significant accounting policies have not changed materially from those disclosed in the 2020 10-K.</span></div>New Accounting Pronouncements<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Financial Accounting Standards Board issued a new standard on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span>Simplifying the Accounting for Income Taxes. The new standard simplifies the accounting for income taxes and became effective beginning after December 15, 2020. The Company adopted this standard on January 1, 2021. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements and related disclosures. Revenue<div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Genocea entered into a material transfer agreement (the “MTA”) with Shionogi &amp; Co., Ltd. (“Shionogi”) pursuant to which the Company agreed to transfer certain HSV-2 antigens from its GEN-003 program to Shionogi to evaluate the potential development of a novel HSV-2 vaccine. In connection with the agreement, Genocea provided Shionogi with an option to negotiate an exclusive development and commercialization license for the HSV-2 antigens.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the MTA, Shionogi paid the Company a total of $3.0 million in non-refundable, creditable (with respect to the up-front fee pursuant to a development and commercialization agreement) fees. Prior to the expiration of the MTA, Shionogi has the option to negotiate a development and commercialization agreement. If executed, the terms of the development and commercialization agreement are expected to include an upfront payment, regulatory and sales milestones, and tiered royalties. Final terms of the development and commercialization agreement will be based on evaluation of the HSV-2 assets and overall diligence. If licensed, Shionogi will assume responsibility for global development and commercialization of an HSV-2 vaccine product.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genocea evaluated the promised goods and services within the MTA and determined those which represented separate performance obligations. As a result, the Company concluded there were two separate performance obligations at the inception of the MTA: (i) a combined performance obligation consisting of a limited use research license and the delivery of the initial antigen materials and (ii) the right to negotiate a license prior to expiration of the MTA, which was deemed to be a material right. The Company determined that the exclusive limited use research license and the delivery of the initial antigen materials should be combined as they are not capable of being distinct. A third party would not be able to provide the initial antigen materials as it contains Genocea’s proprietary intellectual property, and Shionogi could not benefit from the research license without the initial antigen materials. The Company determined that the option to negotiate the development and commercialization agreement prior to the expiration of the MTA is a material right. The $3.0 million fee associated with the MTA is creditable against the upfront fee for the development and commercialization agreement and represents a discount that would otherwise not be available to the customer without entering into the MTA. </span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genocea estimated the standalone selling price of the initial antigen materials based on the expected cost plus a margin approach. The Company developed its standalone selling price for the material right by applying a probability-weighted likelihood that Shionogi will exercise its option to license the HSV-2 assets.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, $1.6 million allocated to the material right is considered a contract liability and is recorded as deferred revenue on the Company's condensed consolidated balance sheet. Revenue associated with the material right will be recognized upon either (i) the execution of a development and commercialization agreement or (ii) the termination of the MTA.</span></div> 3000000.0 3000000.0 3000000.0 3000000.0 1600000 <div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genocea has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1—Fair values are determined by utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2—Fair values are determined by utilizing quoted prices for similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates; and</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities measured at fair value consist of cash equivalents and warrant liabilities, respectively.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Genocea’s cash equivalents is determined using quoted prices in active markets. The Company's cash equivalents consist of money market funds that are classified as Level 1.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Genocea’s warrant liabilities is determined using a Monte Carlo simulation. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for assumptions used and methodologies utilized in calculating the estimated fair value. The Company’s warrant liabilities are classified as Level 3.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company's assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%"><tr><td style="width:1.0%"/><td style="width:39.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted prices in active markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant other observable inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant unobservable inputs</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,144 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,144 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,264 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,264 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,866 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,866 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,118 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,118 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the change in Genocea’s Level 3 warrant liabilities (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:67.500%"><tr><td style="width:1.0%"/><td style="width:49.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.814%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Warrant Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(854)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,264 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genocea has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1—Fair values are determined by utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2—Fair values are determined by utilizing quoted prices for similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates; and</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities measured at fair value consist of cash equivalents and warrant liabilities, respectively.</span></div> <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%"><tr><td style="width:1.0%"/><td style="width:39.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted prices in active markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant other observable inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant unobservable inputs</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,144 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,144 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,264 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,264 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,866 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,866 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,118 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,118 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 64144000 64144000 0 0 64144000 64144000 0 0 55264000 0 0 55264000 55264000 0 0 55264000 76866000 76866000 0 0 76866000 76866000 0 0 56118000 0 0 56118000 56118000 0 0 56118000 <div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the change in Genocea’s Level 3 warrant liabilities (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:67.500%"><tr><td style="width:1.0%"/><td style="width:49.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.814%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Warrant Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(854)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,264 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 56118000 -854000 55264000 Accrued expenses and other current liabilities<div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:67.083%"><tr><td style="width:1.0%"/><td style="width:54.179%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,817 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,592 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payroll and employee-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">866 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,973 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,593 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,344 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:67.083%"><tr><td style="width:1.0%"/><td style="width:54.179%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,817 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,592 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payroll and employee-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">866 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,973 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,593 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,344 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2817000 2592000 910000 2779000 866000 1973000 4593000 7344000 Commitments and contingencies<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating leases</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, Genocea has a lease for two floors of lab and office space in a multi-tenant building in Cambridge, Massachusetts through February 2025. A portion of this leased space is an expansion of the Company's initial lease. Genocea's right to use and control this expansion space began in March 2020. Genocea has the option to extend the lease term for an additional five years, which is not included in the Company's ROU assets and associated lease liabilities as of March 31, 2021. In the fourth quarter of 2020, Genocea incurred costs related to improvements made to its leased office space that were determined to be lessee assets and which were partially reimbursed by the lessor. In the first quarter of 2021, the Company recognized an increase in its lease liabilities of $0.5 million, which reflects the cash received from the lessor during the quarter for previously approved reimbursements. The Company will amortize the reimbursement as an increase to the ROU asset and a reduction in lease expense over the remaining lease term.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, Genocea entered into a sublease agreement for one floor of lab and office space through June 2022, with an option for the sublessee to extend the sublease for an additional two months. After the initial option, which is at the sublessee’s sole discretion, the sublease agreement contains additional options for the Company and the sublessee to mutually extend the sublease for up to an additional eighteen months. As Genocea retained its obligations under the sublease, it will record the payments received from the sublease as a reduction of lease expense. For the three months ended March 31, 2021, the Company recorded sublease income of $0.4 million.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and 2020 lease expense, net of sublease income, was $0.3 million and $0.5 million, respectively.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term and weighted average discount rate of the Company's operating leases are as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:382.50pt"><tr><td style="width:1.0pt"/><td style="width:229.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term in years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.17</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the presentation of leases in the Company's condensed consolidated balance sheets (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:477.75pt"><tr><td style="width:1.0pt"/><td style="width:111.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:166.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:90.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:91.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,831 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,308 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,839 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,995 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,012 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum lease payments related to the Company's operating leases as of March 31, 2021 were as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:35.416%"><tr><td style="width:1.0%"/><td style="width:62.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.979%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,943 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,017 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">517 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,731 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,736)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,995 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2021 and December 31, 2020, the Company had an outstanding letter of credit of $0.6 million, with a financial institution related to a security deposit for the office and lab space lease, which is secured by cash on deposit and expires in February 2025.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual obligations</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genocea has entered into certain agreements with various universities, contract research organizations and contract manufacturing organizations, which generally include cancellation clauses.</span></div><div style="margin-bottom:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Harvard University license agreement</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genocea has an exclusive license agreement with Harvard University (“Harvard”), granting the Company an exclusive, worldwide, royalty-bearing, sublicensable license to three patent families, to develop, make, have made, use, market, offer for sale, sell, have sold and import licensed products and to perform licensed services related to the ATLAS discovery platform. Genocea is also obligated to pay Harvard milestone payments up to $1.6 million in the aggregate upon the achievement of certain development and regulatory milestones. As of March 31, 2021, the Company has paid $0.3 million in aggregate milestone payments. Genocea is obligated under this license agreement to use commercially reasonable efforts to develop, market and sell licensed products in compliance with an agreed-upon development plan. In addition, the Company is obligated to achieve specified development milestones and in the event Genocea is unable to meet its development milestones for any type of product or service, absent any reasonable proposed extension or amendment thereof, Harvard has the right, depending on the type of product or service, to terminate this agreement with respect to such products or to convert the license to a non-exclusive, non-sublicensable license with respect to such products and services.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization of the Company's products covered by the licensed patent rights or discovered using the licensed methods, Genocea is obligated to pay Harvard royalties on the net sales of such products and services sold by the Company, the Company's affiliates, and the Company's sublicensees. This royalty varies depending on the type of product or service but is in the low single digits. The sales-based royalty due by the Company’s sublicensees is the greater of the applicable royalty rate or a percentage in the high single digits or the low double digits of the royalties Genocea receives from such sublicensee, depending on the type of product. Based on the type of commercialized product or service, royalties are payable until the expiration of the last-to-expire valid claim under the licensed patent rights or for a period of 10 years from first commercial sale of such product or service. The royalties payable to Harvard are subject to reduction, capped at a specified percentage, for any third-party payments required to be made. In addition to the royalty payments, if the Company receives any additional revenue (cash or non-cash) under any sublicense, it must pay Harvard a percentage of such revenue, excluding certain categories of payments, varying from the low single digits to up to the low double digits depending on the scope of the license that includes the sublicense.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The license agreement with Harvard will expire on a product-by-product or service-by-service and country-by-country basis until the expiration of the last-to-expire valid claim under the licensed patent rights. The Company may terminate the agreement at any time by giving Harvard advance written notice. Harvard may also terminate the agreement in the event of a material breach by the Company that remains uncured; in the event of the Company's insolvency, bankruptcy, or similar circumstances; or if Genocea challenges the validity of any patents licensed to it.</span></div><div style="margin-bottom:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncovir license and supply agreement</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genocea has a license and supply agreement with Oncovir, Inc. (“Oncovir”) under which Oncovir will manufacture and supply an immunomodulator and vaccine adjuvant, Hiltonol® (poly-ICLC) (“Hiltonol”), to the Company for use in connection with the research, development, use, sale, manufacture, commercialization and marketing of products combining Hiltonol with the Company's technology (the “Combination Product”). Hiltonol is the adjuvant component of GEN-009, which will consist of synthetic long peptides or neoantigens identified using the Company's proprietary ATLAS platform, formulated with Hiltonol. </span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncovir granted the Company a non-exclusive, assignable, royalty-bearing worldwide license, with the right to grant sublicenses through one tier, to certain of Oncovir’s intellectual property in connection with the research, development, or commercialization of Combination Products, including the use of Hiltonol, but not the use of Hiltonol for manufacturing or the use or sale of Hiltonol alone. The license will become perpetual, fully paid-up, and royalty-free on the later of January 25, 2028 or the date on which the last valid claim of any patent licensed to the Company under the agreement expires.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, Genocea is obligated to pay Oncovir low to mid six figure milestone payments upon the achievement of certain clinical trial milestones for each Combination Product and the first marketing approval for each Combination Product in certain territories, as well as tiered royalties in the low-single digits on a product-by-product basis based on the net sales of Combination Products.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genocea may terminate the agreement upon a decision to discontinue the development of the Combination Product or upon a determination by the Company or an applicable regulatory authority that Hiltonol or a Combination Product is not clinically safe or effective. The agreement may also be terminated by either party due to a material uncured breach by the other party, or due to the other party’s bankruptcy, insolvency, or dissolution.</span></div> 2 500000 400000 300000 500000 <div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term and weighted average discount rate of the Company's operating leases are as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:382.50pt"><tr><td style="width:1.0pt"/><td style="width:229.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term in years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.17</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> P3Y10M28D P4Y2M1D 0.0813 0.0812 <div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the presentation of leases in the Company's condensed consolidated balance sheets (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:477.75pt"><tr><td style="width:1.0pt"/><td style="width:111.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:166.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:90.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:91.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,831 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,308 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,839 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,995 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,012 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 8831000 9278000 0 30000 8831000 9308000 2156000 1592000 0 22000 7839000 8398000 9995000 10012000 <div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum lease payments related to the Company's operating leases as of March 31, 2021 were as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:35.416%"><tr><td style="width:1.0%"/><td style="width:62.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.979%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,943 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,017 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">517 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,731 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,736)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,995 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2162000 2943000 3017000 3092000 517000 11731000 1736000 9995000 600000 600000 1600000 300000 P10Y Debt<div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into an amended and restated loan and security agreement, which was subsequently amended in November 2019 (as amended, the “Hercules Loan Agreement”), with Hercules Capital, Inc. (“Hercules”). The Hercules Loan Agreement provided a $14.0 million secured term loan that was scheduled to mature on May 1, 2021 and that accrued interest at a floating rate per annum equal to the greater of (i) 8.00%, or (ii) the sum of 3.00% plus the prime rate. The Company was also obligated to pay a final payment charge of $1.0 million at maturity.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2021 (the "2021 Loan Closing Date"), Genocea entered into a Loan and Security Agreement (the "2021 Loan Agreement") with Silicon Valley Bank ("SVB") for a $10 million secured term loan (the "2021 Term Loan"). $9.0 million of the proceeds from the 2021 Term Loan were used to repay the Company's borrowings that were outstanding at the 2021 Loan Closing Date under its previous loan and security agreement with Hercules, paying off all obligations owing under, and extinguishing, the Hercules Loan Agreement on the 2021 Loan Closing Date. The remaining proceeds from the 2021 Term Loan of $1.0 million were received by the Company for working capital and general corporate purposes.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Term Loan will mature on September 1, 2023, which may be extended to March 1, 2024 if certain performance milestones are achieved and no event of default has occurred or is continuing. The 2021 Term Loan accrues interest at a floating per annum rate equal to the greater of (i) 6.25% or (ii) the sum of 3.0% plus the prime rate. The 2021 Term Loan provides for interest-only payments until September 30, 2021, which may be extended to March 31, 2022 if certain performance milestones are achieved and no event of default has occurred or is continuing. Thereafter, amortization payments will be payable monthly in equal installments of principal and interest (subject to recalculation upon a change in prime rates) upon expiration of the interest-only period through maturity. The 2021 Term Loan is subject to a final payment charge of $0.5 million. The 2021 Term Loan may be prepaid in whole (but not in part), subject to a prepayment charge of 3.0%, if prepaid in any of the first twelve (12) months following the Closing Date, 2.0%, if prepaid after twelve (12) months following the Closing Date but on or prior to twenty four (24) months following the Closing Date, and 1.0% thereafter. </span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Term Loan is secured by a lien on substantially all of the assets of the Company, other than intellectual property, provided that such lien on substantially all assets includes any rights to payments and proceeds from the sale, licensing or disposition of intellectual property.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Loan Agreement contains customary covenants and representations, including a financial reporting covenant and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. There are no financial covenants. As of March 31, 2021, the Company was in compliance with all covenants under the 2021 Loan Agreement.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Loan Agreement also includes customary events of default, including payment defaults, breaches of covenants, change of control and occurrence of a material adverse effect. Amounts outstanding during an event of default shall be payable on demand and shall accrue interest at an additional rate of 4.0% per annum of the past due amount outstanding. The Company has determined that the risk of subjective acceleration under the material adverse events clause was remote and therefore has classified the long-term portion of the outstanding principal in non-current liabilities. </span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2021 Loan Agreement, Genocea issued to SVB a warrant, dated February 18, 2021 (the "SVB Warrant") to purchase 43,478 shares of the common stock of the Company. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recorded the fair value of the SVB warrant as a discount on the 2021 Term Loan that will be amortized over the expected term of the loan. </span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the Company had outstanding borrowings, net of unamortized debt issuance costs, of $9.6 million and $13.9 million, respectively. Interest expense was $0.3 million and $0.4 million for the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future principal payments, including final payment charges, as of March 31, 2021 are as follows:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:49.444%"><tr><td style="width:1.0%"/><td style="width:58.731%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.069%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Principal Payments on Long-Term Debt</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,250 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 14000000.0 0.0800 0.0300 1000000.0 10000000 9000000.0 1000000.0 6.25 3.0 500000 0.030 0.020 0.010 0.040 43478 9600000 13900000 300000 400000 <div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future principal payments, including final payment charges, as of March 31, 2021 are as follows:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:49.444%"><tr><td style="width:1.0%"/><td style="width:58.731%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.069%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Principal Payments on Long-Term Debt</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,250 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1250000 5000000 4250000 10500000 Stockholders' equity<div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agreement with Lincoln Park Capital</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genocea has a purchase agreement with Lincoln Park Capital (“LPC”) pursuant to which, for a period of 30 months beginning in October 2019, the Company has the right, at its sole discretion, to sell up to an additional $27.5 million of the Company's common stock to LPC based on prevailing market prices of its common stock at the time of each sale. The purchase agreement limits the Company's sales of shares of common stock to LPC to approximately 5.2 million shares of common stock, representing 19.99% of the shares of common stock outstanding on the date of the purchase agreement. The purchase agreement also prohibits the Company from directing LPC to purchase any shares of common stock if those shares, when aggregated with all other shares of the Company's common stock then beneficially owned by LPC and its affiliates, would result in LPC and its affiliates having beneficial ownership, at any single point in time, of more than 9.99% of the then total outstanding shares of the Company's common stock. As of March 31, 2021, the Company had $24.0 million remaining under its agreement with LPC. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-market equity offering program</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genocea has an agreement with Cowen and Company, LLC ("Cowen") to establish an at-the-market equity offering program (“ATM”) pursuant to which Cowen is able to offer and sell up to $50.0 million of the Company's common stock at prevailing market prices. In the three months ended March 31, 2021, the Company sold approximately 1.3 million shares under the ATM program and received net proceeds of $4.0 million, after deducting commissions. Through March 31, 2021, the Company has sold an aggregate of approximately 4.2 million shares under the ATM and received $13.8 million in net proceeds. As of March 31, 2021, the Company had $35.8 million in gross proceeds remaining under the ATM.</span></div> P30M 27500000 5200000 0.1999 0.0999 24000000.0 50000000.0 1300000 4000000.0 4200000 13800000 35800000 Warrants<div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company had the following potentially issuable shares of common stock related to unexercised warrants outstanding (shares in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.916%"><tr><td style="width:1.0%"/><td style="width:33.302%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.477%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expiration Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Classification</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hercules Warrant</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q2 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2018 Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019 Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">933 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019 Pre-Funded Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 2039</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020 Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,613 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020 Pre-Funded Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SVB Warrant</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,001 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hercules Warrant</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price and the number of shares are subject to adjustment upon a merger event, reclassification of the shares of common stock, subdivision or combination of the shares of common stock or certain dividend payments. Genocea determined that the Hercules Warrant should be equity-classified.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Warrants</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price and the number of shares are subject to adjustment upon a merger event, reclassification of the shares of common stock, subdivision or combination of the shares of common stock or certain dividend payments. In the event of an “Acquisition,” defined generally to include a merger or consolidation resulting in the sale of 50% or more of the voting securities of the Company, the sale of all, or substantially all, of the assets or voting securities of the Company, or other change of control transaction, as defined in the 2018 Warrants, Genocea will be obligated to use its best efforts to ensure that the holders of the 2018 Warrants receive new warrants from the surviving or acquiring entity (the “Acquirer”). The new warrants to purchase shares in the Acquirer shall have the same expiration date as the 2018 Warrants and a strike price that is based on the proportion of the value of the Acquirer’s stock to the Company’s common stock. If the Company is unable, despite its best efforts, to cause the Acquirer to issue new warrants in the Acquisition as described above, then, if the Company’s stockholders are to receive cash in the Acquisition, Genocea will settle the 2018 Warrants in cash and if the Company’s stockholders are to receive stock in the Acquisition, Genocea will issue shares of its common stock to each Warrant holder.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the Company determined that the 2018 Warrants should be liability-classified. As the 2018 Warrants are liability-classified, the Company remeasures the fair value at each reporting date. Genocea initially recorded the 2018 Warrants at their estimated fair value of $18.2 million. In connection with the Company's remeasurement of the 2018 Warrants to fair value, it recorded income of $0.2 million and $0.8 million for the three months ended March 31, 2021 and 2020, respectively. The fair value of the warrant liability related to the 2018 Warrants is $1.5 million and $1.7 million as of March 31, 2021 and December 31, 2020, respectively.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the assumptions used in the Monte Carlo simulation models used to estimate the fair value of the 2018 Warrants as of March 31, 2021 and December 31, 2020, respectively:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.916%"><tr><td style="width:1.0%"/><td style="width:49.702%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.42 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.0% - 95.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.0% - 101.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition event probability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Warrants and 2019 Pre-Funded Warrants</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of the warrants is subject to appropriate adjustment in the event of stock dividends, subdivisions, stock splits, stock combinations, reclassifications, reorganizations or a change of control affecting the Company's common stock. Genocea determined that the 2019 Warrants and the 2019 Pre-Funded Warrants should be equity-classified. The Company also determined that the 2019 Pre-Funded Warrants should be included in the determination of basic earnings per share.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Warrants and 2020 Pre-Funded Warrants</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of the 2020 Pre-Funded Warrants and the 2020 Warrants is subject to adjustment in the event of stock dividends, subdivisions, stock splits, stock combinations, reclassifications, reorganizations or a change of control affecting the Company's common stock. Genocea determined that the 2020 Pre-Funded Warrants should be equity-classified and be included in the determination of basic earnings per share.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the 2020 Warrants are entitled to down round protection until July 24, 2021. The Company is required to obtain shareholder approval for the adjustment to the exercise price as a result of any common stock issuance at a price per share less than $2.25. As a result, Genocea determined that the 2020 Warrants should be liability-classified for the period from issuance through July 2021. As the 2020 Warrants are liability-classified, the Company remeasures the fair value at each reporting date. Genocea initially recorded the 2020 Warrants at their estimated fair value of $62.5 million. In connection with the Company's remeasurement of the 2020 Warrants to fair value, the Company recorded income of $0.7 million for the three months ended March 31, 2021. The fair value of the warrant liability related to the 2020 Warrants is $53.8 million and $54.5 million as of March 31, 2021 and December 31, 2020, respectively.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the assumptions used in the Monte Carlo simulation models used to estimate the fair value of the 2020 Warrants as of March 31, 2021 and December 31, 2020, respectively:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.972%"><tr><td style="width:1.0%"/><td style="width:46.249%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.495%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.42 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition event probability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> <div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company had the following potentially issuable shares of common stock related to unexercised warrants outstanding (shares in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.916%"><tr><td style="width:1.0%"/><td style="width:33.302%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.477%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expiration Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Classification</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hercules Warrant</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q2 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2018 Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019 Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">933 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019 Pre-Funded Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 2039</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020 Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,613 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020 Pre-Funded Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SVB Warrant</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,001 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div> 41000 6.80 3617000 9.60 933000 4.52 531000 0.08 33613000 2.25 12223000 0.01 43000 3.45 51001000 18200000 200000 800000 1500000 1700000 <div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the assumptions used in the Monte Carlo simulation models used to estimate the fair value of the 2018 Warrants as of March 31, 2021 and December 31, 2020, respectively:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.916%"><tr><td style="width:1.0%"/><td style="width:49.702%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.42 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.0% - 95.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.0% - 101.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition event probability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the assumptions used in the Monte Carlo simulation models used to estimate the fair value of the 2020 Warrants as of March 31, 2021 and December 31, 2020, respectively:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.972%"><tr><td style="width:1.0%"/><td style="width:46.249%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.495%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.42 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition event probability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> 2.71 2.42 0.500 0.953 0.500 1.015 P1Y9M18D P2Y 0 0 0.0016 0.0013 0.250 0.250 2.25 62500000 700000 53800000 54500000 2.71 2.42 0.939 1.191 P3Y3M18D P3Y7M6D 0 0 0.0044 0.0022 0.400 0.400 43478 Employee benefit plans<div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genocea grants equity awards in the form of stock options and service-based and market-based restricted stock units (“RSUs”) to employees and directors of, and consultants and advisors to, the Company through its Amended and Restated 2014 Equity Incentive Plan, ("2014 Equity Incentive Plan"). As of March 31, 2021, there were approximately 0.7 million shares remaining for future issuance under the 2014 Equity Incentive Plan.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options have a ten-year term and were issued with an exercise price equal to the closing market price of Genocea’s common stock on the grant date. For equity awards with service-based vesting conditions, the Company recognizes compensation expense over the vesting period, which is generally over a four-year period. For equity awards with a market-based vesting condition, the Company recognizes compensation expense over the requisite service period. The number of shares issuable, if any, when a market-based RSU award vests will depend on the degree of achievement of the corporate stock price metrics within the performance period of the award. The Company measures the fair value of stock options on the date of grant using the Black-Scholes option pricing model. The fair value of the service-based RSUs is the closing market price of Genocea's common stock on the grant date.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Determining the fair value of market-based RSUs</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of market-based RSUs on the date of grant using a Monte Carlo simulation model. The Monte Carlo simulation requires the input of assumptions, including the Company's stock price, the volatility of its stock price, remaining term in years, expected dividend yield, and risk-free rate. In addition, the valuation model considers the Company's probability of being acquired within the term of the market-based RSUs, as an acquisition event can potentially impact the vesting. The Company used its own trading history to calculate the expected volatility of the market-based RSUs granted. The risk-free interest rate is determined by reference to implied yields available from U.S. Treasury securities with a remaining term equal to the expected term assumed at the grant date.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the assumptions used in the Monte Carlo simulation model used to estimate the fair value of the market-based RSUs granted during the three months ended March 31, 2021:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:52.500%"><tr><td style="width:1.0%"/><td style="width:52.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.197%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.01 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual acquisition event probability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense recognized for stock options and RSUs is as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:52.638%"><tr><td style="width:1.0%"/><td style="width:39.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.397%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">580 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">384 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock options</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity (shares and aggregate intrinsic value in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.861%"><tr><td style="width:1.0%"/><td style="width:34.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average<br/>Remaining Contractual<br/>Term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.05 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">505 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,614 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited/cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at March 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,839 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at March 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">930 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity (shares in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.888%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.208%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,904 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited/cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of March 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,434 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.44 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    _________________________</span></div><div style="margin-bottom:10pt;padding-left:81pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The number granted represents the number of shares issuable upon vesting of service-based and market-based RSUs, assuming the Company achieves its corporate stock price metrics at the target achievement level.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee stock purchase plan</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The 2014 Employee Stock Purchase Plan, as amended (the "ESPP"), issues shares of common stock to participating eligible employees during two six-month offering periods each year. As of March 31, 2021, there were approximately 0.1 million shares remaining for future issuance under the ESPP.</span></div> 700000 <div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the assumptions used in the Monte Carlo simulation model used to estimate the fair value of the market-based RSUs granted during the three months ended March 31, 2021:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:52.500%"><tr><td style="width:1.0%"/><td style="width:52.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.197%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.01 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual acquisition event probability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> 3.01 0.9765 P2Y9M18D 0.0029 0.330 <div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense recognized for stock options and RSUs is as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:52.638%"><tr><td style="width:1.0%"/><td style="width:39.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.397%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">580 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">384 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 258000 160000 322000 224000 580000 384000 <div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity (shares and aggregate intrinsic value in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.861%"><tr><td style="width:1.0%"/><td style="width:34.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average<br/>Remaining Contractual<br/>Term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.05 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">505 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,614 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited/cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at March 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,839 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at March 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">930 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity (shares in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.888%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.208%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,904 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited/cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of March 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,434 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.44 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    _________________________</span></div>1.The number granted represents the number of shares issuable upon vesting of service-based and market-based RSUs, assuming the Company achieves its corporate stock price metrics at the target achievement level 2329000 7.05 505000 1614000 3.01 38000 2.22 66000 12.82 3839000 5.30 P8Y9M18D 715000 930000 12.61 P7Y 134000 550000 2.13 1904000 2.52 11000 1.98 9000 2.11 2434000 2.44 100000 Net loss per share<div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share was calculated as follows for the three months ended March 31, 2021 and 2020 (in thousands, except per share amounts):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:63.472%"><tr><td style="width:1.0%"/><td style="width:64.764%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.873%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.875%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,983)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,853)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: Change in fair value of 2020 Warrants</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">673 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,656)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,853)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average common stock outstanding – basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive effect of common stock issuable from<br/>   assumed exercise of warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,062 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average common stock outstanding – diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74,220 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,141 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potential common shares were excluded from the calculation of net loss per share due to their anti-dilutive effect for the three months ended March 31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.555%"><tr><td style="width:1.0%"/><td style="width:41.708%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.639%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,634 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,591 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,839 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,907 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,006 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share was calculated as follows for the three months ended March 31, 2021 and 2020 (in thousands, except per share amounts):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:63.472%"><tr><td style="width:1.0%"/><td style="width:64.764%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.873%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.875%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,983)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,853)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: Change in fair value of 2020 Warrants</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">673 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,656)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,853)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average common stock outstanding – basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive effect of common stock issuable from<br/>   assumed exercise of warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,062 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average common stock outstanding – diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74,220 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,141 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> -11983000 -12853000 673000 0 -12656000 -12853000 66158000 28141000 8062000 0 74220000 28141000 -0.18 -0.46 -0.17 -0.46 <div style="margin-bottom:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potential common shares were excluded from the calculation of net loss per share due to their anti-dilutive effect for the three months ended March 31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.555%"><tr><td style="width:1.0%"/><td style="width:41.708%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.639%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,634 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,591 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,839 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,907 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,006 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4634000 4591000 3839000 1370000 2434000 45000 10907000 6006000 XML 13 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover Page - shares
 3 Months Ended
Mar. 31, 2021
Apr. 27, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2021  
Document Transition Report false  
Entity File Number 001-36289  
Entity Registrant Name GENOCEA BIOSCIENCES, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 51-0596811  
Entity Address, Address Line One 100 Acorn Park Drive  
Entity Address, City or Town Cambridge  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02140  
City Area Code 617  
Local Phone Number 876-8191  
Title of 12(b) Security Common Stock, $0.001 par value  
Trading Symbol GNCA  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Central Index Key 0001457612  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q1  
Entity Common Stock, Shares Outstanding   54,434,839
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 66,035 $ 79,769
Prepaid expenses and other current assets 2,785 2,458
Total current assets 68,820 82,227
Property and equipment, net 4,853 5,123
Right of use assets 8,831 9,308
Restricted cash 631 631
Other non-current assets 803 1,204
Total assets 83,938 98,493
Current liabilities:    
Accounts payable 1,034 534
Accrued expenses and other current liabilities 4,593 7,344
Deferred revenue 1,641 1,641
Lease liabilities 2,156 1,614
Current portion of long-term debt 2,000 13,862
Total current liabilities 11,424 24,995
Non-current liabilities:    
Long-term debt, net of current portion 7,649 0
Lease liabilities, net of current portion 7,839 8,398
Warrant liabilities 55,264 56,118
Total liabilities 82,176 89,511
Commitments and contingencies (Note 6)
Stockholders’ equity:    
Preferred stock, $0.001 par value; (25,000,000 shares authorized at March 31, 2021 and December 31, 2020; — shares issued and outstanding at March 31, 2021 and December 31, 2020) 0 0
Common stock, $0.001 par value; (170,000,000 shares authorized at March 31, 2021 and December 31, 2020, 54,368,582 shares issued and outstanding at March 31, 2021 and 53,018,813 shares issued and outstanding at December 31, 2020) 54 53
Additional paid-in capital 388,359 383,597
Accumulated deficit (386,651) (374,668)
Total stockholders’ equity 1,762 8,982
Total liabilities and stockholders’ equity $ 83,938 $ 98,493
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Preferred stock, par or stated value per share (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 25,000,000 25,000,000
Preferred stock, shares issued (in dollars per share) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 170,000,000 170,000,000
Common stock, shares issued (in shares) 54,368,582 53,018,813
Common stock, shares outstanding (in shares) 54,368,582 53,018,813
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Operating expenses:    
Research and development $ 8,751 $ 9,987
General and administrative 3,671 3,388
Total operating expenses 12,422 13,375
Loss from operations (12,422) (13,375)
Other income (expense):    
Change in fair value of warrants 854 781
Interest expense, net (279) (259)
Other expense (136) 0
Total other income 439 522
Net loss (11,983) (12,853)
Comprehensive loss $ (11,983) $ (12,853)
Net loss per share:    
Basic (in dollars per share) $ (0.18) $ (0.46)
Diluted (in dollars per share) $ (0.17) $ (0.46)
Weighted-average number of shares used in computing net loss per share:    
Basic (in shares) 66,158 28,141
Diluted (in shares) 74,220 28,141
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Preferred Shares
Additional Paid-In Capital
Accumulated Deficit
Balance - Stockholders' Equity (Deficit) (in shares) at Dec. 31, 2019   27,453 701    
Balance - Stockholders' Equity (Deficit) at Dec. 31, 2019 $ 25,042 $ 27   $ 355,268 $ (330,954)
Increase (Decrease) in Redeemable Convertible Preferred Stock and Stockholders' (Deficit) Equity          
Issuance of common stock (in shares)   187 0    
Issuance of common stock, net 440 $ 1   439  
Stock-based compensation expense 384     384  
Issuance of common stock under employee benefit plans (in shares)   4      
Issuance of common stock under employee benefit plans 0     0  
Net loss (12,853)       (12,853)
Balance - Stockholders' Equity (Deficit) (in shares) at Mar. 31, 2020   27,644 701    
Balance - Stockholders' Equity (Deficit) at Mar. 31, 2020 13,013 $ 28   356,091 (343,807)
Balance - Stockholders' Equity (Deficit) (in shares) at Dec. 31, 2020   53,019 0    
Balance - Stockholders' Equity (Deficit) at Dec. 31, 2020 8,982 $ 53   383,597 (374,668)
Increase (Decrease) in Redeemable Convertible Preferred Stock and Stockholders' (Deficit) Equity          
Issuance of common stock (in shares)   1,301      
Issuance of common stock, net 3,979 $ 1   3,978  
Stock-based compensation expense 580     580  
Issuance of warrants 120     120  
Issuance of common stock under employee benefit plans (in shares)   49      
Issuance of common stock under employee benefit plans 84     84  
Net loss (11,983)       (11,983)
Balance - Stockholders' Equity (Deficit) (in shares) at Mar. 31, 2021   54,369 0    
Balance - Stockholders' Equity (Deficit) at Mar. 31, 2021 $ 1,762 $ 54   $ 388,359 $ (386,651)
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Operating activities    
Net loss $ (11,983) $ (12,853)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 381 276
Stock-based compensation 580 384
Change in fair value of warrant liability (854) (781)
Amortization of Debt Issuance Costs and Discounts 117 109
Payments for Other Operating Activities 101 84
Changes in operating assets and liabilities (735) (1,015)
Net cash used in operating activities (12,393) (13,796)
Investing activities    
Purchases of property and equipment (1,109) (233)
Proceeds from sale of equipment 65 16
Net cash used in investing activities (1,044) (217)
Financing activities    
Proceeds from issuance of common stock, net 3,979 440
Proceeds from issuance of common stock under employee benefit plans 84 0
Payments on finance lease (23) (45)
Payment of deferred financing costs (289) 0
Proceeds from long-term debt 10,000 0
Debt prepayment costs (88) 0
Repayment of long-term debt (13,960) 0
Net cash provided by (used in) financing activities (297) 395
Net decrease in cash, cash equivalents and restricted cash (13,734) (13,618)
Cash, cash equivalents and restricted cash at beginning of period 80,400 40,758
Cash, cash equivalents and restricted cash at end of period 66,666 27,140
Non-cash financing activities and supplemental cash flow information    
Property and equipment included in accounts payable and accrued expenses 306 0
Right-of-use asset obtained in exchange for lease liabilities 0 5,931
Cash paid in connection with operating lease liabilities 709 394
Cash paid for interest $ 166 $ 261
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Organization and operations
 3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and operations Organization and operations
Genocea Biosciences, Inc. ("Genocea" or the "Company”) is a biopharmaceutical company that was incorporated in Delaware on August 16, 2006 and has a principal place of business in Cambridge, Massachusetts. The Company is dedicated to discovering and developing novel cancer immunotherapies using its proprietary ATLASTM platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or “antigen” identified by next generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, InhibigensTM, that drive pro-tumor immune responses. Genocea believes this approach ensures that cancer immunotherapies, such as vaccines and cellular therapies, focus T cell responses on the tumor targets most vulnerable to T cell targeting. Consequently, the Company believes that ATLAS may enable more immunogenic and efficacious cancer immunotherapies. Genocea operates as one segment, which is discovering, researching, developing and commercializing novel cancer immunotherapies.
Genocea's GEN-011 program is an adoptive T cell therapy comprising neoantigen-targeted peripheral T cells ("NPTs"). NPTs are peripheral blood-derived T cells targeted to ATLAS-identified anti-tumor antigens. By employing ATLAS to optimize neoantigen selection and by using T cells derived from peripheral blood, Genocea believes GEN-011 will enable potential patient efficacy, accessibility and cost advantages over other autologous T cell therapies. The Company is conducting a first-in-human clinical trial for GEN-011. Genocea's GEN-009 program is a neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified anti-tumor neoantigens. After reporting initial clinical responses for GEN-009 delivered in combination with standard-of-care checkpoint inhibitors ("CPIs") in 2020, the Company continues to monitor patients to confirm these initial efficacy signals.
Genocea is devoting substantially all of its efforts to product research and development, initial market development, and raising capital. The Company has not generated any product revenue related to its primary business purpose to date and is subject to a number of risks and uncertainties common to companies in the biotech and pharmaceutical industry, including, but not limited to, the risks associated with the uncertainty of success of its preclinical and clinical trials; the challenges associated with gaining regulatory approval of product candidates; the risks associated with commercializing pharmaceutical products, if approved for marketing and sale; the potential for development by third parties of new technological innovations that may compete with Genocea's products; the dependence on key personnel; the challenges of protecting proprietary technology; the need to comply with government regulations; the high cost of drug development; competition from other companies; the uncertainty of being able to secure additional capital when needed to fund operations; and the challenges and uncertainty associated with the outbreak of the novel coronavirus ("COVID-19") that could adversely impact the Company's operations, supply chain, preclinical development work, clinical trials and ability to raise capital.
The Company regularly evaluates whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the financial statements are issued. As of March 31, 2021, Genocea had an accumulated deficit of $386.7 million and anticipates that it will continue to incur significant operating losses for the foreseeable future as it continues to develop its product candidates. Until such time, if ever, as the Company can generate substantial product revenue and achieve profitability, Genocea expects to finance its cash needs through a combination of equity offerings, strategic transactions, or other sources of funding. If the Company is unable to raise additional funds when needed, it may be required to implement further cost reduction strategies, including ceasing development of GEN-011 or other corporate programs and activities.
Genocea had available cash and cash equivalents of $66.0 million at March 31, 2021. In addition, the Company used cash of $12.4 million in its operating activities for the three months ended March 31, 2021. Genocea’s available cash and cash equivalents at March 31, 2021 are expected to fund operations for a period of at least a year from the date the financial statements are issued.
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of significant accounting policies
 3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Summary of significant accounting policies Summary of significant accounting policies
Basis of presentation
The condensed consolidated financial statements include the accounts of the Company and a wholly owned subsidiary. Intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements and accompanying notes in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ materially from those estimates. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and accompanying notes included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “2020 10-K”).
Significant accounting policies
Genocea's significant accounting policies have not changed materially from those disclosed in the 2020 10-K.
New Accounting PronouncementsIn 2019, the Financial Accounting Standards Board issued a new standard on Simplifying the Accounting for Income Taxes. The new standard simplifies the accounting for income taxes and became effective beginning after December 15, 2020. The Company adopted this standard on January 1, 2021. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements and related disclosures.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue
 3 Months Ended
Mar. 31, 2021
Revenue Recognition and Deferred Revenue [Abstract]  
Revenue Revenue
In May 2020, Genocea entered into a material transfer agreement (the “MTA”) with Shionogi & Co., Ltd. (“Shionogi”) pursuant to which the Company agreed to transfer certain HSV-2 antigens from its GEN-003 program to Shionogi to evaluate the potential development of a novel HSV-2 vaccine. In connection with the agreement, Genocea provided Shionogi with an option to negotiate an exclusive development and commercialization license for the HSV-2 antigens.
Under the terms of the MTA, Shionogi paid the Company a total of $3.0 million in non-refundable, creditable (with respect to the up-front fee pursuant to a development and commercialization agreement) fees. Prior to the expiration of the MTA, Shionogi has the option to negotiate a development and commercialization agreement. If executed, the terms of the development and commercialization agreement are expected to include an upfront payment, regulatory and sales milestones, and tiered royalties. Final terms of the development and commercialization agreement will be based on evaluation of the HSV-2 assets and overall diligence. If licensed, Shionogi will assume responsibility for global development and commercialization of an HSV-2 vaccine product.
Genocea evaluated the promised goods and services within the MTA and determined those which represented separate performance obligations. As a result, the Company concluded there were two separate performance obligations at the inception of the MTA: (i) a combined performance obligation consisting of a limited use research license and the delivery of the initial antigen materials and (ii) the right to negotiate a license prior to expiration of the MTA, which was deemed to be a material right. The Company determined that the exclusive limited use research license and the delivery of the initial antigen materials should be combined as they are not capable of being distinct. A third party would not be able to provide the initial antigen materials as it contains Genocea’s proprietary intellectual property, and Shionogi could not benefit from the research license without the initial antigen materials. The Company determined that the option to negotiate the development and commercialization agreement prior to the expiration of the MTA is a material right. The $3.0 million fee associated with the MTA is creditable against the upfront fee for the development and commercialization agreement and represents a discount that would otherwise not be available to the customer without entering into the MTA.
Genocea estimated the standalone selling price of the initial antigen materials based on the expected cost plus a margin approach. The Company developed its standalone selling price for the material right by applying a probability-weighted likelihood that Shionogi will exercise its option to license the HSV-2 assets.
As of March 31, 2021, $1.6 million allocated to the material right is considered a contract liability and is recorded as deferred revenue on the Company's condensed consolidated balance sheet. Revenue associated with the material right will be recognized upon either (i) the execution of a development and commercialization agreement or (ii) the termination of the MTA.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Fair value of financial instruments
 3 Months Ended
Mar. 31, 2021
Cash and Cash Equivalents [Abstract]  
Fair value of financial instruments
Genocea has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.
•Level 1—Fair values are determined by utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access;
•Level 2—Fair values are determined by utilizing quoted prices for similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates; and
•Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
The Company's financial assets and liabilities measured at fair value consist of cash equivalents and warrant liabilities, respectively.
The fair value of Genocea’s cash equivalents is determined using quoted prices in active markets. The Company's cash equivalents consist of money market funds that are classified as Level 1.
The fair value of Genocea’s warrant liabilities is determined using a Monte Carlo simulation. See Note 9. Warrants for assumptions used and methodologies utilized in calculating the estimated fair value. The Company’s warrant liabilities are classified as Level 3.
The following table sets forth the Company's assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in thousands):
Quoted prices in active marketsSignificant other observable inputsSignificant unobservable inputs
Total(Level 1)(Level 2)(Level 3)
March 31, 2021
Assets:
Cash equivalents$64,144 $64,144 $— $— 
Total assets$64,144 $64,144 $— $— 
Liabilities:
Warrant liabilities$55,264 $— $— $55,264 
Total liabilities$55,264 $— $— $55,264 
December 31, 2020
Assets:
Cash equivalents$76,866 $76,866 $— $— 
Total assets$76,866 $76,866 $— $— 
Liabilities:
Warrant liabilities$56,118 $— $— $56,118 
Total liabilities$56,118 $— $— $56,118 
The following table reflects the change in Genocea’s Level 3 warrant liabilities (in thousands):
Warrant Liabilities
Balance at December 31, 2020
$56,118 
Change in fair value(854)
Balance at March 31, 2021
$55,264 
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued expenses and other current liabilities
 3 Months Ended
Mar. 31, 2021
Payables and Accruals [Abstract]  
Accrued expenses and other current liabilities Accrued expenses and other current liabilities
Accrued expenses and other current liabilities consisted of the following (in thousands):
March 31, 2021December 31, 2020
Research and development costs$2,817 $2,592 
Payroll and employee-related costs910 2,779 
Other current liabilities866 1,973 
Total$4,593 $7,344 
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and contingencies
 3 Months Ended
Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies Commitments and contingencies
Operating leases
As of March 31, 2021, Genocea has a lease for two floors of lab and office space in a multi-tenant building in Cambridge, Massachusetts through February 2025. A portion of this leased space is an expansion of the Company's initial lease. Genocea's right to use and control this expansion space began in March 2020. Genocea has the option to extend the lease term for an additional five years, which is not included in the Company's ROU assets and associated lease liabilities as of March 31, 2021. In the fourth quarter of 2020, Genocea incurred costs related to improvements made to its leased office space that were determined to be lessee assets and which were partially reimbursed by the lessor. In the first quarter of 2021, the Company recognized an increase in its lease liabilities of $0.5 million, which reflects the cash received from the lessor during the quarter for previously approved reimbursements. The Company will amortize the reimbursement as an increase to the ROU asset and a reduction in lease expense over the remaining lease term.
In January 2021, Genocea entered into a sublease agreement for one floor of lab and office space through June 2022, with an option for the sublessee to extend the sublease for an additional two months. After the initial option, which is at the sublessee’s sole discretion, the sublease agreement contains additional options for the Company and the sublessee to mutually extend the sublease for up to an additional eighteen months. As Genocea retained its obligations under the sublease, it will record the payments received from the sublease as a reduction of lease expense. For the three months ended March 31, 2021, the Company recorded sublease income of $0.4 million.
For the three months ended March 31, 2021 and 2020 lease expense, net of sublease income, was $0.3 million and $0.5 million, respectively.
The weighted average remaining lease term and weighted average discount rate of the Company's operating leases are as follows:
March 31, 2021December 31, 2020
Weighted average remaining lease term in years3.914.17
Weighted average discount rate8.13 %8.12 %
The following table summarizes the presentation of leases in the Company's condensed consolidated balance sheets (in thousands):
ClassificationMarch 31, 2021December 31, 2020
Assets
OperatingRight of use assets$8,831 $9,278 
FinanceRight of use assets— 30 
Total lease assets$8,831 $9,308 
Liabilities
Current
   OperatingLease liabilities$2,156 $1,592 
   FinanceLease liabilities— 22 
Non-current
   OperatingLease liabilities, net of current portion7,839 8,398 
Total lease liabilities$9,995 $10,012 
The minimum lease payments related to the Company's operating leases as of March 31, 2021 were as follows (in thousands):
Remainder of 2021$2,162 
20222,943 
20233,017 
20243,092 
2025517 
Total lease payments11,731 
Less imputed interest(1,736)
Total$9,995 
At March 31, 2021 and December 31, 2020, the Company had an outstanding letter of credit of $0.6 million, with a financial institution related to a security deposit for the office and lab space lease, which is secured by cash on deposit and expires in February 2025.
Contractual obligations
Genocea has entered into certain agreements with various universities, contract research organizations and contract manufacturing organizations, which generally include cancellation clauses.
Harvard University license agreement
Genocea has an exclusive license agreement with Harvard University (“Harvard”), granting the Company an exclusive, worldwide, royalty-bearing, sublicensable license to three patent families, to develop, make, have made, use, market, offer for sale, sell, have sold and import licensed products and to perform licensed services related to the ATLAS discovery platform. Genocea is also obligated to pay Harvard milestone payments up to $1.6 million in the aggregate upon the achievement of certain development and regulatory milestones. As of March 31, 2021, the Company has paid $0.3 million in aggregate milestone payments. Genocea is obligated under this license agreement to use commercially reasonable efforts to develop, market and sell licensed products in compliance with an agreed-upon development plan. In addition, the Company is obligated to achieve specified development milestones and in the event Genocea is unable to meet its development milestones for any type of product or service, absent any reasonable proposed extension or amendment thereof, Harvard has the right, depending on the type of product or service, to terminate this agreement with respect to such products or to convert the license to a non-exclusive, non-sublicensable license with respect to such products and services.
Upon commercialization of the Company's products covered by the licensed patent rights or discovered using the licensed methods, Genocea is obligated to pay Harvard royalties on the net sales of such products and services sold by the Company, the Company's affiliates, and the Company's sublicensees. This royalty varies depending on the type of product or service but is in the low single digits. The sales-based royalty due by the Company’s sublicensees is the greater of the applicable royalty rate or a percentage in the high single digits or the low double digits of the royalties Genocea receives from such sublicensee, depending on the type of product. Based on the type of commercialized product or service, royalties are payable until the expiration of the last-to-expire valid claim under the licensed patent rights or for a period of 10 years from first commercial sale of such product or service. The royalties payable to Harvard are subject to reduction, capped at a specified percentage, for any third-party payments required to be made. In addition to the royalty payments, if the Company receives any additional revenue (cash or non-cash) under any sublicense, it must pay Harvard a percentage of such revenue, excluding certain categories of payments, varying from the low single digits to up to the low double digits depending on the scope of the license that includes the sublicense.
The license agreement with Harvard will expire on a product-by-product or service-by-service and country-by-country basis until the expiration of the last-to-expire valid claim under the licensed patent rights. The Company may terminate the agreement at any time by giving Harvard advance written notice. Harvard may also terminate the agreement in the event of a material breach by the Company that remains uncured; in the event of the Company's insolvency, bankruptcy, or similar circumstances; or if Genocea challenges the validity of any patents licensed to it.
Oncovir license and supply agreement
Genocea has a license and supply agreement with Oncovir, Inc. (“Oncovir”) under which Oncovir will manufacture and supply an immunomodulator and vaccine adjuvant, Hiltonol® (poly-ICLC) (“Hiltonol”), to the Company for use in connection with the research, development, use, sale, manufacture, commercialization and marketing of products combining Hiltonol with the Company's technology (the “Combination Product”). Hiltonol is the adjuvant component of GEN-009, which will consist of synthetic long peptides or neoantigens identified using the Company's proprietary ATLAS platform, formulated with Hiltonol. 
Oncovir granted the Company a non-exclusive, assignable, royalty-bearing worldwide license, with the right to grant sublicenses through one tier, to certain of Oncovir’s intellectual property in connection with the research, development, or commercialization of Combination Products, including the use of Hiltonol, but not the use of Hiltonol for manufacturing or the use or sale of Hiltonol alone. The license will become perpetual, fully paid-up, and royalty-free on the later of January 25, 2028 or the date on which the last valid claim of any patent licensed to the Company under the agreement expires.
Under this agreement, Genocea is obligated to pay Oncovir low to mid six figure milestone payments upon the achievement of certain clinical trial milestones for each Combination Product and the first marketing approval for each Combination Product in certain territories, as well as tiered royalties in the low-single digits on a product-by-product basis based on the net sales of Combination Products.
Genocea may terminate the agreement upon a decision to discontinue the development of the Combination Product or upon a determination by the Company or an applicable regulatory authority that Hiltonol or a Combination Product is not clinically safe or effective. The agreement may also be terminated by either party due to a material uncured breach by the other party, or due to the other party’s bankruptcy, insolvency, or dissolution.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Debt
 3 Months Ended
Mar. 31, 2021
Debt Disclosure [Abstract]  
Debt Debt
In April 2018, the Company entered into an amended and restated loan and security agreement, which was subsequently amended in November 2019 (as amended, the “Hercules Loan Agreement”), with Hercules Capital, Inc. (“Hercules”). The Hercules Loan Agreement provided a $14.0 million secured term loan that was scheduled to mature on May 1, 2021 and that accrued interest at a floating rate per annum equal to the greater of (i) 8.00%, or (ii) the sum of 3.00% plus the prime rate. The Company was also obligated to pay a final payment charge of $1.0 million at maturity.
On February 18, 2021 (the "2021 Loan Closing Date"), Genocea entered into a Loan and Security Agreement (the "2021 Loan Agreement") with Silicon Valley Bank ("SVB") for a $10 million secured term loan (the "2021 Term Loan"). $9.0 million of the proceeds from the 2021 Term Loan were used to repay the Company's borrowings that were outstanding at the 2021 Loan Closing Date under its previous loan and security agreement with Hercules, paying off all obligations owing under, and extinguishing, the Hercules Loan Agreement on the 2021 Loan Closing Date. The remaining proceeds from the 2021 Term Loan of $1.0 million were received by the Company for working capital and general corporate purposes.
The 2021 Term Loan will mature on September 1, 2023, which may be extended to March 1, 2024 if certain performance milestones are achieved and no event of default has occurred or is continuing. The 2021 Term Loan accrues interest at a floating per annum rate equal to the greater of (i) 6.25% or (ii) the sum of 3.0% plus the prime rate. The 2021 Term Loan provides for interest-only payments until September 30, 2021, which may be extended to March 31, 2022 if certain performance milestones are achieved and no event of default has occurred or is continuing. Thereafter, amortization payments will be payable monthly in equal installments of principal and interest (subject to recalculation upon a change in prime rates) upon expiration of the interest-only period through maturity. The 2021 Term Loan is subject to a final payment charge of $0.5 million. The 2021 Term Loan may be prepaid in whole (but not in part), subject to a prepayment charge of 3.0%, if prepaid in any of the first twelve (12) months following the Closing Date, 2.0%, if prepaid after twelve (12) months following the Closing Date but on or prior to twenty four (24) months following the Closing Date, and 1.0% thereafter.
The 2021 Term Loan is secured by a lien on substantially all of the assets of the Company, other than intellectual property, provided that such lien on substantially all assets includes any rights to payments and proceeds from the sale, licensing or disposition of intellectual property.
The 2021 Loan Agreement contains customary covenants and representations, including a financial reporting covenant and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. There are no financial covenants. As of March 31, 2021, the Company was in compliance with all covenants under the 2021 Loan Agreement.
The 2021 Loan Agreement also includes customary events of default, including payment defaults, breaches of covenants, change of control and occurrence of a material adverse effect. Amounts outstanding during an event of default shall be payable on demand and shall accrue interest at an additional rate of 4.0% per annum of the past due amount outstanding. The Company has determined that the risk of subjective acceleration under the material adverse events clause was remote and therefore has classified the long-term portion of the outstanding principal in non-current liabilities.
In connection with the 2021 Loan Agreement, Genocea issued to SVB a warrant, dated February 18, 2021 (the "SVB Warrant") to purchase 43,478 shares of the common stock of the Company. See Note 9. Warrants. The Company recorded the fair value of the SVB warrant as a discount on the 2021 Term Loan that will be amortized over the expected term of the loan.
As of March 31, 2021 and December 31, 2020, the Company had outstanding borrowings, net of unamortized debt issuance costs, of $9.6 million and $13.9 million, respectively. Interest expense was $0.3 million and $0.4 million for the three months ended March 31, 2021 and 2020, respectively.
Future principal payments, including final payment charges, as of March 31, 2021 are as follows:
Principal Payments on Long-Term Debt
Remainder of 2021$1,250 
20225,000 
20234,250 
$10,500 
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' equity
 3 Months Ended
Mar. 31, 2021
Equity [Abstract]  
Stockholders' equity Stockholders' equity
Agreement with Lincoln Park Capital
Genocea has a purchase agreement with Lincoln Park Capital (“LPC”) pursuant to which, for a period of 30 months beginning in October 2019, the Company has the right, at its sole discretion, to sell up to an additional $27.5 million of the Company's common stock to LPC based on prevailing market prices of its common stock at the time of each sale. The purchase agreement limits the Company's sales of shares of common stock to LPC to approximately 5.2 million shares of common stock, representing 19.99% of the shares of common stock outstanding on the date of the purchase agreement. The purchase agreement also prohibits the Company from directing LPC to purchase any shares of common stock if those shares, when aggregated with all other shares of the Company's common stock then beneficially owned by LPC and its affiliates, would result in LPC and its affiliates having beneficial ownership, at any single point in time, of more than 9.99% of the then total outstanding shares of the Company's common stock. As of March 31, 2021, the Company had $24.0 million remaining under its agreement with LPC.
At-the-market equity offering program
Genocea has an agreement with Cowen and Company, LLC ("Cowen") to establish an at-the-market equity offering program (“ATM”) pursuant to which Cowen is able to offer and sell up to $50.0 million of the Company's common stock at prevailing market prices. In the three months ended March 31, 2021, the Company sold approximately 1.3 million shares under the ATM program and received net proceeds of $4.0 million, after deducting commissions. Through March 31, 2021, the Company has sold an aggregate of approximately 4.2 million shares under the ATM and received $13.8 million in net proceeds. As of March 31, 2021, the Company had $35.8 million in gross proceeds remaining under the ATM.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Warrants Warrants
 3 Months Ended
Mar. 31, 2021
Warrants [Abstract]  
Warrants Warrants
As of March 31, 2021, the Company had the following potentially issuable shares of common stock related to unexercised warrants outstanding (shares in thousands):
SharesExercise PriceExpiration DateClassification
Hercules Warrant41 $6.80 Q2 2023Equity
2018 Warrants3,617 $9.60 Q1 2023Liability
2019 Warrants933 $4.52 Q1 2024Equity
2019 Pre-Funded Warrants531 $0.08 Q1 2039Equity
2020 Warrants33,613 $2.25 Q3 2024Liability
2020 Pre-Funded Warrants12,223 $0.01 N/AEquity
SVB Warrant43 $3.45 Q1 2026Equity
51,001 
Hercules Warrant
The exercise price and the number of shares are subject to adjustment upon a merger event, reclassification of the shares of common stock, subdivision or combination of the shares of common stock or certain dividend payments. Genocea determined that the Hercules Warrant should be equity-classified.
2018 Warrants
The exercise price and the number of shares are subject to adjustment upon a merger event, reclassification of the shares of common stock, subdivision or combination of the shares of common stock or certain dividend payments. In the event of an “Acquisition,” defined generally to include a merger or consolidation resulting in the sale of 50% or more of the voting securities of the Company, the sale of all, or substantially all, of the assets or voting securities of the Company, or other change of control transaction, as defined in the 2018 Warrants, Genocea will be obligated to use its best efforts to ensure that the holders of the 2018 Warrants receive new warrants from the surviving or acquiring entity (the “Acquirer”). The new warrants to purchase shares in the Acquirer shall have the same expiration date as the 2018 Warrants and a strike price that is based on the proportion of the value of the Acquirer’s stock to the Company’s common stock. If the Company is unable, despite its best efforts, to cause the Acquirer to issue new warrants in the Acquisition as described above, then, if the Company’s stockholders are to receive cash in the Acquisition, Genocea will settle the 2018 Warrants in cash and if the Company’s stockholders are to receive stock in the Acquisition, Genocea will issue shares of its common stock to each Warrant holder.
As a result, the Company determined that the 2018 Warrants should be liability-classified. As the 2018 Warrants are liability-classified, the Company remeasures the fair value at each reporting date. Genocea initially recorded the 2018 Warrants at their estimated fair value of $18.2 million. In connection with the Company's remeasurement of the 2018 Warrants to fair value, it recorded income of $0.2 million and $0.8 million for the three months ended March 31, 2021 and 2020, respectively. The fair value of the warrant liability related to the 2018 Warrants is $1.5 million and $1.7 million as of March 31, 2021 and December 31, 2020, respectively.
The following table details the assumptions used in the Monte Carlo simulation models used to estimate the fair value of the 2018 Warrants as of March 31, 2021 and December 31, 2020, respectively:
March 31, 2021December 31, 2020
Stock price$2.71 $2.42 
Volatility
50.0% - 95.3%
50.0% - 101.5%
Remaining term (years)1.82.0
Expected dividend yield— %— %
Risk-free rate0.16 %0.13 %
Acquisition event probability25.0 %25.0 %
2019 Warrants and 2019 Pre-Funded Warrants
The exercise price of the warrants is subject to appropriate adjustment in the event of stock dividends, subdivisions, stock splits, stock combinations, reclassifications, reorganizations or a change of control affecting the Company's common stock. Genocea determined that the 2019 Warrants and the 2019 Pre-Funded Warrants should be equity-classified. The Company also determined that the 2019 Pre-Funded Warrants should be included in the determination of basic earnings per share.
2020 Warrants and 2020 Pre-Funded Warrants
The exercise price of the 2020 Pre-Funded Warrants and the 2020 Warrants is subject to adjustment in the event of stock dividends, subdivisions, stock splits, stock combinations, reclassifications, reorganizations or a change of control affecting the Company's common stock. Genocea determined that the 2020 Pre-Funded Warrants should be equity-classified and be included in the determination of basic earnings per share.
The holders of the 2020 Warrants are entitled to down round protection until July 24, 2021. The Company is required to obtain shareholder approval for the adjustment to the exercise price as a result of any common stock issuance at a price per share less than $2.25. As a result, Genocea determined that the 2020 Warrants should be liability-classified for the period from issuance through July 2021. As the 2020 Warrants are liability-classified, the Company remeasures the fair value at each reporting date. Genocea initially recorded the 2020 Warrants at their estimated fair value of $62.5 million. In connection with the Company's remeasurement of the 2020 Warrants to fair value, the Company recorded income of $0.7 million for the three months ended March 31, 2021. The fair value of the warrant liability related to the 2020 Warrants is $53.8 million and $54.5 million as of March 31, 2021 and December 31, 2020, respectively.
The following table details the assumptions used in the Monte Carlo simulation models used to estimate the fair value of the 2020 Warrants as of March 31, 2021 and December 31, 2020, respectively:
March 31, 2021December 31, 2020
Stock price$2.71 $2.42 
Volatility93.9 %119.1 %
Remaining term (years)3.33.6
Expected dividend yield— — 
Risk-free rate0.44 %0.22 %
Acquisition event probability40.0 %40.0 %
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Employee benefit plans
 3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Employee benefit plans Employee benefit plans
Genocea grants equity awards in the form of stock options and service-based and market-based restricted stock units (“RSUs”) to employees and directors of, and consultants and advisors to, the Company through its Amended and Restated 2014 Equity Incentive Plan, ("2014 Equity Incentive Plan"). As of March 31, 2021, there were approximately 0.7 million shares remaining for future issuance under the 2014 Equity Incentive Plan.
The options have a ten-year term and were issued with an exercise price equal to the closing market price of Genocea’s common stock on the grant date. For equity awards with service-based vesting conditions, the Company recognizes compensation expense over the vesting period, which is generally over a four-year period. For equity awards with a market-based vesting condition, the Company recognizes compensation expense over the requisite service period. The number of shares issuable, if any, when a market-based RSU award vests will depend on the degree of achievement of the corporate stock price metrics within the performance period of the award. The Company measures the fair value of stock options on the date of grant using the Black-Scholes option pricing model. The fair value of the service-based RSUs is the closing market price of Genocea's common stock on the grant date.
Determining the fair value of market-based RSUs
The Company measures the fair value of market-based RSUs on the date of grant using a Monte Carlo simulation model. The Monte Carlo simulation requires the input of assumptions, including the Company's stock price, the volatility of its stock price, remaining term in years, expected dividend yield, and risk-free rate. In addition, the valuation model considers the Company's probability of being acquired within the term of the market-based RSUs, as an acquisition event can potentially impact the vesting. The Company used its own trading history to calculate the expected volatility of the market-based RSUs granted. The risk-free interest rate is determined by reference to implied yields available from U.S. Treasury securities with a remaining term equal to the expected term assumed at the grant date.
The following table details the assumptions used in the Monte Carlo simulation model used to estimate the fair value of the market-based RSUs granted during the three months ended March 31, 2021:
Three Months Ended March 31
2021
Stock price$3.01 
Volatility97.65 %
Remaining term (years)2.8
Risk-free rate0.29 %
Annual acquisition event probability33.0 %
Stock-based compensation expense
Total stock-based compensation expense recognized for stock options and RSUs is as follows (in thousands):
Three Months Ended March 31
20212020
Research and development$258 $160 
General and administrative322 224 
Total$580 $384 
Stock options
The following table summarizes stock option activity (shares and aggregate intrinsic value in thousands):
SharesWeighted-Average
Exercise Price		Weighted-Average
Remaining Contractual
Term (years)		Aggregate
Intrinsic Value
Outstanding at December 31, 2020
2,329 $7.05 $505 
Granted1,614 $3.01   
Exercised(38)$2.22   
Forfeited/cancelled(66)$12.82   
Outstanding at March 31, 2021
3,839 $5.30 8.8$715 
Exercisable at March 31, 2021
930 $12.61 7.0$134 
RSUs
The following table summarizes RSU activity (shares in thousands):
SharesWeighted-Average Grant Date Fair Value
Outstanding as of December 31, 2020
550 $2.13 
Granted(1)
1,904 $2.52 
Vested(11)$1.98 
Forfeited/cancelled(9)$2.11 
Outstanding as of March 31, 2021
2,434 $2.44 
    _________________________
1.The number granted represents the number of shares issuable upon vesting of service-based and market-based RSUs, assuming the Company achieves its corporate stock price metrics at the target achievement level.
Employee stock purchase plan
The 2014 Employee Stock Purchase Plan, as amended (the "ESPP"), issues shares of common stock to participating eligible employees during two six-month offering periods each year. As of March 31, 2021, there were approximately 0.1 million shares remaining for future issuance under the ESPP.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Net loss per share
 3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Net loss per share Net loss per share
Basic and diluted net loss per share was calculated as follows for the three months ended March 31, 2021 and 2020 (in thousands, except per share amounts):
Three Months Ended March 31
20212020
Numerator:
Net loss$(11,983)$(12,853)
Less: Change in fair value of 2020 Warrants
673 — 
Adjusted net loss$(12,656)$(12,853)
Denominator:
Weighted average common stock outstanding – basic66,158 28,141 
Dilutive effect of common stock issuable from
   assumed exercise of warrants		8,062 — 
Weighted average common stock outstanding – diluted74,220 28,141 
Net loss per share:
Basic$(0.18)$(0.46)
Diluted$(0.17)$(0.46)
The following potential common shares were excluded from the calculation of net loss per share due to their anti-dilutive effect for the three months ended March 31, 2021 and 2020 (in thousands):
 Three Months Ended March 31
 20212020
Warrants4,634 4,591 
Stock options3,839 1,370 
RSUs2,434 45 
Total10,907 6,006 
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of significant accounting policies (Policies)
 3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Basis of presentation
Basis of presentation
The condensed consolidated financial statements include the accounts of the Company and a wholly owned subsidiary. Intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements and accompanying notes in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ materially from those estimates. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and accompanying notes included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “2020 10-K”).
Significant accounting policies
Significant accounting policies
Genocea's significant accounting policies have not changed materially from those disclosed in the 2020 10-K.
New Accounting PronouncementsIn 2019, the Financial Accounting Standards Board issued a new standard on Simplifying the Accounting for Income Taxes. The new standard simplifies the accounting for income taxes and became effective beginning after December 15, 2020. The Company adopted this standard on January 1, 2021. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements and related disclosures.
Fair value of financial instruments
Genocea has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.
•Level 1—Fair values are determined by utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access;
•Level 2—Fair values are determined by utilizing quoted prices for similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates; and
•Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
The Company's financial assets and liabilities measured at fair value consist of cash equivalents and warrant liabilities, respectively.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Fair value of financial instruments (Tables)
 3 Months Ended
Mar. 31, 2021
Cash and Cash Equivalents [Abstract]  
Schedule of Stockholders' Equity Note, Warrants or Rights
As of March 31, 2021, the Company had the following potentially issuable shares of common stock related to unexercised warrants outstanding (shares in thousands):
SharesExercise PriceExpiration DateClassification
Hercules Warrant41 $6.80 Q2 2023Equity
2018 Warrants3,617 $9.60 Q1 2023Liability
2019 Warrants933 $4.52 Q1 2024Equity
2019 Pre-Funded Warrants531 $0.08 Q1 2039Equity
2020 Warrants33,613 $2.25 Q3 2024Liability
2020 Pre-Funded Warrants12,223 $0.01 N/AEquity
SVB Warrant43 $3.45 Q1 2026Equity
51,001 
Schedule of financial instruments measured at fair value on recurring basis
Quoted prices in active marketsSignificant other observable inputsSignificant unobservable inputs
Total(Level 1)(Level 2)(Level 3)
March 31, 2021
Assets:
Cash equivalents$64,144 $64,144 $— $— 
Total assets$64,144 $64,144 $— $— 
Liabilities:
Warrant liabilities$55,264 $— $— $55,264 
Total liabilities$55,264 $— $— $55,264 
December 31, 2020
Assets:
Cash equivalents$76,866 $76,866 $— $— 
Total assets$76,866 $76,866 $— $— 
Liabilities:
Warrant liabilities$56,118 $— $— $56,118 
Total liabilities$56,118 $— $— $56,118 
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
The following table reflects the change in Genocea’s Level 3 warrant liabilities (in thousands):
Warrant Liabilities
Balance at December 31, 2020
$56,118 
Change in fair value(854)
Balance at March 31, 2021
$55,264 
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued expenses and other current liabilities (Tables)
 3 Months Ended
Mar. 31, 2021
Payables and Accruals [Abstract]  
Schedule of accrued expenses and other current liabilities
Accrued expenses and other current liabilities consisted of the following (in thousands):
March 31, 2021December 31, 2020
Research and development costs$2,817 $2,592 
Payroll and employee-related costs910 2,779 
Other current liabilities866 1,973 
Total$4,593 $7,344 
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and contingencies (Tables)
 3 Months Ended
Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Lease, Cost
The weighted average remaining lease term and weighted average discount rate of the Company's operating leases are as follows:
March 31, 2021December 31, 2020
Weighted average remaining lease term in years3.914.17
Weighted average discount rate8.13 %8.12 %
Assets And Liabilities, Lessee
The following table summarizes the presentation of leases in the Company's condensed consolidated balance sheets (in thousands):
ClassificationMarch 31, 2021December 31, 2020
Assets
OperatingRight of use assets$8,831 $9,278 
FinanceRight of use assets— 30 
Total lease assets$8,831 $9,308 
Liabilities
Current
   OperatingLease liabilities$2,156 $1,592 
   FinanceLease liabilities— 22 
Non-current
   OperatingLease liabilities, net of current portion7,839 8,398 
Total lease liabilities$9,995 $10,012 
Lessee, Operating Lease, Liability, Maturity
The minimum lease payments related to the Company's operating leases as of March 31, 2021 were as follows (in thousands):
Remainder of 2021$2,162 
20222,943 
20233,017 
20243,092 
2025517 
Total lease payments11,731 
Less imputed interest(1,736)
Total$9,995 
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Debt (Tables)
 3 Months Ended
Mar. 31, 2021
Debt Disclosure [Abstract]  
Schedule of future principal payments
Future principal payments, including final payment charges, as of March 31, 2021 are as follows:
Principal Payments on Long-Term Debt
Remainder of 2021$1,250 
20225,000 
20234,250 
$10,500 
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Warrants (Tables)
 3 Months Ended
Mar. 31, 2021
Warrants [Abstract]  
Schedule of Stockholders' Equity Note, Warrants or Rights
As of March 31, 2021, the Company had the following potentially issuable shares of common stock related to unexercised warrants outstanding (shares in thousands):
SharesExercise PriceExpiration DateClassification
Hercules Warrant41 $6.80 Q2 2023Equity
2018 Warrants3,617 $9.60 Q1 2023Liability
2019 Warrants933 $4.52 Q1 2024Equity
2019 Pre-Funded Warrants531 $0.08 Q1 2039Equity
2020 Warrants33,613 $2.25 Q3 2024Liability
2020 Pre-Funded Warrants12,223 $0.01 N/AEquity
SVB Warrant43 $3.45 Q1 2026Equity
51,001 
Fair Value Measurement Inputs and Valuation Techniques
The following table details the assumptions used in the Monte Carlo simulation models used to estimate the fair value of the 2018 Warrants as of March 31, 2021 and December 31, 2020, respectively:
March 31, 2021December 31, 2020
Stock price$2.71 $2.42 
Volatility
50.0% - 95.3%
50.0% - 101.5%
Remaining term (years)1.82.0
Expected dividend yield— %— %
Risk-free rate0.16 %0.13 %
Acquisition event probability25.0 %25.0 %
The following table details the assumptions used in the Monte Carlo simulation models used to estimate the fair value of the 2020 Warrants as of March 31, 2021 and December 31, 2020, respectively:
March 31, 2021December 31, 2020
Stock price$2.71 $2.42 
Volatility93.9 %119.1 %
Remaining term (years)3.33.6
Expected dividend yield— — 
Risk-free rate0.44 %0.22 %
Acquisition event probability40.0 %40.0 %
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Employee benefit plans (Tables)
 3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award
The following table details the assumptions used in the Monte Carlo simulation model used to estimate the fair value of the market-based RSUs granted during the three months ended March 31, 2021:
Three Months Ended March 31
2021
Stock price$3.01 
Volatility97.65 %
Remaining term (years)2.8
Risk-free rate0.29 %
Annual acquisition event probability33.0 %
Schedule of stock-based compensation expense for stock options granted to employees and non-employees
Total stock-based compensation expense recognized for stock options and RSUs is as follows (in thousands):
Three Months Ended March 31
20212020
Research and development$258 $160 
General and administrative322 224 
Total$580 $384 
Schedule of stock option activity for employees and nonemployees
The following table summarizes stock option activity (shares and aggregate intrinsic value in thousands):
SharesWeighted-Average
Exercise Price		Weighted-Average
Remaining Contractual
Term (years)		Aggregate
Intrinsic Value
Outstanding at December 31, 2020
2,329 $7.05 $505 
Granted1,614 $3.01   
Exercised(38)$2.22   
Forfeited/cancelled(66)$12.82   
Outstanding at March 31, 2021
3,839 $5.30 8.8$715 
Exercisable at March 31, 2021
930 $12.61 7.0$134 
The following table summarizes RSU activity (shares in thousands):
SharesWeighted-Average Grant Date Fair Value
Outstanding as of December 31, 2020
550 $2.13 
Granted(1)
1,904 $2.52 
Vested(11)$1.98 
Forfeited/cancelled(9)$2.11 
Outstanding as of March 31, 2021
2,434 $2.44 
    _________________________
1.The number granted represents the number of shares issuable upon vesting of service-based and market-based RSUs, assuming the Company achieves its corporate stock price metrics at the target achievement level
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Net loss per share (Tables)
 3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
Basic and diluted net loss per share was calculated as follows for the three months ended March 31, 2021 and 2020 (in thousands, except per share amounts):
Three Months Ended March 31
20212020
Numerator:
Net loss$(11,983)$(12,853)
Less: Change in fair value of 2020 Warrants
673 — 
Adjusted net loss$(12,656)$(12,853)
Denominator:
Weighted average common stock outstanding – basic66,158 28,141 
Dilutive effect of common stock issuable from
   assumed exercise of warrants		8,062 — 
Weighted average common stock outstanding – diluted74,220 28,141 
Net loss per share:
Basic$(0.18)$(0.46)
Diluted$(0.17)$(0.46)
Schedule of common stock equivalents, presented on converted basis, were excluded from calculation of net loss per share due to anti-dilutive effect
The following potential common shares were excluded from the calculation of net loss per share due to their anti-dilutive effect for the three months ended March 31, 2021 and 2020 (in thousands):
 Three Months Ended March 31
 20212020
Warrants4,634 4,591 
Stock options3,839 1,370 
RSUs2,434 45 
Total10,907 6,006 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Organization and operations (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
USD ($)
segments
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Accumulated deficit $ (386,651)   $ (374,668)
Cash and cash equivalents 66,035   $ 79,769
Cash used in operating activities $ (12,393) $ (13,796)  
Number of operating segments | segments 1    
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue (Details) - USD ($)
$ in Thousands
 1 Months Ended
May 31, 2020
Mar. 31, 2021
Dec. 31, 2020
Disaggregation of Revenue [Line Items]      
Deferred revenue   $ 1,641 $ 1,641
Material Transfer Agreement | Shionogi & Co., Ltd.      
Disaggregation of Revenue [Line Items]      
Revenue $ 3,000    
Deferred revenue   $ 1,600  
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Fair value of financial instruments - Schedule of cash equivalents and investments carried at fair value (Details) - Fair Value, Measurements, Recurring - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Assets, Fair Value Disclosure [Abstract]    
Assets, Fair Value Disclosure $ 64,144 $ 76,866
Liabilities, Fair Value Disclosure [Abstract]    
Financial Liabilities Fair Value Disclosure, Total 55,264 56,118
Warrants    
Liabilities, Fair Value Disclosure [Abstract]    
Warrant liabilities 55,264 56,118
Money market funds    
Assets, Fair Value Disclosure [Abstract]    
Included in cash equivalents 64,144 76,866
Level 1    
Assets, Fair Value Disclosure [Abstract]    
Assets, Fair Value Disclosure 64,144 76,866
Liabilities, Fair Value Disclosure [Abstract]    
Financial Liabilities Fair Value Disclosure, Total 0 0
Level 1 | Warrants    
Liabilities, Fair Value Disclosure [Abstract]    
Warrant liabilities 0 0
Level 1 | Money market funds    
Assets, Fair Value Disclosure [Abstract]    
Included in cash equivalents 64,144 76,866
Level 2    
Assets, Fair Value Disclosure [Abstract]    
Assets, Fair Value Disclosure 0 0
Liabilities, Fair Value Disclosure [Abstract]    
Financial Liabilities Fair Value Disclosure, Total 0 0
Level 2 | Warrants    
Liabilities, Fair Value Disclosure [Abstract]    
Warrant liabilities 0 0
Level 2 | Money market funds    
Assets, Fair Value Disclosure [Abstract]    
Included in cash equivalents 0 0
Level 3    
Assets, Fair Value Disclosure [Abstract]    
Assets, Fair Value Disclosure 0 0
Liabilities, Fair Value Disclosure [Abstract]    
Financial Liabilities Fair Value Disclosure, Total 55,264 56,118
Level 3 | Warrants    
Liabilities, Fair Value Disclosure [Abstract]    
Warrant liabilities 55,264 56,118
Level 3 | Money market funds    
Assets, Fair Value Disclosure [Abstract]    
Included in cash equivalents $ 0 $ 0
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Fair value of financial instruments - Change in the Company’s Level 3 Warrant liabilities (Details) - Warrants - Level 3
$ in Thousands
 3 Months Ended
Mar. 31, 2021
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Beginning Balance $ 56,118
Change in fair value (854)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Ending Balance $ 55,264
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued expenses and other current liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Research and development costs $ 2,817 $ 2,592
Payroll and employee-related costs 910 2,779
Other Liabilities, Current 866 1,973
Accrued Expenses and Other Current Liabilities $ 4,593 $ 7,344
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and contingencies - Narrative (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
USD ($)
floor
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Operating Leased Assets [Line Items]      
Operating lease liability $ 9,995    
Sublease Income 400    
Licensing agreement, amount 1,600    
Licensing agreement, milestone payment, amount 300    
Operating lease expense $ 300 $ 500  
Patents      
Operating Leased Assets [Line Items]      
Useful life (in years) 10 years    
Lease Extension for office and lab space      
Operating Leased Assets [Line Items]      
Number of floors leased | floor 2    
Operating lease liability $ 500    
Master Facilities Operating Lease Due February 28, 2025      
Operating Leased Assets [Line Items]      
Restricted cash and cash equivalents $ 600   $ 600
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and contingencies - Operating Lease Term and Discount Rate (Details)
Mar. 31, 2021
Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]    
Weighted average remaining lease term (in years) 3 years 10 months 28 days 4 years 2 months 1 day
Weighted average discount rate 8.13% 8.12%
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and contingencies - Supplemental Balance Sheet (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Lease Assets [Abstract]    
Operating lease, right-of-use asset $ 8,831 $ 9,278
Finance Lease, Right-of-Use Asset 0 30
Finance and Operating Lease, Right-of-Use Asset 8,831 9,308
Lease Liabilities, Current [Abstract]    
Operating Lease, Liability, Current 2,156 1,592
Finance Lease, Liability, Current 0 22
Lease Liabilities, Noncurrent [Abstract]    
Operating Lease, Liability, Noncurrent 7,839 8,398
Total $ 9,995 $ 10,012
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and contingencies - Future minimum lease payments (Details)
$ in Thousands
Mar. 31, 2021
USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]  
Remainder of 2021 $ 2,162
2022 2,943
2023 3,017
2024 3,092
2025 517
Total lease payments 11,731
Less imputed interest (1,736)
Total $ 9,995
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Debt - Narrative (Details) - USD ($)
 3 Months Ended
Feb. 18, 2021
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Nov. 30, 2019
Apr. 24, 2018
Long-Term Debt            
Repayments of Debt   $ 13,960,000 $ 0      
2018 Term Loan | Line of Credit            
Long-Term Debt            
Debt financing           $ 14,000,000.0
Interest rate (as a percent)           8.00%
End of term charge         $ 1,000,000.0  
Repayments of Debt $ 9,000,000.0          
2018 Term Loan | Line of Credit | Prime rate            
Long-Term Debt            
Variable rate (as a percent)           3.00%
2014 Term Loan, First Tranche | Line of Credit            
Long-Term Debt            
Outstanding borrowings   9,600,000   $ 13,900,000    
2014 Term Loan | Line of Credit            
Long-Term Debt            
Interest expense   $ 300,000 $ 400,000      
2021 Term Loan | Notes Payable to Banks            
Long-Term Debt            
Interest rate (as a percent) 625.00%          
End of term charge $ 500,000          
Debt Instrument, Covenant Compliance, Prepayment Charge, Period One, Percent 3.00%          
Debt Instrument, Covenant Compliance, Prepayment Charge, Period Two, Percent 2.00%          
Debt Instrument, Covenant Compliance, Prepayment Charge, Period Three, Percent 1.00%          
Debt Instrument, Interest Rate, Default Rate, Additional Annual Interest Rate, Percent 4.00%          
Debt Instrument, Face Amount $ 10,000,000          
Proceeds from Loans $ 1,000,000.0          
2021 Term Loan | Notes Payable to Banks | Prime rate            
Long-Term Debt            
Debt Instrument, Basis Spread on Variable Rate 300.00%          
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Debt (Details) - 2021 Term Loan - Notes Payable to Banks
$ in Thousands
Mar. 31, 2021
USD ($)
Long-Term Debt  
1250000 $ 1,250
2022 5,000
2023 4,250
Long-term debt $ 10,500
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' equity - Narrative (Details) - USD ($)
shares in Thousands, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 73 Months Ended
Oct. 31, 2019
Mar. 31, 2021
Mar. 31, 2020
Sep. 30, 2016
Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Proceeds from issuance of common stock   $ 3,979 $ 440    
Common Stock          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Issuance of common stock (in shares)   1,301 187    
At-the-market equity offering program | Common Stock          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Issuance of common stock (in shares)         4,200
Shares authorized for issuance, remaining amount (in shares)   $ 35,800     $ 35,800
Proceeds from issuance of common stock         13,800
At-the-market equity offering program | Common Stock | Private placement          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Shares authorized for issuance, value       $ 50,000  
Number of shares issued in transaction (in shares)   1,300      
Sale of stock, consideration received on transaction   $ 4,000      
Lincoln Park Capital | Common Stock          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Purchase agreement period (in months) 30 months        
Shares authorized for issuance, value $ 27,500        
Shares authorized for issuance, remaining amount (in shares)   $ 24,000     $ 24,000
Lincoln Park Capital | Common Stock | Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Issuance of common stock (in shares) 5,200        
Shares outstanding, agreement threshold, percent 19.99%        
Shares outstanding of affiliate beneficial ownership, agreement threshold, percent 9.99%        
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.21.1
Warrants - Issuable Shares of Common Stock Related to Unexercised Warrants Outstanding (Details)
shares in Thousands
Mar. 31, 2021
$ / shares
shares
Total  
Class of Stock [Line Items]  
Shares 51,001
Hercules Warrant  
Class of Stock [Line Items]  
Shares 41
Exercise price (in dollars per share) | $ / shares $ 6.80
2018 Warrants  
Class of Stock [Line Items]  
Shares 3,617
Exercise price (in dollars per share) | $ / shares $ 9.60
2019 Warrants  
Class of Stock [Line Items]  
Shares 933
Exercise price (in dollars per share) | $ / shares $ 4.52
2019 Pre-Funded Warrants  
Class of Stock [Line Items]  
Shares 531
Exercise price (in dollars per share) | $ / shares $ 0.08
2020 Warrants  
Class of Stock [Line Items]  
Shares 33,613
Exercise price (in dollars per share) | $ / shares $ 2.25
2020 Pre-Funded Warrants  
Class of Stock [Line Items]  
Shares 12,223
Exercise price (in dollars per share) | $ / shares $ 0.01
SVB Warrant  
Class of Stock [Line Items]  
Shares 43
Exercise price (in dollars per share) | $ / shares $ 3.45
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Warrants - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Feb. 18, 2021
Dec. 31, 2020
Jul. 24, 2020
Jan. 01, 2018
Class of Stock [Line Items]            
Change in fair value of warrants $ 854 $ 781        
Warrant liabilities 55,264     $ 56,118    
Level 3 | Warrants            
Class of Stock [Line Items]            
Issuance of Warrants 55,264     56,118    
2020 Warrants | Warrants            
Class of Stock [Line Items]            
Issuance of Warrants         $ 62,500  
Change in fair value of warrants 700          
2020 Warrants | Level 3 | Warrants            
Class of Stock [Line Items]            
Warrant liabilities 53,800     54,500    
SVB Warrant | 2021 Term Loan | Notes Payable to Banks            
Class of Stock [Line Items]            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights     43,478      
2018 Warrants | Level 3 | Warrants            
Class of Stock [Line Items]            
Issuance of Warrants           $ 18,200
Change in fair value of warrants 200 $ 800        
Warrant liabilities $ 1,500     $ 1,700    
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.21.1
Warrants - Fair Value Warrant Liability Assumptions (Details)
Mar. 31, 2021
floor
$ / shares
Dec. 31, 2020
$ / shares
floor
Jul. 31, 2020
$ / shares
Stock price | Warrants | 2020 Warrants      
Class of Stock [Line Items]      
Measurement Input | $ / shares 2.71   2.42
Stock price | Warrants | 2018 Warrants      
Class of Stock [Line Items]      
Measurement Input | $ / shares 2.71 2.42  
Volatility | Minimum | 2018 Warrants      
Class of Stock [Line Items]      
Measurement Input | floor 0.500 0.500  
Volatility | Maximum | 2018 Warrants      
Class of Stock [Line Items]      
Measurement Input | floor 0.953 1.015  
Volatility | Warrants | 2020 Warrants      
Class of Stock [Line Items]      
Measurement Input 0.939   1.191
Remaining term (years) | Warrants | 2020 Warrants      
Class of Stock [Line Items]      
Warrants and rights outstanding, term 3 years 3 months 18 days   3 years 7 months 6 days
Remaining term (years) | Warrants | 2018 Warrants      
Class of Stock [Line Items]      
Warrants and rights outstanding, term 1 year 9 months 18 days 2 years  
Expected dividend yield | Warrants | 2020 Warrants      
Class of Stock [Line Items]      
Measurement Input 0   0
Expected dividend yield | Warrants | 2018 Warrants      
Class of Stock [Line Items]      
Measurement Input 0 0  
Risk-free rate | Warrants | 2020 Warrants      
Class of Stock [Line Items]      
Measurement Input 0.0044   0.0022
Risk-free rate | Warrants | 2018 Warrants      
Class of Stock [Line Items]      
Measurement Input 0.0016 0.0013  
Acquisition event probability | Warrants | 2020 Warrants      
Class of Stock [Line Items]      
Measurement Input 0.400 0.400  
Acquisition event probability | Warrants | 2018 Warrants      
Class of Stock [Line Items]      
Measurement Input 0.250 0.250  
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Employee benefit plans - Narrative (Details) - ESPP
shares in Millions
Mar. 31, 2021
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Shares reserved for future issuance 0.1
Amended and Restated 2014 Equity Incentive Plan  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Shares reserved for future issuance 0.7
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.21.1
Employee benefit plans - Weighted-average assumptions used (Details)
 3 Months Ended
Mar. 31, 2021
$ / shares
Fair value of each employee stock award on the grant date and the assumptions regarding the fair value of the underlying common stock  
Share price (in dollars per share) $ 3.01
Volatility 97.65%
Remaining term (years) 2 years 9 months 18 days
Risk-free rate 0.29%
Annual acquisition event probability 33.00%
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.21.1
Employee benefit plans - Stock based compensation expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Stock Based Compensation Expense    
Total stock-based compensation expense $ 580 $ 384
Research and development    
Stock Based Compensation Expense    
Total stock-based compensation expense 258 160
General and administrative    
Stock Based Compensation Expense    
Total stock-based compensation expense $ 322 $ 224
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.21.1
Employee benefit plans - Stock option activity (Details)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2021
USD ($)
$ / shares
shares
Stock options  
Shares  
Outstanding at the beginning of the period (in shares) 2,329
Granted (in shares) 1,614
Exercised (in shares) 38
Canceled (in shares) (66)
Outstanding at the end of the period (in shares) 3,839
Exercisable at the end of the period (in shares) 930
Weighted-Average Exercise Price  
Outstanding at the beginning of the period (in dollars per share) | $ / shares $ 7.05
Granted (in dollars per share) | $ / shares 3.01
Exercised (in dollars per share) | $ / shares 2.22
Canceled (in dollars per share) | $ / shares 12.82
Outstanding at the end of the period (in dollars per share) | $ / shares 5.30
Exercisable at the end of the period (in dollars per share) | $ / shares $ 12.61
Weighted-Average Remaining Contractual Term (years)  
Outstanding at the beginning/end of the period 8 years 9 months 18 days
Exercisable at the end of the period 7 years
Aggregate Intrinsic Value  
Outstanding at the beginning of the period (in dollars) | $ $ 505
Outstanding at the end of the period (in dollars) | $ 715
Exercisable at the end of the period (in dollars) | $ $ 134
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]  
Granted (in shares) 1,614
Restricted Stock Units (RSUs)  
Shares  
Granted (in shares) 1,904
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]  
Beginning Balance (in shares) 550
Granted (in shares) 1,904
Vested, Shares 11
Forfeited/cancelled, Shares (9)
Ending Balance (in shares) 2,434
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Beginning Balance, Weighted-Average Grant Date Fair Value (in dollars per share) | $ / shares $ 2.13
Granted, Weighted-Average Grant Date Fair Value (in dollars per share) | $ / shares 2.52
Vested, Weighted-Average Grant Date Fair Value (in dollars per share) | $ / shares 1.98
Forfeited/cancelled, Weighted-Average Grant Date Fair Value (in dollars per share) | $ / shares 2.11
Ending Balance, Weighted-Average Grant Date Fair Value (in dollars per share) | $ / shares $ 2.44
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Net loss per share - Schedule of earnings per share, basic and diluted (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Earnings Per Share [Abstract]    
Net loss $ (11,983) $ (12,853)
Preferred Stock Dividends and Other Adjustments 673 0
Net Income (Loss) Available to Common Stockholders, Basic, Total $ (12,656) $ (12,853)
Weighted average common stock outstanding - basic (in shares) 66,158 28,141
Dilutive effect of shares of common stock equivalents (in shares) 8,062 0
Weighted average common stock outstanding - Diluted (in shares) 74,220 28,141
Basic (in dollars per share) $ (0.18) $ (0.46)
Diluted (in dollars per share) $ (0.17) $ (0.46)
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.21.1
Net loss per share - Attributable to common stockholders (Details) - shares
shares in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Common Stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 10,907 6,006
Warrants | Common Stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 4,634 4,591
Employee And Nonemployee Stock Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 3,839 1,370
Restricted Stock Units (RSUs)    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 2,434 45
EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 60 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 147 297 1 false 52 0 false 6 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.genocea.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Balance Sheets Sheet http://www.genocea.com/role/CondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.genocea.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 1004005 - Statement - Consolidated Consolidated Statements of Stockholders' Equity (Deficit) Sheet http://www.genocea.com/role/ConsolidatedConsolidatedStatementsofStockholdersEquityDeficit Consolidated Consolidated Statements of Stockholders' Equity (Deficit) Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 2101101 - Disclosure - Organization and operations Sheet http://www.genocea.com/role/Organizationandoperations Organization and operations Notes 7 false false R8.htm 2103102 - Disclosure - Summary of significant accounting policies Sheet http://www.genocea.com/role/Summaryofsignificantaccountingpolicies Summary of significant accounting policies Notes 8 false false R9.htm 2105103 - Disclosure - Revenue Sheet http://www.genocea.com/role/Revenue Revenue Notes 9 false false R10.htm 2107104 - Disclosure - Fair value of financial instruments Sheet http://www.genocea.com/role/Fairvalueoffinancialinstruments Fair value of financial instruments Notes 10 false false R11.htm 2111105 - Disclosure - Accrued expenses and other current liabilities Sheet http://www.genocea.com/role/Accruedexpensesandothercurrentliabilities Accrued expenses and other current liabilities Notes 11 false false R12.htm 2114106 - Disclosure - Commitments and contingencies Sheet http://www.genocea.com/role/Commitmentsandcontingencies Commitments and contingencies Notes 12 false false R13.htm 2120107 - Disclosure - Debt Sheet http://www.genocea.com/role/Debt Debt Notes 13 false false R14.htm 2124108 - Disclosure - Stockholders' equity Sheet http://www.genocea.com/role/Stockholdersequity Stockholders' equity Notes 14 false false R15.htm 2126109 - Disclosure - Warrants Warrants Sheet http://www.genocea.com/role/WarrantsWarrants Warrants Warrants Notes 15 false false R16.htm 2131110 - Disclosure - Employee benefit plans Sheet http://www.genocea.com/role/Employeebenefitplans Employee benefit plans Notes 16 false false R17.htm 2137111 - Disclosure - Net loss per share Sheet http://www.genocea.com/role/Netlosspershare Net loss per share Notes 17 false false R18.htm 2204201 - Disclosure - Summary of significant accounting policies (Policies) Sheet http://www.genocea.com/role/SummaryofsignificantaccountingpoliciesPolicies Summary of significant accounting policies (Policies) Policies 18 false false R19.htm 2308301 - Disclosure - Fair value of financial instruments (Tables) Sheet http://www.genocea.com/role/FairvalueoffinancialinstrumentsTables Fair value of financial instruments (Tables) Tables http://www.genocea.com/role/Fairvalueoffinancialinstruments 19 false false R20.htm 2312302 - Disclosure - Accrued expenses and other current liabilities (Tables) Sheet http://www.genocea.com/role/AccruedexpensesandothercurrentliabilitiesTables Accrued expenses and other current liabilities (Tables) Tables http://www.genocea.com/role/Accruedexpensesandothercurrentliabilities 20 false false R21.htm 2315303 - Disclosure - Commitments and contingencies (Tables) Sheet http://www.genocea.com/role/CommitmentsandcontingenciesTables Commitments and contingencies (Tables) Tables http://www.genocea.com/role/Commitmentsandcontingencies 21 false false R22.htm 2321304 - Disclosure - Debt (Tables) Sheet http://www.genocea.com/role/DebtTables Debt (Tables) Tables http://www.genocea.com/role/Debt 22 false false R23.htm 2327305 - Disclosure - Warrants (Tables) Sheet http://www.genocea.com/role/WarrantsTables Warrants (Tables) Tables http://www.genocea.com/role/WarrantsWarrants 23 false false R24.htm 2332306 - Disclosure - Employee benefit plans (Tables) Sheet http://www.genocea.com/role/EmployeebenefitplansTables Employee benefit plans (Tables) Tables http://www.genocea.com/role/Employeebenefitplans 24 false false R25.htm 2338307 - Disclosure - Net loss per share (Tables) Sheet http://www.genocea.com/role/NetlosspershareTables Net loss per share (Tables) Tables http://www.genocea.com/role/Netlosspershare 25 false false R26.htm 2402401 - Disclosure - Organization and operations (Details) Sheet http://www.genocea.com/role/OrganizationandoperationsDetails Organization and operations (Details) Details http://www.genocea.com/role/Organizationandoperations 26 false false R27.htm 2406402 - Disclosure - Revenue (Details) Sheet http://www.genocea.com/role/RevenueDetails Revenue (Details) Details http://www.genocea.com/role/Revenue 27 false false R28.htm 2409403 - Disclosure - Fair value of financial instruments - Schedule of cash equivalents and investments carried at fair value (Details) Sheet http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails Fair value of financial instruments - Schedule of cash equivalents and investments carried at fair value (Details) Details 28 false false R29.htm 2410404 - Disclosure - Fair value of financial instruments - Change in the Company???s Level 3 Warrant liabilities (Details) Sheet http://www.genocea.com/role/FairvalueoffinancialinstrumentsChangeintheCompanysLevel3WarrantliabilitiesDetails Fair value of financial instruments - Change in the Company???s Level 3 Warrant liabilities (Details) Details 29 false false R30.htm 2413405 - Disclosure - Accrued expenses and other current liabilities (Details) Sheet http://www.genocea.com/role/AccruedexpensesandothercurrentliabilitiesDetails Accrued expenses and other current liabilities (Details) Details http://www.genocea.com/role/AccruedexpensesandothercurrentliabilitiesTables 30 false false R31.htm 2416406 - Disclosure - Commitments and contingencies - Narrative (Details) Sheet http://www.genocea.com/role/CommitmentsandcontingenciesNarrativeDetails Commitments and contingencies - Narrative (Details) Details 31 false false R32.htm 2417407 - Disclosure - Commitments and contingencies - Operating Lease Term and Discount Rate (Details) Sheet http://www.genocea.com/role/CommitmentsandcontingenciesOperatingLeaseTermandDiscountRateDetails Commitments and contingencies - Operating Lease Term and Discount Rate (Details) Details 32 false false R33.htm 2418408 - Disclosure - Commitments and contingencies - Supplemental Balance Sheet (Details) Sheet http://www.genocea.com/role/CommitmentsandcontingenciesSupplementalBalanceSheetDetails Commitments and contingencies - Supplemental Balance Sheet (Details) Details 33 false false R34.htm 2419409 - Disclosure - Commitments and contingencies - Future minimum lease payments (Details) Sheet http://www.genocea.com/role/CommitmentsandcontingenciesFutureminimumleasepaymentsDetails Commitments and contingencies - Future minimum lease payments (Details) Details 34 false false R35.htm 2422410 - Disclosure - Debt - Narrative (Details) Sheet http://www.genocea.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 35 false false R36.htm 2423411 - Disclosure - Debt (Details) Sheet http://www.genocea.com/role/DebtDetails Debt (Details) Details http://www.genocea.com/role/DebtTables 36 false false R37.htm 2425412 - Disclosure - Stockholders' equity - Narrative (Details) Sheet http://www.genocea.com/role/StockholdersequityNarrativeDetails Stockholders' equity - Narrative (Details) Details 37 false false R38.htm 2428413 - Disclosure - Warrants - Issuable Shares of Common Stock Related to Unexercised Warrants Outstanding (Details) Sheet http://www.genocea.com/role/WarrantsIssuableSharesofCommonStockRelatedtoUnexercisedWarrantsOutstandingDetails Warrants - Issuable Shares of Common Stock Related to Unexercised Warrants Outstanding (Details) Details 38 false false R39.htm 2429414 - Disclosure - Warrants - Narrative (Details) Sheet http://www.genocea.com/role/WarrantsNarrativeDetails Warrants - Narrative (Details) Details 39 false false R40.htm 2430415 - Disclosure - Warrants - Fair Value Warrant Liability Assumptions (Details) Sheet http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails Warrants - Fair Value Warrant Liability Assumptions (Details) Details 40 false false R41.htm 2433416 - Disclosure - Employee benefit plans - Narrative (Details) Sheet http://www.genocea.com/role/EmployeebenefitplansNarrativeDetails Employee benefit plans - Narrative (Details) Details 41 false false R42.htm 2434417 - Disclosure - Employee benefit plans - Weighted-average assumptions used (Details) Sheet http://www.genocea.com/role/EmployeebenefitplansWeightedaverageassumptionsusedDetails Employee benefit plans - Weighted-average assumptions used (Details) Details 42 false false R43.htm 2435418 - Disclosure - Employee benefit plans - Stock based compensation expense (Details) Sheet http://www.genocea.com/role/EmployeebenefitplansStockbasedcompensationexpenseDetails Employee benefit plans - Stock based compensation expense (Details) Details 43 false false R44.htm 2436419 - Disclosure - Employee benefit plans - Stock option activity (Details) Sheet http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails Employee benefit plans - Stock option activity (Details) Details 44 false false R45.htm 2439420 - Disclosure - Net loss per share - Schedule of earnings per share, basic and diluted (Details) Sheet http://www.genocea.com/role/NetlosspershareScheduleofearningspersharebasicanddilutedDetails Net loss per share - Schedule of earnings per share, basic and diluted (Details) Details 45 false false R46.htm 2440421 - Disclosure - Net loss per share - Attributable to common stockholders (Details) Sheet http://www.genocea.com/role/NetlosspershareAttributabletocommonstockholdersDetails Net loss per share - Attributable to common stockholders (Details) Details 46 false false All Reports Book All Reports gnca-20210331.htm a2021q1ex101.htm a2021q1ex311.htm a2021q1ex312.htm a2021q1ex32.htm gnca-20210331.xsd gnca-20210331_cal.xml gnca-20210331_def.xml gnca-20210331_lab.xml gnca-20210331_pre.xml gnca-20210331_g1.jpg http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true JSON 64 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "gnca-20210331.htm": { "axisCustom": 0, "axisStandard": 22, "contextCount": 147, "dts": { "calculationLink": { "local": [ "gnca-20210331_cal.xml" ] }, "definitionLink": { "local": [ "gnca-20210331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "gnca-20210331.htm" ] }, "labelLink": { "local": [ "gnca-20210331_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "gnca-20210331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "gnca-20210331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 390, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 5 }, "keyCustom": 22, "keyStandard": 275, "memberCustom": 22, "memberStandard": 26, "nsprefix": "gnca", "nsuri": "http://www.genocea.com/20210331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.genocea.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107104 - Disclosure - Fair value of financial instruments", "role": "http://www.genocea.com/role/Fairvalueoffinancialinstruments", "shortName": "Fair value of financial instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111105 - Disclosure - Accrued expenses and other current liabilities", "role": "http://www.genocea.com/role/Accruedexpensesandothercurrentliabilities", "shortName": "Accrued expenses and other current liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114106 - Disclosure - Commitments and contingencies", "role": "http://www.genocea.com/role/Commitmentsandcontingencies", "shortName": "Commitments and contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120107 - Disclosure - Debt", "role": "http://www.genocea.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "gnca:CommonStockNumberOfSharesParValueAndOtherDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124108 - Disclosure - Stockholders' equity", "role": "http://www.genocea.com/role/Stockholdersequity", "shortName": "Stockholders' equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "gnca:CommonStockNumberOfSharesParValueAndOtherDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "gnca:WarrantsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126109 - Disclosure - Warrants Warrants", "role": "http://www.genocea.com/role/WarrantsWarrants", "shortName": "Warrants Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "gnca:WarrantsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131110 - Disclosure - Employee benefit plans", "role": "http://www.genocea.com/role/Employeebenefitplans", "shortName": "Employee benefit plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137111 - Disclosure - Net loss per share", "role": "http://www.genocea.com/role/Netlosspershare", "shortName": "Net loss per share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Summary of significant accounting policies (Policies)", "role": "http://www.genocea.com/role/SummaryofsignificantaccountingpoliciesPolicies", "shortName": "Summary of significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Fair value of financial instruments (Tables)", "role": "http://www.genocea.com/role/FairvalueoffinancialinstrumentsTables", "shortName": "Fair value of financial instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i23e937e6df284d6e984b1e062817d2be_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Balance Sheets", "role": "http://www.genocea.com/role/CondensedBalanceSheets", "shortName": "Condensed Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i23e937e6df284d6e984b1e062817d2be_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312302 - Disclosure - Accrued expenses and other current liabilities (Tables)", "role": "http://www.genocea.com/role/AccruedexpensesandothercurrentliabilitiesTables", "shortName": "Accrued expenses and other current liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315303 - Disclosure - Commitments and contingencies (Tables)", "role": "http://www.genocea.com/role/CommitmentsandcontingenciesTables", "shortName": "Commitments and contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321304 - Disclosure - Debt (Tables)", "role": "http://www.genocea.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327305 - Disclosure - Warrants (Tables)", "role": "http://www.genocea.com/role/WarrantsTables", "shortName": "Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2332306 - Disclosure - Employee benefit plans (Tables)", "role": "http://www.genocea.com/role/EmployeebenefitplansTables", "shortName": "Employee benefit plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2338307 - Disclosure - Net loss per share (Tables)", "role": "http://www.genocea.com/role/NetlosspershareTables", "shortName": "Net loss per share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i23e937e6df284d6e984b1e062817d2be_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Organization and operations (Details)", "role": "http://www.genocea.com/role/OrganizationandoperationsDetails", "shortName": "Organization and operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segments", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i23e937e6df284d6e984b1e062817d2be_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Revenue (Details)", "role": "http://www.genocea.com/role/RevenueDetails", "shortName": "Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i203c7c116861463a820096ab3b86eaa0_D20200501-20200531", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i7c913f8a244b4a988b4fa327809dcf00_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Fair value of financial instruments - Schedule of cash equivalents and investments carried at fair value (Details)", "role": "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails", "shortName": "Fair value of financial instruments - Schedule of cash equivalents and investments carried at fair value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i7c913f8a244b4a988b4fa327809dcf00_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ic201e2215c684e99b1b3906fd2a219a1_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Fair value of financial instruments - Change in the Company\u2019s Level 3 Warrant liabilities (Details)", "role": "http://www.genocea.com/role/FairvalueoffinancialinstrumentsChangeintheCompanysLevel3WarrantliabilitiesDetails", "shortName": "Fair value of financial instruments - Change in the Company\u2019s Level 3 Warrant liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i3b40789f98894a56899b2f31b041718e_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i23e937e6df284d6e984b1e062817d2be_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.genocea.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i23e937e6df284d6e984b1e062817d2be_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i23e937e6df284d6e984b1e062817d2be_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "gnca:AccruedResearchAndDevelopmentCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413405 - Disclosure - Accrued expenses and other current liabilities (Details)", "role": "http://www.genocea.com/role/AccruedexpensesandothercurrentliabilitiesDetails", "shortName": "Accrued expenses and other current liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i23e937e6df284d6e984b1e062817d2be_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "gnca:AccruedResearchAndDevelopmentCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i23e937e6df284d6e984b1e062817d2be_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416406 - Disclosure - Commitments and contingencies - Narrative (Details)", "role": "http://www.genocea.com/role/CommitmentsandcontingenciesNarrativeDetails", "shortName": "Commitments and contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:SubleaseIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i23e937e6df284d6e984b1e062817d2be_I20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417407 - Disclosure - Commitments and contingencies - Operating Lease Term and Discount Rate (Details)", "role": "http://www.genocea.com/role/CommitmentsandcontingenciesOperatingLeaseTermandDiscountRateDetails", "shortName": "Commitments and contingencies - Operating Lease Term and Discount Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i23e937e6df284d6e984b1e062817d2be_I20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gnca:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i23e937e6df284d6e984b1e062817d2be_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418408 - Disclosure - Commitments and contingencies - Supplemental Balance Sheet (Details)", "role": "http://www.genocea.com/role/CommitmentsandcontingenciesSupplementalBalanceSheetDetails", "shortName": "Commitments and contingencies - Supplemental Balance Sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gnca:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i23e937e6df284d6e984b1e062817d2be_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i23e937e6df284d6e984b1e062817d2be_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419409 - Disclosure - Commitments and contingencies - Future minimum lease payments (Details)", "role": "http://www.genocea.com/role/CommitmentsandcontingenciesFutureminimumleasepaymentsDetails", "shortName": "Commitments and contingencies - Future minimum lease payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i23e937e6df284d6e984b1e062817d2be_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RepaymentsOfDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422410 - Disclosure - Debt - Narrative (Details)", "role": "http://www.genocea.com/role/DebtNarrativeDetails", "shortName": "Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "icf676ed25fd1464280c2fd41cb9d8c99_I20180424", "decimals": "-5", "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i6f2941d727e74599b21e6ab701f0693a_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423411 - Disclosure - Debt (Details)", "role": "http://www.genocea.com/role/DebtDetails", "shortName": "Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i6f2941d727e74599b21e6ab701f0693a_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425412 - Disclosure - Stockholders' equity - Narrative (Details)", "role": "http://www.genocea.com/role/StockholdersequityNarrativeDetails", "shortName": "Stockholders' equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i4f946548283d49d08c1fba20f5915d96_D20150302-20210331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i90c1923b62364958a20a922e5a5f5c3a_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428413 - Disclosure - Warrants - Issuable Shares of Common Stock Related to Unexercised Warrants Outstanding (Details)", "role": "http://www.genocea.com/role/WarrantsIssuableSharesofCommonStockRelatedtoUnexercisedWarrantsOutstandingDetails", "shortName": "Warrants - Issuable Shares of Common Stock Related to Unexercised Warrants Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i90c1923b62364958a20a922e5a5f5c3a_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:UnrealizedGainLossOnDerivatives", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429414 - Disclosure - Warrants - Narrative (Details)", "role": "http://www.genocea.com/role/WarrantsNarrativeDetails", "shortName": "Warrants - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "iddc53968a16c4a84a9ee3fbcfa380921_I20200724", "decimals": "-5", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "role": "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i8fa380b1ff354846a51a6bbc58016ef0_I20210331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430415 - Disclosure - Warrants - Fair Value Warrant Liability Assumptions (Details)", "role": "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails", "shortName": "Warrants - Fair Value Warrant Liability Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i8fa380b1ff354846a51a6bbc58016ef0_I20210331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i5bc50083988d4d51ac316328abe340eb_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433416 - Disclosure - Employee benefit plans - Narrative (Details)", "role": "http://www.genocea.com/role/EmployeebenefitplansNarrativeDetails", "shortName": "Employee benefit plans - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i5bc50083988d4d51ac316328abe340eb_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i23e937e6df284d6e984b1e062817d2be_I20210331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434417 - Disclosure - Employee benefit plans - Weighted-average assumptions used (Details)", "role": "http://www.genocea.com/role/EmployeebenefitplansWeightedaverageassumptionsusedDetails", "shortName": "Employee benefit plans - Weighted-average assumptions used (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i23e937e6df284d6e984b1e062817d2be_I20210331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435418 - Disclosure - Employee benefit plans - Stock based compensation expense (Details)", "role": "http://www.genocea.com/role/EmployeebenefitplansStockbasedcompensationexpenseDetails", "shortName": "Employee benefit plans - Stock based compensation expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i8d058fef9a44426fad0fd666e6ad019c_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436419 - Disclosure - Employee benefit plans - Stock option activity (Details)", "role": "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails", "shortName": "Employee benefit plans - Stock option activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i8d058fef9a44426fad0fd666e6ad019c_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439420 - Disclosure - Net loss per share - Schedule of earnings per share, basic and diluted (Details)", "role": "http://www.genocea.com/role/NetlosspershareScheduleofearningspersharebasicanddilutedDetails", "shortName": "Net loss per share - Schedule of earnings per share, basic and diluted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PreferredStockDividendsAndOtherAdjustments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i6eb658e52632452a979e80d0c16b1cba_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440421 - Disclosure - Net loss per share - Attributable to common stockholders (Details)", "role": "http://www.genocea.com/role/NetlosspershareAttributabletocommonstockholdersDetails", "shortName": "Net loss per share - Attributable to common stockholders (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "i6eb658e52632452a979e80d0c16b1cba_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "idceac5a7c85442f1a8f52e84de4f5a81_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Consolidated Consolidated Statements of Stockholders' Equity (Deficit)", "role": "http://www.genocea.com/role/ConsolidatedConsolidatedStatementsofStockholdersEquityDeficit", "shortName": "Consolidated Consolidated Statements of Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "idceac5a7c85442f1a8f52e84de4f5a81_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization and operations", "role": "http://www.genocea.com/role/Organizationandoperations", "shortName": "Organization and operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Summary of significant accounting policies", "role": "http://www.genocea.com/role/Summaryofsignificantaccountingpolicies", "shortName": "Summary of significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105103 - Disclosure - Revenue", "role": "http://www.genocea.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20210331.htm", "contextRef": "ideedc729d982478383cc5ed805f30426_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 52, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.genocea.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "gnca_A2018TermLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2018 Term Loan Agreement [Member]", "label": "2018 Term Loan Agreement [Member]", "terseLabel": "2018 Term Loan" } } }, "localname": "A2018TermLoanAgreementMember", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "gnca_A2018WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2018 Warrants", "label": "2018 Warrants [Member]", "terseLabel": "2018 Warrants" } } }, "localname": "A2018WarrantsMember", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "gnca_A2020PreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Pre-Funded Warrants", "label": "2020 Pre-Funded Warrants [Member]", "terseLabel": "2020 Pre-Funded Warrants" } } }, "localname": "A2020PreFundedWarrantsMember", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/WarrantsIssuableSharesofCommonStockRelatedtoUnexercisedWarrantsOutstandingDetails" ], "xbrltype": "domainItemType" }, "gnca_A2020WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Warrants", "label": "2020 Warrants [Member]", "terseLabel": "2020 Warrants" } } }, "localname": "A2020WarrantsMember", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails", "http://www.genocea.com/role/WarrantsIssuableSharesofCommonStockRelatedtoUnexercisedWarrantsOutstandingDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "gnca_A2021TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Term Loan", "label": "2021 Term Loan [Member]", "terseLabel": "2021 Term Loan" } } }, "localname": "A2021TermLoanMember", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/DebtDetails", "http://www.genocea.com/role/DebtNarrativeDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "gnca_AccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.genocea.com/role/AccruedexpensesandothercurrentliabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of total accrued expenses and other current liabilities which are due within one year or within the normal operating cycle if longer.", "label": "Accrued Expenses and Other Current Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Accrued Expenses and Other Current Liabilities" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/AccruedexpensesandothercurrentliabilitiesDetails", "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "gnca_AccruedResearchAndDevelopmentCostsCurrent": { "auth_ref": [], "calculation": { "http://www.genocea.com/role/AccruedexpensesandothercurrentliabilitiesDetails": { "order": 1.0, "parentTag": "gnca_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Research And Development Costs, Current", "label": "Accrued Research And Development Costs, Current", "terseLabel": "Research and development costs" } } }, "localname": "AccruedResearchAndDevelopmentCostsCurrent", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/AccruedexpensesandothercurrentliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "gnca_AmendedandRestated2014EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended and Restated 2014 Equity Incentive Plan [Member]", "label": "Amended and Restated 2014 Equity Incentive Plan [Member]", "terseLabel": "Amended and Restated 2014 Equity Incentive Plan" } } }, "localname": "AmendedandRestated2014EquityIncentivePlanMember", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansNarrativeDetails" ], "xbrltype": "domainItemType" }, "gnca_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets And Liabilities, Lessee [Table Text Block]", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Assets And Liabilities, Lessee" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesTables" ], "xbrltype": "textBlockItemType" }, "gnca_AtTheMarketEquityOfferingProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At-The-Market Equity Offering Program [Member]", "label": "At-The-Market Equity Offering Program [Member]", "terseLabel": "At-the-market equity offering program" } } }, "localname": "AtTheMarketEquityOfferingProgramMember", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "domainItemType" }, "gnca_CommitmentsandContingenciesLicensingAgreementAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Commitments and Contingencies, Licensing Agreement, Amount", "label": "Commitments and Contingencies, Licensing Agreement, Amount", "terseLabel": "Licensing agreement, amount" } } }, "localname": "CommitmentsandContingenciesLicensingAgreementAmount", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gnca_CommitmentsandContingenciesLicensingAgreementMilestonePaymentAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Commitments and Contingencies, Licensing Agreement, Milestone Payment, Amount", "label": "Commitments and Contingencies, Licensing Agreement, Milestone Payment, Amount", "terseLabel": "Licensing agreement, milestone payment, amount" } } }, "localname": "CommitmentsandContingenciesLicensingAgreementMilestonePaymentAmount", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gnca_CommonStockNumberOfSharesParValueAndOtherDisclosuresTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure regarding common stock of the entity.", "label": "Common Stock Number of Shares Par Value and Other Disclosures [Text Block]", "terseLabel": "Stockholders' equity" } } }, "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresTextBlock", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/Stockholdersequity" ], "xbrltype": "textBlockItemType" }, "gnca_CommonStockSharesOutstandingAgreementThresholdPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Shares Outstanding, Agreement Threshold, Percent", "label": "Common Stock, Shares Outstanding, Agreement Threshold, Percent", "terseLabel": "Shares outstanding, agreement threshold, percent" } } }, "localname": "CommonStockSharesOutstandingAgreementThresholdPercent", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "percentItemType" }, "gnca_CommonStockSharesOutstandingofAffiliateBeneficialOwnershipAgreementThresholdPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Shares Outstanding of Affiliate Beneficial Ownership, Agreement Threshold, Percent", "label": "Common Stock, Shares Outstanding of Affiliate Beneficial Ownership, Agreement Threshold, Percent", "terseLabel": "Shares outstanding of affiliate beneficial ownership, agreement threshold, percent" } } }, "localname": "CommonStockSharesOutstandingofAffiliateBeneficialOwnershipAgreementThresholdPercent", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "percentItemType" }, "gnca_DebtInstrumentCovenantCompliancePrepaymentChargePeriodOnePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Compliance, Prepayment Charge, Period One, Percent", "label": "Debt Instrument, Covenant Compliance, Prepayment Charge, Period One, Percent", "terseLabel": "Debt Instrument, Covenant Compliance, Prepayment Charge, Period One, Percent" } } }, "localname": "DebtInstrumentCovenantCompliancePrepaymentChargePeriodOnePercent", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "gnca_DebtInstrumentCovenantCompliancePrepaymentChargePeriodThreePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Compliance, Prepayment Charge, Period Three, Percent", "label": "Debt Instrument, Covenant Compliance, Prepayment Charge, Period Three, Percent", "terseLabel": "Debt Instrument, Covenant Compliance, Prepayment Charge, Period Three, Percent" } } }, "localname": "DebtInstrumentCovenantCompliancePrepaymentChargePeriodThreePercent", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "gnca_DebtInstrumentCovenantCompliancePrepaymentChargePeriodTwoPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Compliance, Prepayment Charge, Period Two, Percent", "label": "Debt Instrument, Covenant Compliance, Prepayment Charge, Period Two, Percent", "terseLabel": "Debt Instrument, Covenant Compliance, Prepayment Charge, Period Two, Percent" } } }, "localname": "DebtInstrumentCovenantCompliancePrepaymentChargePeriodTwoPercent", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "gnca_DebtInstrumentEndOfTermCharge": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, End Of Term Charge", "label": "Debt Instrument, End Of Term Charge", "terseLabel": "End of term charge" } } }, "localname": "DebtInstrumentEndOfTermCharge", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gnca_DebtInstrumentInterestRateDefaultRateAdditionalAnnualInterestRatePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Interest Rate, Default Rate, Additional Annual Interest Rate, Percent", "label": "Debt Instrument, Interest Rate, Default Rate, Additional Annual Interest Rate, Percent", "terseLabel": "Debt Instrument, Interest Rate, Default Rate, Additional Annual Interest Rate, Percent" } } }, "localname": "DebtInstrumentInterestRateDefaultRateAdditionalAnnualInterestRatePercent", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "gnca_EmployeeAndNonemployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to employee and non-employee stock options.", "label": "Employee And Nonemployee Stock Option [Member]", "terseLabel": "Stock options", "verboseLabel": "Employee And Nonemployee Stock Option [Member]" } } }, "localname": "EmployeeAndNonemployeeStockOptionMember", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails", "http://www.genocea.com/role/NetlosspershareAttributabletocommonstockholdersDetails" ], "xbrltype": "domainItemType" }, "gnca_FinanceandOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://www.genocea.com/role/CommitmentsandcontingenciesSupplementalBalanceSheetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance and Operating Lease, Liability", "label": "Finance and Operating Lease, Liability", "totalLabel": "Total" } } }, "localname": "FinanceandOperatingLeaseLiability", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesSupplementalBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "gnca_FinanceandOperatingLeaseLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance and Operating Lease, Liability, Current", "label": "Finance and Operating Lease, Liability, Current", "terseLabel": "Lease liabilities" } } }, "localname": "FinanceandOperatingLeaseLiabilityCurrent", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "gnca_FinanceandOperatingLeaseRightofUseAsset": { "auth_ref": [], "calculation": { "http://www.genocea.com/role/CommitmentsandcontingenciesSupplementalBalanceSheetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance and Operating Lease, Right-of-Use Asset", "label": "Finance and Operating Lease, Right-of-Use Asset", "terseLabel": "Right of use assets", "totalLabel": "Finance and Operating Lease, Right-of-Use Asset" } } }, "localname": "FinanceandOperatingLeaseRightofUseAsset", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesSupplementalBalanceSheetDetails", "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "gnca_FinanceandOperatingleaseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance and Operating lease, Liability, Noncurrent", "label": "Finance and Operating lease, Liability, Noncurrent", "terseLabel": "Lease liabilities, net of current portion" } } }, "localname": "FinanceandOperatingleaseLiabilityNoncurrent", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "gnca_InitialClosingPreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial Closing Pre-Funded Warrants [Member]", "label": "Initial Closing Pre-Funded Warrants [Member]", "terseLabel": "2019 Pre-Funded Warrants" } } }, "localname": "InitialClosingPreFundedWarrantsMember", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/WarrantsIssuableSharesofCommonStockRelatedtoUnexercisedWarrantsOutstandingDetails" ], "xbrltype": "domainItemType" }, "gnca_InitialClosingPrivatePlacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial Closing Private Placement Warrants [Member]", "label": "Initial Closing Private Placement Warrants [Member]", "terseLabel": "2019 Warrants" } } }, "localname": "InitialClosingPrivatePlacementWarrantsMember", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/WarrantsIssuableSharesofCommonStockRelatedtoUnexercisedWarrantsOutstandingDetails" ], "xbrltype": "domainItemType" }, "gnca_LeaseAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Assets [Abstract]", "label": "Lease Assets [Abstract]", "terseLabel": "Lease Assets [Abstract]" } } }, "localname": "LeaseAssetsAbstract", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesSupplementalBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "gnca_LeaseExtensionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Extension [Member]", "label": "Lease Extension [Member]", "terseLabel": "Lease Extension for office and lab space" } } }, "localname": "LeaseExtensionMember", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "gnca_LeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Liabilities [Abstract]", "label": "Lease Liabilities [Abstract]", "terseLabel": "Lease Liabilities [Abstract]" } } }, "localname": "LeaseLiabilitiesAbstract", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesSupplementalBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "gnca_LeaseLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Liabilities, Current [Abstract]", "label": "Lease Liabilities, Current [Abstract]", "terseLabel": "Lease Liabilities, Current [Abstract]" } } }, "localname": "LeaseLiabilitiesCurrentAbstract", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesSupplementalBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "gnca_LeaseLiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Liabilities, Noncurrent [Abstract]", "label": "Lease Liabilities, Noncurrent [Abstract]", "terseLabel": "Lease Liabilities, Noncurrent [Abstract]" } } }, "localname": "LeaseLiabilitiesNoncurrentAbstract", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesSupplementalBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "gnca_LincolnParkCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lincoln Park Capital [Member]", "label": "Lincoln Park Capital [Member]", "terseLabel": "Lincoln Park Capital" } } }, "localname": "LincolnParkCapitalMember", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "domainItemType" }, "gnca_MasterFacilitiesOperatingLeaseDueFebruary282025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Master Facilities Operating Lease Due February 28, 2025 [Member]", "label": "Master Facilities Operating Lease Due February 28, 2025 [Member]", "terseLabel": "Master Facilities Operating Lease Due February 28, 2025" } } }, "localname": "MasterFacilitiesOperatingLeaseDueFebruary282025Member", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "gnca_MaterialTransferAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Material Transfer Agreement [Member]", "label": "Material Transfer Agreement [Member]", "terseLabel": "Material Transfer Agreement" } } }, "localname": "MaterialTransferAgreementMember", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "gnca_MeasurementInputAcquisitionEventProbabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input, Acquisition Event Probability [Member]", "label": "Measurement Input, Acquisition Event Probability [Member]", "terseLabel": "Acquisition event probability" } } }, "localname": "MeasurementInputAcquisitionEventProbabilityMember", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails" ], "xbrltype": "domainItemType" }, "gnca_OperatingLeaseNumberOfFloors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Number of Floors", "label": "Operating Lease, Number of Floors", "terseLabel": "Number of floors leased" } } }, "localname": "OperatingLeaseNumberOfFloors", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "gnca_PublicOfferingWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Offering Warrants [Member]", "label": "Public Offering Warrants [Member]", "terseLabel": "2018 Warrants" } } }, "localname": "PublicOfferingWarrantsMember", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/WarrantsIssuableSharesofCommonStockRelatedtoUnexercisedWarrantsOutstandingDetails" ], "xbrltype": "domainItemType" }, "gnca_SVBWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SVB Warrant", "label": "SVB Warrant [Member]", "terseLabel": "SVB Warrant" } } }, "localname": "SVBWarrantMember", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails", "http://www.genocea.com/role/WarrantsIssuableSharesofCommonStockRelatedtoUnexercisedWarrantsOutstandingDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "gnca_SaleofStockSharesAuthorizedforIssuanceValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sale of Stock, Shares Authorized for Issuance, Value", "label": "Sale of Stock, Shares Authorized for Issuance, Value", "terseLabel": "Shares authorized for issuance, value" } } }, "localname": "SaleofStockSharesAuthorizedforIssuanceValue", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gnca_SaleofstockSharesAuthorizedforIssuanceRemainingAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sale of stock, Shares Authorized for Issuance, Remaining Amount", "label": "Sale of stock, Shares Authorized for Issuance, Remaining Amount", "terseLabel": "Shares authorized for issuance, remaining amount (in shares)" } } }, "localname": "SaleofstockSharesAuthorizedforIssuanceRemainingAmount", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gnca_SecondWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second Warrant [Member]", "label": "Second Warrant [Member]", "terseLabel": "Hercules Warrant" } } }, "localname": "SecondWarrantMember", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/WarrantsIssuableSharesofCommonStockRelatedtoUnexercisedWarrantsOutstandingDetails" ], "xbrltype": "domainItemType" }, "gnca_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualAcquisitionEventProbability": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Annual Acquisition Event Probability", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Annual Acquisition Event Probability", "terseLabel": "Annual acquisition event probability" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualAcquisitionEventProbability", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansWeightedaverageassumptionsusedDetails" ], "xbrltype": "percentItemType" }, "gnca_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award Options Outstanding Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "stringItemType" }, "gnca_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]", "terseLabel": "Weighted-Average Remaining Contractual Term\u00a0(years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "stringItemType" }, "gnca_ShionogiCo.Ltd.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shionogi & Co., Ltd. [Member]", "label": "Shionogi & Co., Ltd. [Member]", "terseLabel": "Shionogi & Co., Ltd." } } }, "localname": "ShionogiCo.Ltd.Member", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "gnca_TermLoan2014Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the 2014 Term Loan.", "label": "Term Loan2014 [Member]", "terseLabel": "2014 Term Loan" } } }, "localname": "TermLoan2014Member", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "gnca_TermLoan2014Tranche1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the first tranche of the 2014 Term Loan.", "label": "Term Loan2014 Tranche1 [Member]", "terseLabel": "2014 Term Loan, First Tranche" } } }, "localname": "TermLoan2014Tranche1Member", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "gnca_WarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants [Abstract]", "label": "Warrants [Abstract]", "terseLabel": "Warrants [Abstract]" } } }, "localname": "WarrantsAbstract", "nsuri": "http://www.genocea.com/20210331", "xbrltype": "stringItemType" }, "gnca_WarrantsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the entire disclosure pertaining to warrants.", "label": "Warrants Disclosure [Text Block]", "terseLabel": "Warrants" } } }, "localname": "WarrantsDisclosureTextBlock", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/WarrantsWarrants" ], "xbrltype": "textBlockItemType" }, "gnca_WarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to warrants that gives right to purchase common stock.", "label": "Warrants To Purchase Common Stock [Member]", "terseLabel": "Total" } } }, "localname": "WarrantsToPurchaseCommonStockMember", "nsuri": "http://www.genocea.com/20210331", "presentation": [ "http://www.genocea.com/role/WarrantsIssuableSharesofCommonStockRelatedtoUnexercisedWarrantsOutstandingDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r136", "r184", "r189", "r323" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.genocea.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r204", "r205", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r321", "r324" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.genocea.com/role/StockholdersequityNarrativeDetails", "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r204", "r205", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r321", "r324" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r136", "r184", "r189", "r323" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.genocea.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r134", "r184", "r187", "r296", "r320", "r322" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.genocea.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r134", "r184", "r187", "r296", "r320", "r322" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.genocea.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r195", "r204", "r205", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r321", "r324" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.genocea.com/role/StockholdersequityNarrativeDetails", "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r195", "r204", "r205", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r321", "r324" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.genocea.com/role/StockholdersequityNarrativeDetails", "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/Accruedexpensesandothercurrentliabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r18", "r231" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r84", "r85", "r86", "r228", "r229", "r230" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r206", "r208", "r234", "r235" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r156", "r164", "r171" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Issuance of warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r208", "r225", "r233" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockbasedcompensationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r70", "r271" ], "calculation": { "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of Debt Issuance Costs and Discounts" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/NetlosspershareAttributabletocommonstockholdersDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/NetlosspershareAttributabletocommonstockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "verboseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/NetlosspershareAttributabletocommonstockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/NetlosspershareAttributabletocommonstockholdersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r80", "r123", "r126", "r132", "r138", "r241", "r243", "r260", "r300", "r311" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r4", "r40", "r80", "r138", "r241", "r243", "r260" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r246" ], "calculation": { "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Assets, Fair Value Disclosure" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets, Fair Value Disclosure [Abstract]" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r209", "r226" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansNarrativeDetails", "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r74", "r75", "r76" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property and equipment included in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r25", "r72" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets", "http://www.genocea.com/role/OrganizationandoperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Included in cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r65", "r72", "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r65", "r261" ], "calculation": { "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r79", "r80", "r100", "r101", "r102", "r105", "r107", "r116", "r117", "r118", "r138", "r260" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/NetlosspershareAttributabletocommonstockholdersDetails", "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails", "http://www.genocea.com/role/WarrantsIssuableSharesofCommonStockRelatedtoUnexercisedWarrantsOutstandingDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r172", "r207" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails", "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails", "http://www.genocea.com/role/WarrantsIssuableSharesofCommonStockRelatedtoUnexercisedWarrantsOutstandingDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails", "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails", "http://www.genocea.com/role/WarrantsIssuableSharesofCommonStockRelatedtoUnexercisedWarrantsOutstandingDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/WarrantsIssuableSharesofCommonStockRelatedtoUnexercisedWarrantsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsChangeintheCompanysLevel3WarrantliabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Shares" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/WarrantsIssuableSharesofCommonStockRelatedtoUnexercisedWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r172", "r207" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]", "terseLabel": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsChangeintheCompanysLevel3WarrantliabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r36", "r152", "r304", "r316" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r149", "r150", "r151", "r153" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/Commitmentsandcontingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r84", "r85" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedConsolidatedStatementsofStockholdersEquityDeficit", "http://www.genocea.com/role/NetlosspershareAttributabletocommonstockholdersDetails", "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r164" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r17" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "terseLabel": "Common stock, $0.001 par value; (170,000,000 shares authorized at March\u00a031, 2021 and December\u00a031, 2020, 54,368,582 shares issued and outstanding at March\u00a031, 2021 and 53,018,813 shares issued and outstanding at December\u00a031, 2020)" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r44", "r46", "r47", "r50", "r306", "r318" ], "calculation": { "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r173", "r174", "r185" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets", "http://www.genocea.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r12", "r13", "r14", "r301", "r302", "r310" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtDetails", "http://www.genocea.com/role/DebtNarrativeDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r14", "r157", "r302", "r310" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Long-term debt" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r270", "r272" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Long-Term Debt" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtDetails", "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtDetails", "http://www.genocea.com/role/DebtNarrativeDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r35", "r81", "r165", "r168", "r169", "r170", "r269", "r270", "r272", "r309" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtDetails", "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r70", "r145" ], "calculation": { "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation and amortization" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeBasisSpreadOnVariableRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage points added to the reference rate to compute the variable rate on the interest rate derivative.", "label": "Derivative, Basis Spread on Variable Rate", "terseLabel": "Variable rate (as a percent)" } } }, "localname": "DerivativeBasisSpreadOnVariableRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r41", "r42", "r259" ], "calculation": { "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails": { "order": 1.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Warrant liabilities" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Noncurrent", "terseLabel": "Warrant liabilities" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r184", "r187", "r188", "r189", "r190", "r191", "r192", "r193" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Employee benefit plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/Employeebenefitplans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r209", "r226" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r51", "r89", "r90", "r91", "r92", "r93", "r97", "r100", "r105", "r106", "r107", "r112", "r113", "r307", "r319" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.genocea.com/role/NetlosspershareScheduleofearningspersharebasicanddilutedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Net loss per share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r51", "r89", "r90", "r91", "r92", "r93", "r100", "r105", "r106", "r107", "r112", "r113", "r307", "r319" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.genocea.com/role/NetlosspershareScheduleofearningspersharebasicanddilutedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r109", "r110", "r111", "r114" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net loss per share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/Netlosspershare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.genocea.com/role/AccruedexpensesandothercurrentliabilitiesDetails": { "order": 2.0, "parentTag": "gnca_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and employee-related costs" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/AccruedexpensesandothercurrentliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Stock Based Compensation Expense" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockbasedcompensationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "ESPP" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r84", "r85", "r86", "r88", "r94", "r96", "r115", "r139", "r164", "r171", "r228", "r229", "r230", "r238", "r239", "r262", "r263", "r264", "r265", "r266", "r267", "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedConsolidatedStatementsofStockholdersEquityDeficit", "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r70", "r160" ], "calculation": { "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "terseLabel": "Change in fair value of warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r246", "r247", "r248", "r255" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r246", "r247", "r248", "r254", "r255" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Schedule of financial instruments measured at fair value on recurring basis" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r247", "r286", "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsChangeintheCompanysLevel3WarrantliabilitiesDetails", "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r253", "r255" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsChangeintheCompanysLevel3WarrantliabilitiesDetails", "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails", "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r246", "r247", "r250", "r251", "r256" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value of financial instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/Fairvalueoffinancialinstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r196", "r197", "r202", "r203", "r247", "r286" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r196", "r197", "r202", "r203", "r247", "r287" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r247", "r288" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsChangeintheCompanysLevel3WarrantliabilitiesDetails", "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsChangeintheCompanysLevel3WarrantliabilitiesDetails", "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails", "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsChangeintheCompanysLevel3WarrantliabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r252", "r255" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)", "terseLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsChangeintheCompanysLevel3WarrantliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r252" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Ending Balance", "periodStartLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Beginning Balance", "verboseLabel": "Issuance of Warrants" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsChangeintheCompanysLevel3WarrantliabilitiesDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r286", "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsChangeintheCompanysLevel3WarrantliabilitiesDetails", "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r253", "r256" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r78", "r257", "r258" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair value of financial instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r274" ], "calculation": { "http://www.genocea.com/role/CommitmentsandcontingenciesSupplementalBalanceSheetDetails": { "order": 2.0, "parentTag": "gnca_FinanceandOperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance Lease, Liability, Current" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesSupplementalBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r276", "r279" ], "calculation": { "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Payments on finance lease" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r273" ], "calculation": { "http://www.genocea.com/role/CommitmentsandcontingenciesSupplementalBalanceSheetDetails": { "order": 2.0, "parentTag": "gnca_FinanceandOperatingLeaseRightofUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Finance Lease, Right-of-Use Asset" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesSupplementalBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "totalLabel": "Financial Liabilities Fair Value Disclosure, Total" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Useful life (in years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r140", "r141", "r143", "r144", "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r140", "r142" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r53" ], "calculation": { "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockbasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockbasedcompensationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockbasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r69" ], "calculation": { "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedTerseLabel": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Redeemable Convertible Preferred Stock and Stockholders' (Deficit) Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r48", "r122", "r268", "r271", "r308" ], "calculation": { "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense, net" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r55", "r158" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r64", "r67", "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease, Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Lessee, Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r284" ], "calculation": { "http://www.genocea.com/role/CommitmentsandcontingenciesFutureminimumleasepaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesFutureminimumleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesFutureminimumleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesFutureminimumleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesFutureminimumleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesFutureminimumleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesFutureminimumleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r284" ], "calculation": { "http://www.genocea.com/role/CommitmentsandcontingenciesFutureminimumleasepaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesFutureminimumleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r31", "r80", "r127", "r138", "r242", "r243", "r244", "r260" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r80", "r138", "r260", "r303", "r314" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r33", "r80", "r138", "r242", "r243", "r244", "r260" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-current liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r14", "r302", "r310" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Outstanding borrowings" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r29" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Debt financing" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r82", "r154" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r82", "r154" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r82" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "1250000" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net of current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtDetails", "http://www.genocea.com/role/DebtNarrativeDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r35", "r155" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtDetails", "http://www.genocea.com/role/DebtNarrativeDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermPurchaseCommitmentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Long-term Purchase Commitment, Period", "terseLabel": "Purchase agreement period (in months)" } } }, "localname": "LongtermPurchaseCommitmentPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]", "terseLabel": "Expected dividend yield" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Remaining term (years)" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk-free rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]", "terseLabel": "Stock price" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r65" ], "calculation": { "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r65" ], "calculation": { "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r65", "r68", "r71" ], "calculation": { "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Cash used in operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.genocea.com/role/OrganizationandoperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r43", "r45", "r49", "r71", "r80", "r87", "r89", "r90", "r91", "r92", "r95", "r96", "r103", "r123", "r125", "r128", "r131", "r133", "r138", "r260", "r305", "r317" ], "calculation": { "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.genocea.com/role/NetlosspershareScheduleofearningspersharebasicanddilutedDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.genocea.com/role/ConsolidatedConsolidatedStatementsofStockholdersEquityDeficit", "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.genocea.com/role/NetlosspershareScheduleofearningspersharebasicanddilutedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r89", "r90", "r91", "r92", "r97", "r98", "r104", "r107", "r123", "r125", "r128", "r131", "r133" ], "calculation": { "http://www.genocea.com/role/NetlosspershareScheduleofearningspersharebasicanddilutedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/NetlosspershareScheduleofearningspersharebasicanddilutedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Significant accounting policies" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r54" ], "calculation": { "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableToBanksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a bank.", "label": "Notes Payable to Banks [Member]", "terseLabel": "Notes Payable to Banks" } } }, "localname": "NotesPayableToBanksMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtDetails", "http://www.genocea.com/role/DebtNarrativeDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/OrganizationandoperationsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r123", "r125", "r128", "r131", "r133" ], "calculation": { "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r275" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesFutureminimumleasepaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r274" ], "calculation": { "http://www.genocea.com/role/CommitmentsandcontingenciesFutureminimumleasepaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total", "verboseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesFutureminimumleasepaymentsDetails", "http://www.genocea.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r274" ], "calculation": { "http://www.genocea.com/role/CommitmentsandcontingenciesSupplementalBalanceSheetDetails": { "order": 1.0, "parentTag": "gnca_FinanceandOperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "verboseLabel": "Operating Lease, Liability, Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesSupplementalBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r274" ], "calculation": { "http://www.genocea.com/role/CommitmentsandcontingenciesSupplementalBalanceSheetDetails": { "order": 3.0, "parentTag": "gnca_FinanceandOperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Operating Lease, Liability, Noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesSupplementalBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r277", "r279" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid in connection with operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r273" ], "calculation": { "http://www.genocea.com/role/CommitmentsandcontingenciesSupplementalBalanceSheetDetails": { "order": 1.0, "parentTag": "gnca_FinanceandOperatingLeaseRightofUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Operating lease, right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesSupplementalBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r282", "r285" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesOperatingLeaseTermandDiscountRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r281", "r285" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesOperatingLeaseTermandDiscountRateDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r245" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and operations" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/Organizationandoperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r6", "r7", "r32" ], "calculation": { "http://www.genocea.com/role/AccruedexpensesandothercurrentliabilitiesDetails": { "order": 3.0, "parentTag": "gnca_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other Liabilities, Current" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/AccruedexpensesandothercurrentliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r56" ], "calculation": { "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Payments for Other Operating Activities" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "auth_ref": [ "r62" ], "calculation": { "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "negatedTerseLabel": "Debt prepayment costs" } } }, "localname": "PaymentsOfDebtExtinguishmentCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r63" ], "calculation": { "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedTerseLabel": "Payment of deferred financing costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r58" ], "calculation": { "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r209", "r226" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansNarrativeDetails", "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansNarrativeDetails", "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendsAndOtherAdjustments": { "auth_ref": [ "r98", "r108" ], "calculation": { "http://www.genocea.com/role/NetlosspershareScheduleofearningspersharebasicanddilutedDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.", "label": "Preferred Stock Dividends and Other Adjustments", "terseLabel": "Preferred Stock Dividends and Other Adjustments" } } }, "localname": "PreferredStockDividendsAndOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/NetlosspershareScheduleofearningspersharebasicanddilutedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Shares" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par or stated value per share (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in dollars per share)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValueOutstanding": { "auth_ref": [ "r16" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.", "label": "Preferred Stock, Value, Outstanding", "terseLabel": "Preferred stock, $0.001 par value; (25,000,000 shares authorized at March\u00a031, 2021 and December\u00a031, 2020; \u2014 shares issued and outstanding at March\u00a031, 2021 and December\u00a031, 2020)" } } }, "localname": "PreferredStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r3", "r23", "r24" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]", "terseLabel": "Prime rate" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r59" ], "calculation": { "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "verboseLabel": "Proceeds from issuance of common stock, net" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r60" ], "calculation": { "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from long-term debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "auth_ref": [ "r59", "r227" ], "calculation": { "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised", "terseLabel": "Proceeds from issuance of common stock under employee benefit plans" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLoans": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from principal payments made on loans related to operating activities.", "label": "Proceeds from Loans", "terseLabel": "Proceeds from Loans" } } }, "localname": "ProceedsFromLoans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": { "auth_ref": [ "r57" ], "calculation": { "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from sale of machinery and equipment.", "label": "Proceeds from Sale of Machinery and Equipment", "terseLabel": "Proceeds from sale of equipment" } } }, "localname": "ProceedsFromSaleOfMachineryAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r26", "r147" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r9", "r10", "r147", "r315" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r9", "r146" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r61" ], "calculation": { "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedLabel": "Repayment of long-term debt", "terseLabel": "Repayments of Debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r237", "r331" ], "calculation": { "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockbasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r8", "r72", "r77", "r299", "r312" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash and cash equivalents" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r5", "r11", "r72", "r77", "r330" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails", "http://www.genocea.com/role/NetlosspershareAttributabletocommonstockholdersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r19", "r171", "r231", "r313", "r328", "r329" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets", "http://www.genocea.com/role/OrganizationandoperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r84", "r85", "r86", "r88", "r94", "r96", "r139", "r228", "r229", "r230", "r238", "r239", "r325", "r327" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r120", "r121", "r124", "r129", "r130", "r134", "r135", "r136", "r183", "r184", "r296" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r186", "r194" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Recognition and Deferred Revenue [Abstract]", "terseLabel": "Revenue Recognition and Deferred Revenue [Abstract]" } } }, "localname": "RevenueRecognitionAndDeferredRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r280", "r285" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Right-of-use asset obtained in exchange for lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Sale of stock, consideration received on transaction" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of shares issued in transaction (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails", "http://www.genocea.com/role/StockholdersequityNarrativeDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other current liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/AccruedexpensesandothercurrentliabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/NetlosspershareAttributabletocommonstockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of common stock equivalents, presented on converted basis, were excluded from calculation of net loss per share due to anti-dilutive effect" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/NetlosspershareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/NetlosspershareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r208", "r224", "r233" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockbasedcompensationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r208", "r224", "r233" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense for stock options granted to employees and non-employees" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of future principal payments" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Operating Leased Assets [Table]", "terseLabel": "Schedule of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r209", "r226" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansNarrativeDetails", "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails", "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r211", "r217", "r219" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity for employees and nonemployees" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r37", "r79", "r116", "r117", "r161", "r162", "r163", "r165", "r166", "r167", "r168", "r169", "r170", "r171" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails", "http://www.genocea.com/role/WarrantsIssuableSharesofCommonStockRelatedtoUnexercisedWarrantsOutstandingDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r172", "r207" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of Stockholders' Equity Note, Warrants or Rights" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsTables", "http://www.genocea.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r69" ], "calculation": { "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Fair value of each employee stock award on the grant date and the assumptions regarding the fair value of the underlying common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansWeightedaverageassumptionsusedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansWeightedaverageassumptionsusedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansWeightedaverageassumptionsusedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "verboseLabel": "Stock option activity for employees and nonemployees" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansNarrativeDetails", "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails", "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at the end of the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at the end of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Canceled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted, Weighted-Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r226" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Outstanding at the end of the period (in dollars)", "periodStartLabel": "Outstanding at the beginning of the period (in dollars)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r213", "r226" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at the end of the period (in shares)", "periodStartLabel": "Outstanding at the beginning of the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at the end of the period (in dollars per share)", "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r207", "r210" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansNarrativeDetails", "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Canceled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansWeightedaverageassumptionsusedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r221", "r232" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Remaining term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansWeightedaverageassumptionsusedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r226" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable at the end of the period (in dollars)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable at the end of the period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options forfeited.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares", "negatedTerseLabel": "Forfeited/cancelled, Shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options forfeited.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited/cancelled, Weighted-Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Ending Balance, Weighted-Average Grant Date Fair Value (in dollars per share)", "periodStartLabel": "Beginning Balance, Weighted-Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding at the beginning/end of the period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Vested, Shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Vested, Weighted-Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance - Stockholders' Equity (Deficit) (in shares)", "periodStartLabel": "Balance - Stockholders' Equity (Deficit) (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of significant accounting policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/Summaryofsignificantaccountingpolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r15", "r16", "r17", "r79", "r80", "r100", "r101", "r102", "r105", "r107", "r116", "r117", "r118", "r138", "r164", "r260" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/NetlosspershareAttributabletocommonstockholdersDetails", "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r39", "r84", "r85", "r86", "r88", "r94", "r96", "r115", "r139", "r164", "r171", "r228", "r229", "r230", "r238", "r239", "r262", "r263", "r264", "r265", "r266", "r267", "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedConsolidatedStatementsofStockholdersEquityDeficit", "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r84", "r85", "r86", "r115", "r296" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Shares, Employee Benefit Plan", "terseLabel": "Issuance of common stock under employee benefit plans (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r16", "r17", "r164", "r171" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedConsolidatedStatementsofStockholdersEquityDeficit", "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r16", "r17", "r164", "r171", "r215" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/EmployeebenefitplansStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Value, Employee Benefit Plan", "terseLabel": "Issuance of common stock under employee benefit plans" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r16", "r17", "r164", "r171" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r20", "r21", "r80", "r137", "r138", "r260" ], "calculation": { "http://www.genocea.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance - Stockholders' Equity (Deficit)", "periodStartLabel": "Balance - Stockholders' Equity (Deficit)", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets", "http://www.genocea.com/role/ConsolidatedConsolidatedStatementsofStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r278", "r285" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "terseLabel": "Sublease Income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/StockholdersequityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Non-cash financing activities and supplemental cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_UnrealizedGainLossOnDerivatives": { "auth_ref": [ "r70" ], "calculation": { "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain (Loss) on Derivatives", "terseLabel": "Change in fair value of warrants" } } }, "localname": "UnrealizedGainLossOnDerivatives", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/FairvalueoffinancialinstrumentsChangeintheCompanysLevel3WarrantliabilitiesDetails", "http://www.genocea.com/role/FairvalueoffinancialinstrumentsScheduleofcashequivalentsandinvestmentscarriedatfairvalueDetails", "http://www.genocea.com/role/NetlosspershareAttributabletocommonstockholdersDetails", "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails", "http://www.genocea.com/role/WarrantsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Measurement Input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrants and rights outstanding, term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/WarrantsFairValueWarrantLiabilityAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Dilutive effect of shares of common stock equivalents (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/NetlosspershareScheduleofearningspersharebasicanddilutedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r99", "r107" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common stock outstanding - Diluted (in shares)", "verboseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.genocea.com/role/NetlosspershareScheduleofearningspersharebasicanddilutedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r97", "r107" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average common stock outstanding - basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.genocea.com/role/NetlosspershareScheduleofearningspersharebasicanddilutedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted-average number of shares used in computing net loss per share:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.genocea.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r151": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r194": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r245": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r332": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r333": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r334": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r335": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r336": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r337": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r83": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" } }, "version": "2.1" } ZIP 65 0001457612-21-000063-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001457612-21-000063-xbrl.zip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

"1VO)>\Q\X I6 MK]D0K#L?-D."*R8'61.<&_"\GYJNZ-W=TCBS3Q?S&_5%/LOYD_PTGJS151$F!J=-MU9D.Q\97N_(:7]5&XNAW(W-4 M">UZEW4.=,N;K1ZA#'W/=1F*[O=>EM#T>@MVKL]A[\0L$3BX(;-]SS.;\8RN M5DT=VLWWSF',H,(0:$N(:))A&#")):"L*#(NJ(B)DV/7T5[&QBR5D.N*RQ?0 MR7%,[3CD8J0"$XP?P', MPK>%V=G<+A?F.DJ\>?EM)<7'^9$-T#J;/H9,82I2P.(4 IA1 H@F$5"DI(!( M)"3!RLVWIG\AQT8X6SJ:FB3+5LMH+C4+:0W-7\W/)E%"]+2JB@AN!QVO-?R+ MJP]/@"_ \BKKE<I0'*)2>8H)QDL('Y M_5P, 7+;S7\;B.V6/5_0 B]7;86*6K">@X/VU.T]@J=M?_@PFSW-CL;"[#_C M$5]^G<8);G:EJ[;B0I9BGM,$")8239P< 4;-C%9<%3DDA"96%P"G.AB;C6PD M;&.(+;?C)['KGJI](!)XNNZ X1-O?@P5AY#S"]$9*.K<[I-QBSOOT+PS]/S8 M>\-%GW=(O1. WO7O8&.[#3NH=UW](YH M8(;<"I378*Y%W@KJT]9.+77T>_/?;_)'&;W1D^;O(1++V@ 7)&EL9\>ODQ#6 M!HN3R5ZM7O8OZMJ4BJUMMYNGJA-RR\O2GH ,?6>Z56KZ:ET3 M<$O6?NNNGD.D[S*K)_L;O*KJ.(BSZG]%NY,9V,CE$KKM-1F9X=I^XYW(GZI7S*) ML]^9BH:+1_,!M37S4H92+F0.N-E;PI1)0)$).$IHG&0Q4WF6.>;>/]W;V BW M%;:*#Q8;<9WS[G< ;&>N]09;8);=06Q+TOZ+%%HATG,"_8X.A\Z9?U[W(VGR M+5ZZX'KRH(#R80*K-R<26&T9CWM9K-IBWK?+*9>3.-'DD^4$C6D;EO8R8O)O.J\#*A:K^4$O37_;$ ;X4 M1=,XU]L!O4^@&8!89H!@Q NTDP6/,=,I5Z7MV/\3L+?"Q_Y2J1F^#_N]^%P M\SRN$1_B4KNG[)I;VA])L=DB$%40]'Q]/MR8]7XS/X#HPU_Z#S<>1_T)!NS> MSX#ZO"CE2O=N"JM]6[RA\[^W-\S8N /G0@$F4V6\D(1>R*@ .80HEU#H?W2* M)CC9T]@V7Y6@42.I M9W7>IYOS+_1TRW;]5-XOEJ8TQP1K9F $*Z#B' +(8@4(3Q @28PREA:0*:?4 MG!U]C8TDCMZQT;6X/5ZQ;>'M>]7#O4 M^^S=VI%7O"L8+A[D.N'"^K("<97F.>> "*(9)!4)P$@0D"),*9)*;Y^=KNE/ M]#,V]FAB2M9R.M\$GJ?O7 M^;B?CW0:WR[EAZ>YD&+/M;7(8\%R# $7N#I!BP'1- 2*3@6":-IX>0L?;*G ML;&"$372LH):6$\'ZM/ 6ERK]P578%HXA92G=_5IR-S/S=GU M^BP:YWRP3SC3K/IQDUS] M>CY_,BZ7F\=NI?YRYN6$4YPD(I>@D$35>6*(R!) 4%+D"N>0R-R:7ON2:FQ4 MO%=3Y"IJ98Z,T%=1HUWSVU;%@5K#_<<;+1U8J;?AMB#]UQC$P O$?Y_Q.AMN#>T;GYWUMO?&/;/8MA'X.SYS+Y\U/+73 MW 1G-$E4S@'.,A-!+R7 19*"F G,F.)22#1YEDNVL,Y?>ZY/EXF\W7/ Z_QU M@HQ*YJM-6J*K:".W8^+:L]#;G8;T"F?@]>U"'-WST]IBTVM>VK.=#IN/UA:# M@SRTUB]ZIH9:K61YX <.%9&4(0$H-GR391!@)C3?B#RG*18,"N&4V^E8+V.S MVUMG<%H)ZYI@Z2B.=N1Q,3J!":.6+XRWO!4&O685.MK1L&F!NG0]R.O3^;"G MXX8LCV4"^CA_UG;-;KKKQ5S_X4G_K2&BQ7R3_RN7.,4IRT 2*P4@R8AF"<)! MDJ4%R2%2@CI=P/0CUMAH92W^5O8V1X>0?H;+CHR&'X3 [&7RL'6D7=L,ST[" M_K5NT4:Y(,37+]Z]>K/T(]FPKB^]HGG@)]-OZQXGN?L55:[Y/YZFJVI_^OY9 M_U&+QAH3L;F%D(0C::JZ97F> $ -"CX YUT M]C\(;H>9WAAVGEJZMSK<\:2WQCOGD/ZM>/ME/B[EO9ROIL^R=M'02]N-^D9_ M3!C*+:NL/)4HAI(4JU*1W3-/=C>T>^8YO8^X9YY]Q;-P.BWEQND%0<8)43%((14 ,I$ _1L%,:&$ MYABBU,[-GQ@C<*@9F@D2M W,91C7LM,+[3P; UQ(_I M=E F_.A#'EO&K_?:C%C<3=\N_ORI%']NOCL"!2Q2IF$1F $H"0.TH#E0#*49 MYQ1F/+'>%A[M8FR3M14R^A_TX?%_1EK6J\A(Z[ !.0ZEQ<[N8H "S^-3V/CL MTHZ#Y+ 3NQBL@79;_J"Y[:HZ\>C<.1U_<[C=4:?D.SN@[B<]#1,-C5PNI:B" M4K3M>;.L'-%%E5SR5BZK.)6)P*G$,E9 ,U\"(,PAP%1E((W8V'$M=1N6]DB7&FW]FQ&]R5:[SH_02]8$R_&QM)!Z1SVTZ;0&O ECNZT! MKZ5N,MIJN>OPMAX-*R>@>K6X['H>UA1S0N/ 1G-[VX_&/BWF=Z9@NG%6^Y66 M3\OJ@N&+?&P*>=^HV^5TSJ>/QC7ML_Q1?OLN9\_RU\6\O%]-1"(Q-U%Q2OI#3=TXZ[+!L*.RP2 .S'!&#V 4B8PF M5U&CR\M5])]2<]W-O$=6ZP6S/LGN,H$&YL-NGQGX:=6-,(:>33_*.SM[/ M2_V=7?^8KB9%DC "L=G=\AS +*8 %WJXI.0<0X9Q)JRJ%!YI>VQL5HD7U?)% MOQL)+;=MQW#KIJH+T0A-/ Y 6#--A\H;WEBUQ+&2_,]WB^=?]%LU9^@?]JGB M6(N#3/P.5=IIW/6([S'Q2U.ETK^@.=73]LB[:V8@=M7+KS9B1_*I" M^?U9E#T.MUT!Z_?DV[KW@8_%75$Y/#-W;L'=PGAK^' IZ=N%D!.4)HA*F("" M8Z3-BSP'C&(!1)8I08I"Z1V6K7FQW?#8; LC6V2$BXQT]F;%#ECG;0I?" )S MA:7V3K;$,54O,"1VFAO,BCBFQ+8)!S(\_/R M8G@"3U!G9)RF:J?V%\S9X^T.-GD[U=J>Q=T/7GZJ:@:Y=QW:'#U^HGFT+>DY30 I*< )JD'$!$DKI*J$"4(9QCD11.54*=)1@;130I+I>- MO)%:+"-521Q-&Y&],X5:CHD=NP1%.K25OY-5M!&_S2[Z91OZ6H7HXSGH+\DW MZ@9?H"RDED*\5FY2-XPZ,I8Z-G1!O1EV/JD[.Y'4_?.BBC.38B^E^W^8+&'& M)%L73IUP%BN3:AWDR 1]Q91I N4I4#D74&4,02P\2\X,HH +*PQ7=>;-NL3, M&SHS'\2F0 1H"T14NE1[CVBK,G%O14:&^7P493PND (Y-%DTXUQOJM., BPI MXB(EDK#$JP[-2#^>\*5HWM=5:/Z;?S=V-L(XOX3 QD5O)6JJ'#VU_D/7IQET MS'HO43.,],-7J1ET5(X6JAE6 C_CZ]UT1>_NEN;&5O=[H[Z8Z.\G^P#FSKPTB??)E9W^#,IR-YON<9/6._ZEUV1Z/Z2;>+1[H M=#Y)"%,I3CA A&E[&;($4)))H%2.M"DML*).Z=*.=S,VYM@]J;V*C*31[[6L MCJQQ E?[$^W+T!KT2-L6**]#[=,X]'VJ?:2GP8^U3VM[[%R[X^D^"PA/"L%A M03@&LDJ+%J<,$$@RD%&A;0PB\Z)PJFQUO)NQL4%UCM9L7/B6G'U44KVH\.F( MB.#HYFYC*]?I5TVJLMX+CW=#$[XZN4OO,-FN8%"G*$BY M2F !()4%(%2:]"I(L3C7ZL76'F+;#8]M_K?NUD[K_P%:W1/]$@P"3VU;]9T< M3X[I>H&_R4YS@[F9'%-BV[ODZ+\'#Y7[(DU_NND;]6&ZXG1F8I*,_TDL8FVY MIY3JI5MA"@AB @C.9(Q5D21V]4WZ$FALDSQ)3FO*&6O8JF>Y5(NDX87RF8[KA,8XVGZT3P@I"Z[G8]?-X7SW*Y3B2< MTA07/.% Y(0 "+,<8 3UJ&4YR5*&<8JM-C@'+8^-[BKAG.MK'@)VWJKQAB$P M$UDCX.;[?DS;2YS?=]H;SOO]F!H[[N]''[CLZ+$-!S/>*]-RXY8[@9C$*8LI M2$2*31Z3##"5(8 3R%FBN,JYT['#N0['-EE;.2-ZMY3U?6I]NU_=HC]4@<6. M5^=G,7<[H.P#R<&.*M=P;J2]:MSK^S^R/(=,B,/+DWV^RC'F.01.'6B>?<^/ M;?8STIHSTRHN'"=8X((E(&

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�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end

"JW&:7PJ$);PUT)[ D_)+@?1$79(^U?PA4.P F[@]2>&?^$0)/X%O;?Q&FXXK 01& M+LUIY*'V)X>C@^FQ<9EK>0B4IMJ>@6*"$TDQ"ULI*=$%5@N4U?\,P<_J#.Z9 M6"JP11UZN7JJ&8%U-??27J30$^0]S&@:\C[GB?CY3RWY"]2&&AV8"DA#HC+M M9))2W1 2Z<+^6*]X7ZHIXWG @9S+%)7N$IQ6;=[.['%C5#((H6X6[$SXW228DD=G#FQ M4JQR(VAUT9T")P0M0[%5/HD@0.'_LMPLOR:DSV4#7& MUI=KGD/*Q&4U8]/(!>A,4R)36A\\ 80ZS5-J;4P40^6,)B!"4=/+M,XIT6QG M.2HS[9-9O[Z-.);5-HH6^1..N'R%=[$E[!'Z8L LNY*D)[U>J#S7[;'W@@EO MLE#ETU9$@V(.^Z]J+,;58(?-'),L@1_#5:T33],9Q_[9(A\3:YBM5+);7T>\ MF#%,N*2+&+(QY8Z6%YS/5*-/$*LT8[)Z\-%5TU6ZY699HW6'03+F?S*MA3IE M'2F/?!%[AZ.?;3S?9#*=RO_-R#>,5LN\G3\L-*Z]]QC<9S[AQ;8,K3CZ^-!:> MZ:Y;"UZ] +Q'0J6G8Y[P N?='+=P[-8=6SI#K8;I4TT$5Y5H' 8ZYX!?0?EI<^,UVT:!=Q!G U]?;3"O?WCKU7;S_[VK] M1"E@!;+#@M3U_;CYV!Q>B +T[,KC5=IFP06ALGF1CZ4",YF.\SGG=;U:I?0, M5C9"$G3..SI0_0\TK@NX."5ZN=,BUO$BS9OO9_AE7>)V@'V0T*N<%W/I5A(S M4*V1X &P4,4[A$8,%FLU%C]HIMEV5.>7O, 2O!)+@N$>Y9:]X(1-P45< 06C MA =*$(I=R.M $>Y;?BV9U)IK!EKCOKELZ]V2KB'^)2WE3JP)TA-5E56"9CL7 M7BH\P+P0 [30$A@<3&,=V)!5^\Z%7Q++/?/S--*F8/'0@ZA7X[$W(Z@Y2/U? M5LW!P>B8:2#I@*(KD']"(X4B,LFW3A2Y,_#$R51.](*">W,2;(I L'QR@>X7 M-75\H$+7"WI.A%W(T.M%'NKF-1+AHY5YGI$'D^)6,1Q%*F$9*)T% M&I%%6GX6Q8BJ3)J%),1AGGF4-GX;9;P,.A8('10P=5Z@+R7]2B= JB#P_ F+ M>$7X.1620'VWFH[5F!1L'>=@?VH@X@4B,CY(4!$_:6[GTM'=@@O49NC MZS?HWK^N>DB>KNLN6W].WYDYPI'(0P %?T:Z&,]0SZ\U@IBP)/T1/?P12<40 M"P',VP?5-I,6S"TV91$\W9_6%F@;Y'DBY9&"KKP _6*"OI84],4%+UO+_L&Q M9 1@04/I3_7A3Q7V?Y8R 7!8%FUTT ,%WJW&,^DY;UP=Y0Q, EYV71XM?9.L MDIGLZ$- KP@CSC'%M\D9F<\03="87:T'>H)XA&O.BXFL]UM+4#(#A=E(]4+( M085.@8%V+BL!CU/0X4M)-!F2"OV=J].G"KOGTLR4^%-R%M1PM_ZP'T$""^_! M\FE+K'>I3BFL>;V$LW_F=+CMDY0 N '%['.P0,G3U/A!6B22$ R*. XBZ 7[ MP8A$5HJJT#P#YA$)P$@]I9EP2RF20K#\&"M;5X)YB&@>@;C:W@ITS0.1Y1FO M5S70BGS.QK/6.D5<9";!_FI2HN&86B0Z8Y;0\6T@&A4ZHE6V8$L]%WL$PJ[M M,4JN+#I$1T>MSA@1X^+8&?K7(\77$,$TDR@F^8.91)F)A+CK:$] )H":!:[^ M',8I9^M^HSKBC5DZZ6GE$6B%O.HM5#7& C-=W6,$E49"R^WH,5)&\N@B@_F? MI[VV\AAG1S)G.A.>%\34TH5#5.ME;T\\*N-=#K0L0/&D#3BHS?XFHKEL"0P0 ML'M5I^BL..RVQ&\FTM5L:EU3)@HUB2>#9L0!@KY%XP>180!#+'LA0EF^\#E^ M?Y,*?3VAW9W09 91DW)!N*6&XAH$O(QZ+E#3W@2F*5Z7<:&-YB'!9#%K=L:$ M28V;-Q,]=%6\#^&=!66-Y(1=&O,97[+<6_DL;7B!NFO7W-]KS/VA=B:CU%+@ M2K6Z8"GJR\U45>Q2E0^@Y (XT57H=#(WJ?()%;D4^<0$DZCM!+1;0-%J?T=A M606EK[-N:XJIX_OTBHM\#/M5*CM(X3D0/)N.JYE,;FYL9Q'F+=NSP4CR.)8< M"BTAK'LAP\_-AF$WC;]?,-;!.-S_KGE@,CA3"@) HO$CE-,TIBQ MY-5;(&S2# M+83+97 K8'%OA+&6APC[.=--Z.^/(OKI#W"7$RQ MV3A.6Q)3.0^@ILN53'##FC+^-M>4>91(%/++8':%X'8QC9@,IZ$&*[BDGZ?1>D4-7P)J9;R4]6- MFK OH.%_%6"T"2>'(YY15T;)UFT$>8)3$U@H-3?^94K'*WR;=+3XD'3.$(=. MQA5Z;@06+LV:4AV%3.FK6^$).2T2$UII3(0?DXC,,7)GW(;?AQ^'"T,-M5]@ MDS*94ID7,P&HSF0%D:0IA+[JH$A@AR"4."6U4AV1LHJ!OEH=\.02N^^5 @39 M2JB0>$+8RW1/+V>$FAI:#_P+Z)\EZ?WP'J'^L0R?4)=/X;H('%J0Q*%E MJ,Z*(D[4O=\262AI"RR43[(HA-1NV_=$$B]QFD5B= [Z2OXH$ I> RSEQD/H!V$'!=)"\T+! Q5<4DFM_HO1< M];,+'I^3;Z>MPVAOJ@*?&BPBJ/&T6@F-'*&Y&?G4X0R)P<9H,Q02_]KZI;3H M6O2XR.475CIO5B1X9H?H]X,:CK-D+$Q3*:UJTY-2[L..*!7FN,@!)K-L!1"@ ME7:PBOVE]?M0 VF)&2[LW;S.1UV6)5HL/'*;)TRM/Z,?#O?JKL>]WL!"&!WL M(5AV>^P9S;FQ*7.$G#677KSWF*@6H^6R#9EIUR[WA&7LO*[19XZ>E]IKU +J M- UD XTIIMUYG5O,A/]L:3IQL^2HO>1IO>1&:T$?UWDFU':>"7DMF6Q>3,1. MMH$<(5?#-XFJHMUVXV)*4N$R S$).D^KYM#'QK^)\WFM1.-A1/+ #&QGH#75 M&;4G^*.#]F,'3P=8ONJ)^;1N(#X0ZRI+_+.L)BC6O^+?PMN&4Y,9.2JO%DOD MB*H_I89%&$!C:1;S\?5134T%59?#<7 S9)S^B?44JTA4DVK,E"\7/6852C!I M "'A36KJ;$>:1'Q!&JB@'!"F '5NS/R2I;B:[QN=4WY/185 PN97M Q27Z*4 MJE>AWYT5[12=N$4)^Z%JO%O8UQHJ1+G&N&?MJW^G?>:"DW#AJ!>J!9K94L'' M\3>X9VQ=)1RJ0@H669H)TON I"8>,6VFF^X3_E2Z3&!$TXW;'S4WJG.'G@I] MM=D@NB.@D7^M;SR8SFNF.D U'"X\5D>[ /*ZXI39);D#A6JFHK+? V\VKK+ MLS%B4EB9BYA!8^0A#"NZ +U-*EQIT7+IU&%2-=6,XQT6*CD3F:M4W>A3%9^K M.@OR3-H16UW4.IH)SPO> PS0((XG!ZN4<@A7K[?VY]R61(3% Z-3B":669/5 M5):LXHTD@EV,BC3$;0QSJ<4.UI/&8%/BHAJ4-66J"F KSX+\1UN1:WY]98G& MJJ;WL1$65_Y,,>U:T2'BNC=//*.5$1>3N#P8W6VEOR-6&G']^ M1ANRPO>''\[$M3H^!EEU]J_7'[3CTS?O/IPO4Y*CI8R0JHO@\JA)A5:899>-(%(-ELWD) 5K!U/>@N"V3B6.EF^ M&K(\:".M.GD=#8)/:)XKG7YR-8W'623Z4;L ^(<$3=(=*+ .8BT2^,4C!Q.GU'QCU:8M&[F\*T?WQJ?81K>-F-Q M6NS^<"V_1PR%]D84&=D+EGZVK,[7-*'T^KHY 45S98D5#:NJ):#>7BB]_S#+ MJMHX0N[Q!E-L34/_=UUO:8[UEH1=\0IL;J3TA8IRO:*L%.71_2C*P>XKRK"# MD0Z_QPCLS\++.G^^36Q#\VZL(+[^(@J#WP2-WU*+UUD+U(NP(7YJ[4L@U&G) M?U9_/%>]#-.,UD,_6NS("&^1)QY80\_V\=!E_UPY_+=;Q_O#P''NOB;+.F0KN%IA0QY@P[:-V@]?LUF/%Q/UYMMQ4W: M1J]KGHT3O3$=3-(X'O-'4@3LX2;MZ&_>=/[&>[.*+& 0(7/6[DV2?+^T'II< MC"$_,NI^)O\B/@5S8BN%%!>D]/S1)ZB!U9R \C2;37]^]NSJZFH(TQR"'?KL ML(@N,!CRC,?GK'@6LQE[9CKNR#.M9S!=TS0)_O!]XS9CJZZXR( )12714CG.5 ,JM(J?I/4_!?*TSB9! MLT/>0PTH4I6*/,*ZQ=F\#HX>"7M\4=?T]7\/M#<8 3[-AQHL0K<]RP\HFUJT M-7G#PZ)"UX5IH<)I.D__SS.VJ'^T+OZB]DE$?V],\;:/WK< >F3&8SVJR.EY MRX/S%O&GZ>/<7>?9>18QSW)-W_\,S$7RE@4&0DQF(E/?J8?4#G&=7ZN,:Y9+ M',?O.<[C^YZU/#YK<7O6\L.R%M-RR8 J),_ M'@]Y JQ!7\EGCD0'#.0?BBM\0^?9C!EAC0RA4FDOT[S$1B+4( :>&F[,J=QU MG.JWBA5P[<;S%='%W[[)K.!GEMUSJ^W@5J8Q-/^'2C4YSWNVM<-LBR$>^#\F M_V(:RAV,-Q(8P7M171O!W_I+0J8C#RE2PAU]I YEOV=PX0^O6!%KAW6SW0:W MNYZ5H,]6>RV*),$'6+?FDFOOQRSK;_9CZR$FW.S^2N_#E;9->:41A:\1_MYY MPIYJST0V$/W=J -2_K^O\U5>U_DL[T2^2G\W'_]N6OW=W).[:=WE;C993/W= MW)*[:?U/?S7WXVK*F_E16MBF[1K=NUA^0U#*\@#]9=W6RXK&SO'IQVVXL(^3 M 82?:?__RP]OP?S"TKT1UU[E$54^T\A?8SX7/;+5M['Z-LYA'I0=,9TB#EQF MJE"RK2SC^HK-F/#FA+*I*KUIQLY%Y21$C,=QMZ1">TKJ7:LP?/WE>)#+\?'H M7_WE>*N=L2_8=G<.+'Z&C61 &GR,+OB$U;=EV!/IHQ'IT>';GDA7$ND1&T>5 M+''V-LT^8V6)GF2W@&1?O7[3D^Q*DGV%12/2GF*WC6+?'K[L*78EQ;YE(1_W MQ+I-Q/K^P^N>6%<2ZWNL;9[-UJ@$/7%+BU& G'6K>@XBPGO)4J%U'5(5#ETV;!G"I)"]-R: M$@YCS9H?K(+#RGH!VU+6P;^7L@ZF=?!BU\LZ;&_]LX_'OYP>GOW^X?7'O:CQ M\K[5]5E4Z:02O1/5*V>A//+JTLCBA^?8;1*'PO)!,2(KR4V/Y;G24M8[E*6: M9?564!JQE&K(+]@X0>PG#D0A-/& K"A99=@'# =DU>PBIS+*=ZL;C#KG]ZB& MX0Q]S[Q--0QG- P<_]X+5SC#P+#N?U1[Z+OKO[Z?["BO;EL-!F^UD[G!;I6+,"46'X!E;MUJ_OY?SG^U_.]RF1 ML^&*GI7/M#^/W[X]/CS17@VUH[>''_Z]JZ1)(VY>7/(;G&4[UW@_*[K/4CZ/ M2KY_8O,Y-B'2';/B[&T(_/OX MXK>$/=QPQY]<@]5BGV8[JX'/[9+9/4:XQ;>J6]JC*^.#T_/_G6HO?K] MC\.W;W=5Z.Z?^.FUPRYS25DVNV#:J^J2C<>[2J:]WO1@:]PR944HA"MR1GH= M\)YTP&9O4PW\N9I/QB_\'4$L# M!!0 ( (" G5+SPJ3F0PX &>+ 1 9VYC82TR,#(Q,#,S,2YX]^N9\%Y);)B(OPI.7L=5N$A9[P M>3@Y:7V].6\?MGYY_^;-NW^TV[^?7@W)!^'%,Q8J?1=_) M6(H9^2;D=WY+V^WWFNA,S!\DGTP5Z75[SNJO\MAW7-?MN7[[:-_;;[L]_P ^ M]5B;CEEOW(4?>OV#GR?'^WZ?^D[?:X_IV&F[7?>P?=3MCMJCMT?4=T>'3M_O M:J;WT7'D3=F,$NA8&!W?1R>MJ5+SXT[G[NYN[ZZ_)^2DT^MVG<[OGX?7NFDK M;1OP\'NA]?U(!EG[?@=_'M&(9YZ8=;"WW7[?R1HC*VY@ MSL-(T=!;, ]%&,:S]02^DAWU,&<=:-2&5DQR;T%739014*4D'\6*G0LY^\#& M- [422L._XQIP,><^> * 4.P"PUR/RLJ)TQ]H3,6S:G'JHWQ_@TA"!&?S854 M)"Q1CFDTTNI&4B%9M]UUVFC%!-2A\*C2GIJVU]TK$758H"+\UEZRV+N/_%;' M7H$X:D\HG==7(D^8*)(^J:],SF.=HZ.CSCVZX$8URDZEV[?Q8]OIU1.[R3OM M9<.W=D;W%#HLAU\]'3*Z1^JP?M#9J)*G_)(0HBY'J(MS\#A=MM-C6R4TJXAY M>Q-QV_$9KQP,C_%KV?2U:W]T 206:Q#?I(?P._$^Z?M,X$)*^7= +ZX?.O5Y\V9B%:[K)] MQC1CN\3C?1?20_A+VLMTMTTT)4'2=YU5@A56<<3\B_"]_KS:T90X;6(@7!D> MUG1%OUI+EC[,#&DT;^BS$(A/:8 3^?64,159VWHML<'PCC9\#ZQ]#19C"\NG M?$C*B"2 !/FTXR2))X^\0$2Q9/ ESTL'V26W M5T3"Z -3E >/!B9C8\+'[<+?.OA@"-1LFQ0"K^/9C,H',8[X).0P U#HBN>) M.%0\G,PAS'BPM+3$RY*9>53U';VJ**"6,L8(EV--EKQ)QOP5NA5K7SX'A)I"G2T$55S,OO_6T2OD B;( MD6B6&(863$F.ZRM*F25NZ"BPGC[L>)D0ZW\_:_ M$=%:D3Y)]2(YQ1KI3P//DS'SV?TGS%S@#^Z MPEK /^5-,N9)"0'9DY1_'LY7$,M&KY5.U.5J3"PUG6$O,3B&;%7\(O8G,<* M3#H#6;-X%N"HF=,'W?+)X*\687: ([=[5-YUG7)T1K*&&;160ILC,&:N/:=?KMXA<1,35.SWEIGH6E)CJ.EAZ72M MY9N>6:(1ZEO?SNA]UREMFB7NWD!#YP^X,GV\U?;T2YG0',+!U4MY5?%X;<*F MT<;?,O18,#*/B7W7*9\D6P-.XP-3NA,59?]: E0B,X^5 Z><@F:DBP\-M'JM M_&>%R)P#O>V7B^(+BS#>)ID:)-%#OS>@-4FB(TEU M(4J0G#9+#CE]&ATNMYS7-I*;03URG=*")@?JZPR&AL#S&;_A\8STP3#=WWL8 M@,_/YBBM9DUF&\Y&(&%=ZFR.RND1$RUI<4)D(8ODA#42YX^S>2 >&!NQ$-BJ M>4"MW_)92VK,6/IX!&05J8P-2?D0S:CA$-1*80P,C.E,O]YONO88M7TN6N=M;\QO(B-^?2623IA=!GV4R7G'/ R/TB* >!$-]$\"3H+V>J1GC ]':VA*Y52IS5OK6*9?Z@0-!%@1X$,VDN4:OE8RNIS7GH8?] M\KYM&8 FYJ KUER^^<.H#'DX6?P"\P&^]^O[/(A5W83FL5+,D>_([946?6O0 M+;X^E$E>-OB9:.GZ8$4J_S4B2C9(;[+%H0&SABX[1KD]F4=Y@BUSHP.X7;=G M$5_Q?'E.'!9+$X$D+_'O#OF[3O'"S^1[X5)0O!(TO9Q8.P3>1_C']6^G:7'K M,YN-F&P1.HJ4A-SAI*4DOOZ.5YJ>M,KM0AX$:/"LG;ZM^1A@X<*_T5<1^G%R MH4>+1#$PY2K&;[]*$<]/6DESKMBL19*;"Y/KFX]],:,\_ 0_()?E#:NR*(3N(:8,9'OK, M=W%,@VB)T';GCP!]N! %OIGZQ2P_1?H=?I-+U(N]!K%/&JMR7<^DO& SZ?%FZ=X MZVE(\5]0F:.C7,KLE.C9%.]_O]2J783XP3,Y\>,9U_!M.]. 7>8)NF[7<7C]!]B=LY&,H;1T#N$$+UO]HW<.XJGB<_RAWN'W,-;'R$< M3R339)\Y+%44N/ME@FM%U'\2WG4L]",G 8WK9 M C,QX6=B;ZC\O8I5Y?K&.W>95+76WDXNV7&(&X M&"<+R4N:'+B!//P"7]I?%F2B&W:O3@.@,"8HC^#Z7*Z@,A$U9K6EAM7=-M*\ MA$X5W3.#YCP00D8;>V4F>NJE1OHD5&S"I-U,Y1QFTX]E3F6FV7D@TG;^>*\P MD:]:+J]ON_,N)'6IZXJZE X%%;4M2QXO=36CBY"P8#^/0W]YIMBB<+F19N?8 M9@I5)4#E=KM.4[8KK-S>IV.09[[9BDY9-/Z97]62S<[J&'N8O 3,77FTX MO-14J @BI-H,8DYZW8/^+QWQX\#W]48-#08P:FB0;U;/2QXC8+?>\MB5378: M;9 <1EOL3F A"\T&O<;)^;D76+75V'7XJE7V>\H2XN.WC9YWY [4S91]IO([ M4\G_IW(Q'C.IZRQB(NFL8KJUI-[YQ)ON](1^+IP.&3Q,#LY4KT_L&;R$Q4IN M$9GD?X6*2.J:-U/X ;?[JX+OEMQV&VF'//1$$,*J^?L9G7-%@XK5P,;V.W?> M;+D%2R\7:]G>E#GFSI@H7E1W[+OQ8M0?P%=86X#[7T%N@>\;HGI)^/L4HG?R M6RQ/5]5^Z[+9><JN,!<0XZ_I?GKM4E^)_H4>L;AFG@A]N],_ZYKN',#5 M?;XO(O2VVR%<1[GK%&]5Q[I]>CD]T9/L:75V?KJ:G2]>]!)9( MKXX^P@I;07XVJBK-_V@UGGY\U$H8BDO,CQ"EQCC_)%4'RX5IB>J%AK(UH3@H M[+HL!WB=<+Z9QXM=_F YV[JT6&ZZ\YANRLW%># > Q207)SJ%U_PQO^+NQ / M'?/YTZX#MI:UVU7"EM5'Z,4S'44KLM[Q8308SGAWHZZXS6-EB-X5!W'J,]KY MP*KSZ9J;Y<5W2+RU$L+B? MT?=O_@=02P,$% @ @("=4B>?&9?Z%@ $=T !4 !G;F-A+3(P,C$P M,S,Q7V-A;"YX;6S=7=ESFS>2?\]?H?6\+F+<1VJ2*<5.IESEL5T^-O/&PM&0 MN*%([4?2Q_SUV_A$RI1$B1<@TWF1+8D"?GV@#Z#1^/L_/E^,3CY"-QU.QC\_ M83_2)R__1=:! MGT$Z^32G<]...7L]F^[ MGQ*34G*9B%-1$SV>5/3Y]^^O3IQ\^A&_TXZ MT_^WU1Z?#=1_$8=G3?__KY;MX#A>>#,?3 MF1_',L%T^-.T_^'+2?2SGN<;<9W<^XGR'5E^C)0?$<:)8#]^GJ8GO_QP03\J_']Z^N#'E&8PG$?R/<7+QM/S^Z;,):L,;?U;0]G\]^W()/S^9 M#B\N1]<_.^\@__SD;!P]*6*EXFK.OWW]XZ=?IX]^%.>CGMJ7^/UBB#+97DC@ M\PS&"=+J%#M2B'\^GD+ZU8^*6-Z= \RF^Y&[=J0JM&_&>,V(,MURPM$DWOC0 MJ.C9I%O^Y<@'&/4_'=?AVAY8%J77CA-*%<75 MY@6N1R,(%2Y&'9FR+-_DS8*67CVSGX9>1Q3/OR_Y-^3YP?JP)!5M M[*SS(XRT][+2(/D8&4+#;@+Y7 7>7$Q&??C_H\? MS>'U?%92V;([,,A).B>4)I'Y2*2.B5C,Q8EQQF!J[FA@L8UGO!?3,072!^K% M78=81Q+5]/XTI6%A@Q^]\TE M>.&2M4U2J_5XCBFVKJP2-21031W>PLP/QQCL^VZ,.CG%V']^45@-Z3GD81QB MTBYI::,9F:,<42%=6DLIRJ:8O;U# @&X[ MK3=I&JRP.CA"<_;%I&EBK<-O30B11:.Y:;)!\S"L8PJR*^M)17G42::!. 2!,SSITT:FH*FNKDD;0F'J6?O@X1RQ#5!1HMLQCH.BZ(#,55 M9R3-AI E\C(PUF;C<17%,85)>\CXCA_,.54U!((SKIAQ"#KF9^>HT*6?XI2?O0CU,KIJ\DX+CQTBIQFKYIXA.TA'E/44\%6-))--=WISTBNZ%R!HC"KUY)B?*X\&C$* M#J&@@V,F!^8LE*6 J-SF'?R!:W&,/<>TJ.YT]\UWW!:UVGVL,%)5&.J"$@<#7!\DW2=6;08")&4 M;%F?"3$I#2AC)YF#Y TT20NWP'9\T74-?:DME'JG<*N5! Z#/ #82H8J;2++K4N7:IYJ+CBCS)D8RVWQ&+8B@O16N*X3X1KZ3 ^X4'XYN>* MNX4 WZ!F:2?Y/W2FN"?CF^6/HQN'WBOH@-HLO!,D>Y-P16.8XK1!04H;024( M-&^L8]QUTF.R;X<*ORG#6YBXZQHZ)#5"3&C E2$R, P M[L3WE@57/ =O!/I@7,!(#]>ED$S;XI*IITYE99O(?Y-6'TUD5%\-#I1"Q2+N MBXOA[*+?N1BG4C:,L1N,8U'/H*)RB(F(#*4DE#D2F)0D@G,@$X\EMQKW$[_>_"#:=C(:I%,/'?@ZS(4YT$\G6 M%\.V&;G.1;&=::AQ@^YZTG9(7R1/^UA>97UQV< [C:8F8)M-];]CM M,U-EQNY+8Z4;>C=F>3%&B/ *9J_S>_]Y(#&XC%1X$KQ%%QP#)UYE03!5X9Q: MB4M*-;)Q]V$ZU*3C.%<#%H8.DC!*H1DBGE.,V*/C&+$72R1E%C%)R*G)-N\- M%,<4W=72AML6>W^V5W/F-R%DX:25+!% V!A/."!6!B @(.0@Z! M3*^GT)/QY":6Q>G)P("*&$)IHE+&E9K+W36&A')F'4T<%":@>2IB?^^@Z1"R1,@ MA\J)\G/X"*-)7W^WY+826NA,#6$2?8IDQA%+I2!*&L\2MQ8B;4'F@ZB.R?@= MIAEK:IPJ":.:ZO\3QDCA"!&=IHOA>#B==?U>ZA(4U<&YB%$+AB@8L%C/B8M] MAP#GLN/>.MXDSMN ZYC,8ET=J2F0^@9RQ?YKSX,')X@SJ51P A#OK"0T@N4Q MH@V/XIN$2S7LOPJ!*2,94:8<2%"-L;M+B6A%O3;:2J&:Q $;[/]&8T@>1]/W M5(-[ \*]^/X(X:#7"8/0I$AD!HD38(C5*1+-;(B"8:Q"VV2YVX6#NY/Z8=R! M'PW_ ^F??C@N GP]_GJ AI;+\X1):B"<9[1<@(&8+U^HL\K$X 2P)LG=!ES' M%!+4T9;;2Z&F8*HMC!?C&70P78E0G/-4 $D*O9D42)M7$ET11"XH>B89FAQ: MWL*QH_-O:Q/;J,,AG*];\GX_?3P;8P#C52<$PU0-T3E=ZK%2#-SD+(-JH@T/ MPSJFHYPVNE%1+(]UC'/?KOW=TZWEU>\##R5VG[#RV<2!%-?KIG@?D%)?_OMH M\NFP#HN;1Z_9=7%'6BJ=\[R"69G@33?Y.,31?OWR :&\&+\8HU\NR^\THHN^ MJKQ@3@<5N"-&8O8NA<-E)ZD@-$C,[#V5S#;93]D>XL%7 /R7GNGO)Z<1U;># M>^]X#BA50"T#PGPYZ]"QE.J6[G$:LN#"!>6:Q)+;0SRJY*J1FMVY+M!&@#7O M;$> -/T=&?3.C^!U_I>/Y\,Q=%]N@%-*1"T=YH>V[)8!6'1X)I*HC(]11:-% MDPQ]2WS'M$'U6)K50'+U"I*0 ;>N5-VY<7KS!RN??(.)V 0Y%KM2??XQ',_/H.WZ)%^RQGB;* MTB)RQJ@NXM(!H8@WEA%GA,XN:T^AB>U[ M7#(K'"RO4\SK;:$5Q>2H%EYR21(OBNE4Z1;@# E"2TJMYB#=(WK6-1"/:8_B MB+5]37U#"QVH6?RPK?&T229- R2R[+[1W[?U M2M^_CAZJ ZUU].KZU$U\069-HV!(O.-$4B.(]2P3F:,U23K+39L"AZTA'M,& MSO>OHX?J0&L=76OGE;0T85A8KG@2*3.R 4+I[\' 6(DK*,(Q^?H]=U;7C+O< MR+C>W!@X39F2U!-D2BGX8Y2$C/&Y3AJ5I&\EVJ[!R#8(CRGL::1C:S=@JTNO MXMW$RP[BL&?8@%$C$[6)1.L8*6N[%/5[HAQ7'M<_<-YDDWX5Q#%%'8^D(GO+ MH%[+FHM)-QO^IT?P.E^[@6>3:7_UX_EP>O4$R"#GX%A6B8 2&E-^JXC+% BE M+H52:ZQI$VN[+27N:R*[BJ?#MB.:F05PT/"X]_JR3!K@)!$?!C"VG M5+K_2R(PPDA0^J&VZ:NY/<0=;T1_DRW@VNK52(#UKI*>^PY^]?V!ST4YU+PR MHQY44K%T$!,>L5 52.C5GD5CHE34FC;]^]?".:9F:X^D-Q7D4DU'?O?#KN^$ M=9K^=S[M;S2^SG_XKO/%+@K+N>$ZD9"T+@\7!F."\2?N%!U%M MHS'ZKZ4Q]:34Z#*3]PR 14J2B!B:)>:)Y<$2 PBL5%RC\6N4:NYVV\?\M11C M?RE\BTTS5W;O# #A-DDB?<8TCFFD--A$A4LYMWEX<=]-L\-.75],I_-R8?EU M7GG=!),80.DD4[I(E*:KL3Q?@=+&<" )R%*%-N7>&Y%]!QL0A^K40R>MATNK MR=']5UBE;=L =.;6;TPQ@E@"X"(X;AQ]+53)VI&@=2 Y4BX4E"M.;2*H30#:0FS4P>1+7C1L=?0FGJB:GE99W7 MW9D?+TZ<_#A-KKMI[7,[Y/[!*EP&V1+IP1=H[IWG>7FZ<527,Z# MV?2NK+;NRR1/AV?C81Y&/Y[YV!]/XAJZG(R&?7_%/9BUY<@56+8/#8_$N#?- M&?CFT1FYGJ:#&?H6/L)X#OMP:OFG%5BP%D4MV@XP/;=&J$=I&[-2#HX^EH.C M2?3>A]%^AF.[@=OS:QT%K;GV+IY# MFH_PMQ�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